- Search History will be lost after eight hours of inactivity.
- To combine searches use # before search number, e.g., #2 AND #6.
- Search numbers may not be continuous; all searches are represented.
- Click on query # to add to strategy

Search	Most Recent Queries	Time	Result
#4	Search **XIAP and alnemri**	17:28:51	12
#3	Search **XIAP**	17:28:39	412
#2	Search **alnemri** Field: **All Fields,** Limits: **Publication Date from 1999/01/01 to 2003/01/01**	17:28:08	54
#1	Search **alnemri**	17:27:30	135

Clear History

```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:sssptal653adk

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *  Welcome to STN
International  * * * * * * * * * *

 NEWS  1        Web Page URLs for STN Seminar
Schedule - N. America
 NEWS  2        "Ask CAS" for self-help around
the clock
 NEWS  3  May 12  EXTEND option available in
structure searching
 NEWS  4  May 12  Polymer links for the POLYLINK
command completed in REGISTRY
 NEWS  5  May 27  New UPM (Update Code Maximum)
field for more efficient patent
                SDIs in CAplus
 NEWS  6  May 27  CAplus super roles and
document types searchable in REGISTRY
 NEWS  7  Jun 22  STN Patent Forums to be held
July 19-22, 2004
 NEWS  8  Jun 28  Additional enzyme-catalyzed
reactions added to CASREACT
 NEWS  9  Jun 28  ANTE, AQUALINE, BIOENG,
CIVILENG, ENVIROENG, MECHENG,
                and WATER from CSA now
available on STN(R)
 NEWS 10  Jul 12  BEILSTEIN enhanced with new
display and select options,
                resulting in a closer
connection to BABS

 NEWS EXPRESS  MARCH 31 CURRENT WINDOWS VERSION
IS V7.00A, CURRENT
                MACINTOSH VERSION IS V6.0c(ENG)
AND V6.0Jc(JP),
                AND CURRENT DISCOVER FILE IS
DATED 26 APRIL 2004
 NEWS HOURS     STN Operating Hours Plus Help
Desk Availability
 NEWS INTER     General Internet Information
 NEWS LOGIN     Welcome Banner and News Items
 NEWS PHONE     Direct Dial and Telecommunication
Network Access to STN
 NEWS WWW       CAS World Wide Web Site (general
information)

Enter NEWS followed by the item number or name
to see news on that
specific topic.

  All use of STN is subject to the provisions of
the STN Customer
  agreement.  Please note that this agreement
limits use to scientific
  research.  Use for software development or
design or implementation
  of commercial gateways or other similar uses
is prohibited and may
  result in loss of user privileges and other
penalties.

  * * * * * * * * * * * * STN  Columbus  * * *
* * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:51:43 ON 26 JUL 2004

=> fil reg
COST IN U.S. DOLLARS
SINCE FILE      TOTAL

ENTRY    SESSION
FULL ESTIMATED COST
0.21       0.21

FILE 'REGISTRY' ENTERED AT 15:51:52 ON 26 JUL
2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER
AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society
(ACS)

Property values tagged with IC are from the
ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   25 JUL 2004  HIGHEST
RN 716315-35-4
DICTIONARY FILE UPDATES:  25 JUL 2004  HIGHEST
RN 716315-35-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 21,
2004

  Please note that search-term pricing does
apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP
CROSSOVER for details.

Experimental and calculated property data are
now available. For more
information enter HELP PROP at an arrow prompt
in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> s a[vti][pa][gavlipstcmnq]/sqsp
L1      898099 A[VTI][PA][GAVLIPSTCMNQ]/SQSP

=> fil caplus
COST IN U.S. DOLLARS
SINCE FILE      TOTAL

ENTRY    SESSION
FULL ESTIMATED COST
26.92      27.13

FILE 'CAPLUS' ENTERED AT 15:52:42 ON 26 JUL 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER
AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY
(ACS)


Copyright of the articles to which records in
this database refer is
held by the publishers listed in the PUBLISHER
(PB) field (available
for records published or updated in Chemical
Abstracts after December
26, 1996), unless otherwise indicated in the
original publications.
The CA Lexicon is the copyrighted intellectual
property of the
American Chemical Society and is provided to
assist you in searching
databases on STN.  Any dissemination,
distribution, copying, or storing
of this information, without the prior written
consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 26 Jul 2004  VOL 141 ISS 5
FILE LAST UPDATED: 25 Jul 2004  (20040725/ED)

  This file contains CAS Registry Numbers for
easy and accurate
  substance identification.


=> s l1
TOO MANY TERMS FOR FILE CROSSOVER IN L1
There are limits on the size of an answer set
being crossed over from
one file to another.  Enter HELP CROSSOVER at an
arrow prompt (=>)
for specific information.

=> fil reg
COST IN U.S. DOLLARS
SINCE FILE      TOTAL

ENTRY    SESSION
FULL ESTIMATED COST
0.46      27.59

FILE 'REGISTRY' ENTERED AT 15:52:49 ON 26 JUL
2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER
AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society
(ACS)

Property values tagged with IC are from the
ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   25 JUL 2004  HIGHEST
RN 716315-35-4
DICTIONARY FILE UPDATES:  25 JUL 2004  HIGHEST
RN 716315-35-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 21,
2004

  Please note that search-term pricing does
apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP
CROSSOVER for details.

Experimental and calculated property data are
now available. For more
information enter HELP PROP at an arrow prompt
in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> s l1 and pd<20010208
        105611 PD<20010208
L2            0 L1 AND PD<20010208

=> d l1 1-3

L1   ANSWER 1 OF 898099  REGISTRY  COPYRIGHT
2004 ACS on STN
RN   715134-09-1  REGISTRY
CN   Peptide, (Met-Ala-Thr-Pro-Ala-Asn-Ala-Xaa-
Phe-Ser-Phe-Tyr-Ser-Glu-Asn)
       (9CI)  (CA INDEX NAME)
FS   PROTEIN SEQUENCE
MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   CAPLUS
DT.CA  CAplus document type:  Patent
RL.P   Roles from patents:  PRP (Properties)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY
SEQUENCE ***
                1 REFERENCES IN FILE CAPLUS (1907
TO DATE)

L1   ANSWER 2 OF 898099  REGISTRY  COPYRIGHT
2004 ACS on STN
RN   715131-09-2  REGISTRY
CN   INDEX NAME NOT YET ASSIGNED
FS   PROTEIN SEQUENCE
MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   CAPLUS
DT.CA  CAplus document type:  Journal
RL.NP  Roles from non-patents:  BIOL (Biological
study); PRP (Properties)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY
SEQUENCE ***
                1 REFERENCES IN FILE CAPLUS (1907
TO DATE)

L1   ANSWER 3 OF 898099  REGISTRY  COPYRIGHT
2004 ACS on STN
RN   714978-89-9  REGISTRY
CN   INDEX NAME NOT YET ASSIGNED
FS   PROTEIN SEQUENCE
MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   CAPLUS
DT.CA  CAplus document type:  Journal
RL.NP  Roles from non-patents:  BIOL (Biological
study); PRP (Properties)

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY
SEQUENCE ***
                1 REFERENCES IN FILE CAPLUS (1907
TO DATE)


=> help crossover

 The term 'file crossover' refers to the use of
an answer set created
 by a search in one file as a search term or
profile in another file.

 You may use a REGISTRY File answer set as a
search term or
 profile in other STN files.  If the file
contains CAS Registry
 Numbers as search terms, the Registry Numbers
in the answer set
 and any associated Deleted Registry Numbers
(DR) or Alternate
 Registry Numbers (AR) will be searched, e.g.,
in the CA File.
 If the file does not contain CAS Registry
Numbers as search terms
 the query used to create the REGISTRY File
answer set will be
 searched, e.g., in the DRUGLAUNCH File.

 You may also crossover and search a set of
terms extracted from an
 answer set.  For more information on crossover
of extracted terms,
 enter HELP TRANSFER at an arrow prompt (=>).

 There is a limit of 10,000 answers (30,000 for
CAOLD/HCAOLD,
 CASREACT, CHEMCATS, and CHEMLIST/HCHEMLIST;
300,000 for CA/HCA/ZCA
 and CAPLUS/HCAPLUS/ZCAPLUS crossovers) that can
be crossed over from
 the REGISTRY File to another file containing
CAS Registry Numbers in
 a single crossover L-number.  If the REGISTRY
File answer set is
 larger than the answer limit, the answer set
size may be reduced by
 doing range searches on the L-number or by
TRANSFERing the L-number
 in the other file.  Enter HELP TRANSFER for
more information.  The
 most cost efficient way to do the range
searches is:

        In the REGISTRY File:

        => S 2-BUTENOIC ACID/HP(L)ESTER
              22898 2-BUTENOIC ACID/HP
            2128715 ESTER
        L1       16940 2-BUTENOIC
ACID/HP(L)ESTER

        => D REG 10000
```

```
      10000     RN              76390-27-7
REGISTRY

        => S L1 OR L1 RAN=(76390-27-7,)
        L2        10000 L1 OR L1

        => S L1 OR L1 RAN=(,76390-26-6)
        L3         6940 L1 NOT L2

        In another file that contains CAS
Registry Numbers:

        => S L2
        => S L3

 When the REGISTRY answer set L-number is ORed
with the same L-number,
 there are no additional RANGE search fees.
This method of reducing
 the answer set size for no additional fee may
be used for dictionary,
 biosequence, or structure search answer sets.

 Saved REGISTRY File answer sets must be
activated before they can be
 crossed over to another file.

 You may search an answer set created in any
other file in the
 REGISTRY File.  If the answer set is from a
file where the Accession
 Numbers are CAS Registry Numbers, the Registry
Numbers will be
 searched.  Otherwise, the search query used in
that file to create
 the answer set will be searched.

 Additional information on Deleted Registry
Numbers and Alternate
 Registry Numbers is available in HELP
ACCESSION.


=> l1 and /sql<20
FIELD QUALIFICATION NOT ALLOWED FOR OPERATOR
'AND /SQL<20'
Operators ('AND', 'OR', 'NOT', '(W)', '(NOTW)',
'(A)', '(NOTA)',
'(S)', '(NOTS)', '(P)', '(NOTP)', '(L)',
'(NOTL)') cannot have field
qualifiers.

=> s a[vti][pa][gavlipstcmnq]/sqsp/sql<=20
QUALIFICATION NOT VALID FOR NUMERIC DATA
'A[VTI][PA][GAVLIPSTCMNQ]/SQSP/SQL'
Numeric data cannot be field qualified.

=> s a[vti][pa][gavlipstcmnq]/sql<=20
QUALIFICATION NOT VALID FOR NUMERIC DATA
'A[VTI][PA][GAVLIPSTCMNQ]/SQL'
Numeric data cannot be field qualified.

=> l1 and sql<=20
      2430847 SQL<=20
L3        5628 L1 AND SQL<=20

=> l3 and sql<=10
       514818 SQL<=10
L4         1977 L3 AND SQL<=10

=> l4 and sql=4
        61451 SQL=4
L5          75 L4 AND SQL=4

=> l4 and sql>=5
      45783637 SQL>=5
L6         1903 L4 AND SQL>=5

=> l4 not l6
L7          74 L4 NOT L6

=> l7 not l5
L8           0 L7 NOT L5

=> d l7 1-4 all
```

```
L7   ANSWER 1 OF 74  REGISTRY  COPYRIGHT 2004
ACS on STN
RN   477328-83-9  REGISTRY
ED   Entered STN:  20 Dec 2002
CN   L-Isoleucine, L-alanyl-N-methyl-L-valyl-L-
prolyl- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   54: PN: WO02096930 SEQID: 68 claimed
protein
FS   PROTEIN SEQUENCE; STEREOSEARCH
SQL  4
NTE  modified (modifications unspecified)
-------------------------------------------------
---------------------
 type            ------ location ------
description
-------------------------------------------------
---------------------
modification     Val-2           -
methyl<Me>
-------------------------------------------------
---------------------

PATENT ANNOTATIONS (PNTE):
Sequence |Patent
Source   |Reference
=========+===========
Not Given|WO2002096930
         |claimed
         |SEQID 68


SEQ      1 AVPI
           ====
HITS AT:   1-4

SEQ3     1 Ala-Val-Pro-Ile
           === === === ===
HITS AT:   1-4

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

MF   C20 H36 N4 O5
SR   CA
LC   STN Files:   CA, CAPLUS
DT.CA  CAplus document type:  Patent
RL.P   Roles from patents:  BIOL (Biological
study)

Ring System Data

Elemental|Elemental| Size of |Ring System|
Ring     |   RID
Analysis |Sequence |the Rings|  Formula
|Identifier|Occurrence
   EA    |   ES    |   SZ    |    RF     |   RID
  Count
=========+=========+=========+===========+======
====+==========
C4N       |NC4      |5        |C4N
|16.136.1  |1


Absolute stereochemistry.
```



```
Calculated Properties (CALC)

      PROPERTY (CODE)        |        VALUE
| CONDITION | NOTE
=============================+==================
+===========+=======
Bioconc. Factor (BCF)        |1
|pH 1       |(1) ACD
Bioconc. Factor (BCF)        |1
|pH 4       |(1) ACD
Bioconc. Factor (BCF)        |1
|pH 7       |(1) ACD
Bioconc. Factor (BCF)        |1
|pH 8       |(1) ACD
Bioconc. Factor (BCF)        |1
|pH 10      |(1) ACD
Boiling Point (BP)           |658.7+/-55.0 deg C
|760.0 Torr |(1) ACD
Enthalpy of Vap. (HVAP)      |105.74+/-6.0
kJ/mol|      |(1) ACD
Flash Point (FP)             |352.2+/-56.7 deg C
|           |(1) ACD
Freely Rotatable Bonds (FRB)|14
|           |(1) ACD
H acceptors (HAC)            |9
|           |(1) ACD
H donors (HD)                |4
|           |(1) ACD
Koc (KOC)                    |1
|pH 1       |(1) ACD
Koc (KOC)                    |1
|pH 4       |(1) ACD
Koc (KOC)                    |1
|pH 7       |(1) ACD
Koc (KOC)                    |1
|pH 8       |(1) ACD
Koc (KOC)                    |1
|pH 10      |(1) ACD
logD (LOGD)                  |-2.23
|pH 1       |(1) ACD
logD (LOGD)                  |-1.74
|pH 4       |(1) ACD
logD (LOGD)                  |-1.64
|pH 7       |(1) ACD
logD (LOGD)                  |-1.77
|pH 8       |(1) ACD
logD (LOGD)                  |-2.95
|pH 10      |(1) ACD
logP (LOGP)                  |0.876+/-0.715
|           |(1) ACD
Molar Solubility (SLB.MOL)   |>=0.1 - <1 mol/L
|pH 1       |(1) ACD
Molar Solubility (SLB.MOL)   |>=0.1 - <1 mol/L
|pH 4       |(1) ACD
Molar Solubility (SLB.MOL)   |>=0.1 - <1 mol/L
|pH 7       |(1) ACD
Molar Solubility (SLB.MOL)   |>=0.1 - <1 mol/L
|pH 8       |(1) ACD
Molar Solubility (SLB.MOL)   |>=1 mol/L
|pH 10      |(1) ACD
Molecular Weight (MW)        |412.52
|           |(1) ACD
pKa (PKA)                    |3.68+/-0.22
|Most Acidic|(1) ACD
pKa (PKA)                    |8.37+/-0.29
|Most Basic |(1) ACD
Vapor Pressure (VP)          |4.70E-19 Torr
|25.0 deg C |(1) ACD

(1)  Calculated using Advanced Chemistry
Development (ACD/Labs) Software
     Solaris V4.76 ((C) 1994-2004 ACD/Labs)


See HELP PROPERTIES for information about
property data sources in REGISTRY.
               1 REFERENCES IN FILE CA (1907 TO
DATE)
               1 REFERENCES IN FILE CAPLUS (1907
TO DATE)
```

```
REFERENCE  1

AN   138:19527  CA Full-text
TI   IAP binding peptides and assays for
identifying compounds that bind IAP
IN   McLendon, George; Kipp, Rachel A.; Case,
Martin; Shi, Yigong
PA   The Trustees of Princeton University, USA
SO   PCT Int. Appl., 56 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
IC   ICM  C07K
CC   1-12 (Pharmacology)
     Section cross-reference(s): 34
FAN.CNT 1
     PATENT NO.          KIND  DATE
APPLICATION NO.  DATE
     ---------------  ----  --------       -----
---------  --------
PI   WO 2002096930       A2   20021205       WO
2002-US17342  20020531
     WO 2002096930       A3   20040318
          W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB,
BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EC,
EE, ES, FI, GB, GD, GE, GH,
              GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR,
              LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NO, NZ, OM, PH,
              PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA,
              UG, US, UZ, VN, YU, ZA, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM
          RW:  GH, GM, KE, LS, MW, MZ, SD, SL, SZ,
TZ, UG, ZM, ZW, AT, BE, CH,
               CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR,
               BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG
     EP 1421204          A2   20040526       EP
2002-729333   20020531
          R:  AT, BE, CH, DE, DK, ES, FR, GB, GR,
IT, LI, LU, NL, SE, MC, PT,
              IE, SI, LT, LV, FI, RO, MK, CY, AL,
TR
PRAI US 2001-294682P  20010531
     US 2002-345630P  20020103
     WO 2002-US17342  20020531
AB   Assays are disclosed for identifying
peptides and peptidomimetics for
promoting apoptosis in cells, through a
pathway involving the Inhibitor of
Apoptosis Proteins (IAPs), exemplified
by XIAP, and the mitochondrial protein
Smac/DIABLO (hereinafter Smac) and
homologs thereof.  The present invention
features an assay for use in high
throughput screening or rational drug
design of agents that can, like the Smac
tetrapeptide or its homologs in other
species, bind to a BIR domain of an IAP,
thereby relieving IAP-mediated
suppression of apoptosis.  The assay
comprises the following basic steps: (a)
providing a labeled mimetic of an IAP-
binding tetrapeptide that binds to the
appropriate BIR domain (preferably
BIR3), wherein at least one measurable
feature of the label changes as a
function of the mimetic being bound to
the IAP or free in solution; (b)
contacting the BIR domain of an IAP with
the labeled mimetic under conditions
enabling binding of the mimetic to the
BIR domain, thereby forming a BIR-
labeled mimetic complex having the
measurable feature; (c) contacting the
BIR-labeled mimetic complex with the
compound to be tested for BIR binding;
and (d) measuring displacement of the
labeled mimetic from the BIR-labeled
mimetic complex, if any, by the test
```

compound, by measuring the change in the measurable feature of the labeled mimetic, thereby determining if the test compound is capable of binding to the IAP. In a preferred embodiment, the labeled mimetic is AVPX, wherein X is directly or indirectly linked to a fluorogenic dye. Preferably, it is AVPC attached to a badan dye. The present invention also provides a library of peptides or peptidomimetics that have been demonstrated by the methods of the invention to bind to the BIR3 domain of XIAP.

ST IAP binding peptide identification apoptosis promotion; peptidomimetic IAP binding identification apoptosis promotion

IT Protein motifs
(BIR domain; IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)

IT Protein motifs
(BIR2 domain; IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)

IT Protein motifs
(BIR3 domain; IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)

IT Proteins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(DIABLO; IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)

IT Proteins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(IAP (inhibitor of apoptosis proteins); IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)

IT Apoptosis
Drug design
Drug screening
High throughput screening
Peptide library
Peptidomimetics
(IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)

IT Peptides, biological studies
RL: PAC (Pharmacological activity); BIOL (Biological study)
(IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)

IT Fluorescent dyes
Fluorescent indicators
Indicators
(IAP-binding peptides and peptidomimetics containing; IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)

IT Structure-activity relationship
(IAP-binding; IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)

IT Proteins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)

IT 243647-68-9 401913-54-0 401913-59-5 401913-64-2 402594-17-6 411230-24-5 433717-47-6 443302-76-9 443302-77-0 443302-78-1 443302-79-2 443302-80-5 443302-81-6 443302-82-7 443302-83-8 443302-84-9 443302-85-0 443302-86-1 443302-87-2 443302-88-3 443302-89-4 443302-90-7 443302-91-8 443302-92-9 443302-93-0 443302-94-1 443302-95-2 443302-96-3 443302-97-4 443302-98-5 443302-99-6 443303-00-2 443303-01-3 443303-02-4 443303-03-5 443303-04-6 443303-05-7 443303-06-8 443303-07-9 443303-08-0 443303-09-1 443303-10-4 443303-11-5 443303-12-6 443303-13-7 443303-14-8 443303-15-9 443303-16-0 443303-17-1 443303-18-2 477328-80-6 477328-83-9
RL: PAC (Pharmacological activity); BIOL (Biological study)
(IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)

IT 210832-86-3, Badan
RL: RCT (Reactant); RACT (Reactant or reagent)
(IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)

IT 477998-57-5 477998-58-6 477998-59-7
RL: PRP (Properties)
(unclaimed protein sequence; IAP binding peptides and assays for identifying compds. that bind IAP)

IT 401913-62-0 411230-31-4 477978-39-5 477978-40-8 477978-41-9 477978-42-0 477978-43-1 477978-44-2 477978-45-3 477978-46-4
RL: PRP (Properties)
(unclaimed sequence; IAP binding peptides and assays for identifying compds. that bind IAP)

L7 ANSWER 2 OF 74 REGISTRY COPYRIGHT 2004 ACS on STN
RN 477328-79-3 REGISTRY
ED Entered STN: 20 Dec 2002
CN L-Cysteine, L-alanyl-L-valyl-L-prolyl-S-[2-[6-(dimethylamino)-2-naphthalenyl]-2-oxoethyl]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 27: PN: WO02096930 FIGURE: 1 claimed sequence
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 4
NTE modified (modifications unspecified)

type	location	description
modification	Cys-4	undetermined modification

PATENT ANNOTATIONS (PNTE):

Sequence	Patent Source	Reference
Not Given	WO2002096930	claimed
		FIGURE 1

SEQ 1 AVPC
HITS AT: 1-4

SEQ3 1 Ala-Val-Pro-Cys
HITS AT: 1-4

RELATED SEQUENCES AVAILABLE WITH SEQLINK

MF C30 H41 N5 O6 S
SR CA
LC STN Files: CA, CAPLUS
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)

Ring System Data

Ring Analysis	Elemental Sequence Identifier	Elemental the Rings Occurrence	Size of Ring System RID	Ring System Formula RID	Ring System Count
EA	ES	SZ	RF	RID	
C4N	NC4	5	C4N	16.136.1	1
C6-C6	C6-C6	6-6	C10	591.49.57	1

Absolute stereochemistry.



Calculated Properties (CALC)

PROPERTY (CODE)	CONDITION	NOTE	VALUE
Bioconc. Factor (BCF)	pH 1	(1) ACD	1
Bioconc. Factor (BCF)	pH 4	(1) ACD	1
Bioconc. Factor (BCF)	pH 7	(1) ACD	1
Bioconc. Factor (BCF)	pH 8	(1) ACD	1
Bioconc. Factor (BCF)	pH 10	(1) ACD	1
Boiling Point (BP)	760.0 Torr	(1) ACD	922.7+/-65.0 deg C
Enthalpy of Vap. (HVAP)		(1) ACD	140.58+/-3.0 kJ/mol
Flash Point (FP)		(1) ACD	511.8+/-61.7 deg C
Freely Rotatable Bonds (FRB)		(1) ACD	18
H acceptors (HAC)		(1) ACD	11
H donors (HD)		(1) ACD	5
Koc (KOC)	pH 1	(1) ACD	1
Koc (KOC)	pH 4	(1) ACD	2.01
Koc (KOC)	pH 7	(1) ACD	5.26
Koc (KOC)	pH 8	(1) ACD	3.30
Koc (KOC)	pH 10	(1) ACD	1
logD (LOGD)	pH 1	(1) ACD	-1.46
logD (LOGD)	pH 4	(1) ACD	0.50
logD (LOGD)	pH 7	(1) ACD	0.91
logD (LOGD)	pH 8	(1) ACD	0.71
logD (LOGD)	pH 10	(1) ACD	-0.47
logP (LOGP)		(1) ACD	3.444+/-1.128
Molar Solubility (SLB.MOL)	pH 1	(1) ACD	<0.01 mol/L
Molar Solubility (SLB.MOL)	pH 4	(1) ACD	<0.01 mol/L
Molar Solubility (SLB.MOL)	pH 7	(1) ACD	<0.01 mol/L
Molar Solubility (SLB.MOL)	pH 8	(1) ACD	<0.01 mol/L
Molar Solubility (SLB.MOL)	pH 10	(1) ACD	<0.01 mol/L
Molecular Weight (MW)		(1) ACD	599.74
pKa (PKA)	Most Acidic	(1) ACD	3.15+/-0.10
pKa (PKA)	Most Basic	(1) ACD	8.13+/-0.29
Vapor Pressure (VP)	25.0 deg C	(1) ACD	7.09E-37 Torr

(1) Calculated using Advanced Chemistry Development (ACD/Labs) Software Solaris V4.76 ((C) 1994-2004 ACD/Labs)

See HELP PROPERTIES for information about property data sources in REGISTRY.

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

AN 138:19527 CA Full-text
TI IAP binding peptides and assays for identifying compounds that bind IAP
IN McLendon, George; Kipp, Rachel A.; Case, Martin; Shi, Yigong
PA The Trustees of Princeton University, USA
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07K
CC 1-12 (Pharmacology)
Section cross-reference(s): 34
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002096930	A2	20021205	WO 2002-US17342	20020531
WO 2002096930	A3	20040318		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1421204	A2	20040526	EP 2002-729333	20020531

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRAI US 2001-294682P	20010531	
US 2002-345630P	20020103	
WO 2002-US17342	20020531	

AB Assays are disclosed for identifying peptides and peptidomimetics for promoting apoptosis in cells, through a pathway involving the Inhibitor of Apoptosis Proteins (IAPs), exemplified by XIAP, and the mitochondrial protein Smac/DIABLO (hereinafter Smac) and homologs thereof. The present invention features an assay for use in high throughput screening or rational drug design of agents that can, like the Smac tetrapeptide or its homologs in other species, bind to a BIR domain of an IAP, thereby relieving IAP-mediated suppression of apoptosis. The assay comprises the following basic steps: (a) providing a labeled mimetic of an IAP-binding tetrapeptide that binds to the appropriate BIR domain (preferably BIR3), wherein at least one measurable feature of the label changes as a function of the mimetic being bound to the IAP or free in solution; (b) contacting the BIR domain of an IAP with the labeled mimetic under conditions enabling binding of the mimetic to the BIR domain, thereby forming a BIR-labeled mimetic complex having the measurable feature; (c) contacting the BIR-labeled mimetic complex with the compound to be tested for BIR binding; and (d) measuring displacement of the labeled mimetic from the BIR-labeled mimetic complex, if any, by the test compound, by measuring the change in the measurable feature of the labeled mimetic, thereby determining if the test compound is capable of binding to the IAP. In a preferred embodiment, the labeled mimetic is AVPX, wherein X is directly or indirectly linked to a fluorogenic dye. Preferably, it is AVPC attached to a badan dye. The present invention also provides a library of peptides or peptidomimetics that have been demonstrated by the methods of the invention to bind to the BIR3 domain of XIAP.

ST IAP binding peptide identification apoptosis promotion; peptidomimetic IAP binding identification apoptosis promotion

IT Protein motifs
(BIR domain; IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)
IT Protein motifs
(BIR2 domain; IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)
IT Protein motifs
(BIR3 domain; IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)
IT Proteins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(DIABLO; IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)
IT Proteins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(IAP (inhibitor of apoptosis proteins); IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)
IT Apoptosis
Drug design
Drug screening
High throughput screening
Peptide library
Peptidomimetics
(IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)
IT Peptides, biological studies
RL: PAC (Pharmacological activity); BIOL (Biological study)
(IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)
IT Fluorescent dyes
Fluorescent indicators
Indicators
(IAP-binding peptides and peptidomimetics containing; IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)
IT Structure-activity relationship
(IAP-binding; IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)
IT Proteins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(XIAP (X-linked inhibitor of apoptosis protein); IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)
IT 477724-03-1D, labeled derivs.
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)
IT 477328-79-3P
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)
IT 243647-68-9 401913-54-0 401913-59-5 401913-64-2 402594-17-6
411230-24-5 433717-47-6 443302-76-9 443302-77-0 443302-78-1
443302-79-2 443302-80-5 443302-81-6 443302-82-7 443302-83-8
443302-84-9 443302-85-0 443302-86-1 443302-87-2 443302-88-3
443302-89-4 443302-90-7 443302-91-8 443302-92-9 443302-93-0
443302-94-1 443302-95-2 443302-96-3 443302-97-4 443302-98-5
443302-99-6 443303-00-2 443303-01-3 443303-02-4 443303-03-5
443303-04-6 443303-05-7 443303-06-8 443303-07-9 443303-08-0
443303-09-1 443303-10-4 443303-11-5 443303-12-6 443303-13-7
443303-14-8 443303-15-9 443303-16-0 443303-17-1 443303-18-2
477328-80-6 477328-83-9
RL: PAC (Pharmacological activity); BIOL (Biological study)
(IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)
IT 210832-86-3, Badan
RL: RCT (Reactant); RACT (Reactant or reagent)
(IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)
IT 477998-57-5 477998-58-6 477998-59-7
RL: PRP (Properties)
(unclaimed protein sequence; IAP binding peptides and assays for identifying compds. that bind IAP)
IT 401913-62-0 411230-31-4 477978-39-5 477978-40-8 477978-41-9 477978-42-0 477978-43-1 477978-44-2 477978-45-3 477978-46-4
RL: PRP (Properties)
(unclaimed sequence; IAP binding peptides and assays for identifying compds. that bind IAP)

L7 ANSWER 3 OF 74 REGISTRY COPYRIGHT 2004

ACS on STN
RN 466687-11-6 REGISTRY
ED Entered STN: 28 Oct 2002
CN L-Threonine, L-alanyl-L-threonyl-L-alanyl-(9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 4

SEQ 1 ATAT
====
HITS AT: 1-4

SEQ3 1 Ala-Thr-Ala-Thr
=== === === ===
HITS AT: 1-4

MF C14 H26 N4 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PRP (Properties)

Absolute stereochemistry.



Calculated Properties (CALC)

PROPERTY (CODE)	CONDITION	NOTE	VALUE
Bioconc. Factor (BCF)	pH 1	(1) ACD	1
Bioconc. Factor (BCF)	pH 4	(1) ACD	1
Bioconc. Factor (BCF)	pH 7	(1) ACD	1
Bioconc. Factor (BCF)	pH 8	(1) ACD	1
Bioconc. Factor (BCF)	pH 10	(1) ACD	1
Boiling Point (BP)	760.0 Torr	(1) ACD	806.9+/-65.0 deg C
Enthalpy of Vap. (HVAP)		(1) ACD	133.59+/-6.0 kJ/mol
Flash Point (FP)		(1) ACD	441.8+/-61.7 deg C
Freely Rotatable Bonds (FRB)		(1) ACD	16
H acceptors (HAC)		(1) ACD	11
H donors (HD)		(1) ACD	8
Koc (KOC)	pH 1	(1) ACD	1
Koc (KOC)	pH 4	(1) ACD	1
Koc (KOC)	pH 7	(1) ACD	1
Koc (KOC)	pH 8	(1) ACD	1
Koc (KOC)	pH 10	(1) ACD	1
logD (LOGD)	pH 1	(1) ACD	-5.71
logD (LOGD)	pH 4	(1) ACD	-5.16
logD (LOGD)	pH 7	(1) ACD	-5.14

```
logD (LOGD)                    |-5.36
|pH 8          |(1) ACD
logD (LOGD)                    |-6.54
|pH 10         |(1) ACD
logP (LOGP)                    |-2.611+/-0.778
|              |(1) ACD
Molar Solubility (SLB.MOL)     |>=1 mol/L
|pH 1          |(1) ACD
Molar Solubility (SLB.MOL)     |>=1 mol/L
|pH 4          |(1) ACD
Molar Solubility (SLB.MOL)     |>=1 mol/L
|pH 7          |(1) ACD
Molar Solubility (SLB.MOL)     |>=1 mol/L
|pH 8          |(1) ACD
Molar Solubility (SLB.MOL)     |>=1 mol/L
|pH 10         |(1) ACD
Molecular Weight (MW)          |362.38
|              |(1) ACD
pKa (PKA)                      |3.22+/-0.10
|Most Acidic|(1) ACD
pKa (PKA)                      |8.09+/-0.29
|Most Basic |(1) ACD
Vapor Pressure (VP)            |3.90E-30 Torr
|25.0 deg C |(1) ACD

(1)  Calculated using Advanced Chemistry
Development (ACD/Labs) Software
     Solaris V4.76 ((C) 1994-2004 ACD/Labs)


See HELP PROPERTIES for information about
property data sources in REGISTRY.
                1 REFERENCES IN FILE CA (1907 TO
DATE)
                1 REFERENCES IN FILE CAPLUS (1907
TO DATE)

REFERENCE  1

AN   137:293537  CA Full-text
TI   Reducing the immunogenicity of fusion
proteins
IN   Gillies, Stephen D.
PA   Lexigen Pharmaceuticals Corp., USA
SO   PCT Int. Appl., 67 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
IC   ICM  C12N
CC   15-2 (Immunochemistry)
     Section cross-reference(s): 1, 2
FAN.CNT 2
     PATENT NO.       KIND  DATE
APPLICATION NO.  DATE
     ---------------  ----  --------        -----
----------  --------
PI   WO 2002079415    A2   20021010        WO
2002-US9650   20020329
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB,
BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC,
EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ,
TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG
     US 2003166877    A1   20030904        US
2002-112582   20020329
PRAI US 2001-280625P  20010330
AB   Compns. and methods for producing fusion
proteins with reduced immunogenicity are
disclosed.  Fusion proteins of the
invention include a junction region
having an amino acid change that reduces
the ability of the neoepitope to bind to
MHC Class II, thereby reducing its
interaction with T-cells.  In one
example, reduced immunogenicity was
observed for an interleukin-2
immunocytokine targeting EP-CAM wherein
the C-terminal Fc region of the
construct was engineered to eliminate a
potential T-cell epitope.
ST   immunogenicity fusion protein
IT   Antigens
     RL: BSU (Biological study, unclassified);
BIOL (Biological study)
        (17-1A; reduced immunogenicity of
immunocytokine targeted to)
IT   TCR (T cell receptors)
     RL: ADV (Adverse effect, including
toxicity); BIOL (Biological study)
        (CD3 complex; reduced immunogenicity of
fusion proteins by elimination
        of MHC class II-restricted epitopes
recognized by)
IT   Histocompatibility antigens
     RL: ADV (Adverse effect, including
toxicity); BIOL (Biological study)
        (HLA, class II; reduced immunogenicity
of fusion proteins by
        elimination of MHC class II-restricted
T-cell epitopes in junction
        region)
IT   CD3 (antigen)
     RL: ADV (Adverse effect, including
toxicity); BIOL (Biological study)
        (TCR complex; reduced immunogenicity of
fusion proteins by elimination
        of MHC class II-restricted epitopes
recognized by)
IT   Interleukin 4
     RL: BSU (Biological study, unclassified);
PRP (Properties); BIOL
     (Biological study)
        (fusion products, with Fc domains;
reduced immunogenicity of fusion
        proteins by elimination of MHC class II-
restricted T-cell epitopes in
        junction region of)
IT   Interleukin 2
     RL: BSU (Biological study, unclassified);
PRP (Properties); BIOL
     (Biological study)
        (fusion products, with anti-EP-CAM
antibody; reduced immunogenicity of
        fusion proteins by elimination of MHC
class II-restricted T-cell
        epitopes in junction region)
IT   CD4 (antigen)
     RL: BSU (Biological study, unclassified);
PRP (Properties); BIOL
     (Biological study)
        (fusion products, with human serum
albumin; reduced immunogenicity of
        fusion proteins by elimination of MHC
class II-restricted T-cell
        epitopes in junction region)
IT   Cytokines
     RL: BSU (Biological study, unclassified);
PRP (Properties); BIOL
     (Biological study)
        (fusion products; reduced immunogenicity
of fusion proteins by
        elimination of MHC class II-restricted
T-cell epitopes in junction
        region)
IT   Hormones, animal, biological studies
     RL: BSU (Biological study, unclassified);
PRP (Properties); BIOL
     (Biological study)
        (fusion products; reduced immunogenicity
of fusion proteins by
        elimination of MHC class II-restricted
T-cell epitopes in junction
        region of)
IT   Protein motifs
        (glycosylation site; reduced
immunogenicity of fusion proteins by
        engineering of junction region with)
IT   Antibodies and Immunoglobulins
     RL: BSU (Biological study, unclassified);
PRP (Properties); BIOL
     (Biological study)
        (heavy chain, fusion products; reduced
immunogenicity of fusion
        proteins by elimination of MHC class II-
restricted T-cell epitopes in
        junction region of)
IT   Antibodies and Immunoglobulins
     RL: BSU (Biological study, unclassified);
PRP (Properties); BIOL
     (Biological study)
        (immunoadhesins; reduced immunogenicity
of fusion proteins by
        elimination of MHC class II-restricted
T-cell epitopes in junction
        region)
IT   Algorithm
        (in anal. of fusion products and
engineering for reduced
        immunogenicity)
IT   Antibodies and Immunoglobulins
     RL: BSU (Biological study, unclassified);
PRP (Properties); BIOL
     (Biological study)
        (light chain, fusion products; reduced
immunogenicity of fusion
        proteins by elimination of MHC class II-
restricted T-cell epitopes in
        junction region of)
IT   Antibodies and Immunoglobulins
     RL: BSU (Biological study, unclassified);
PRP (Properties); BIOL
     (Biological study)
        (monoclonal, fusion products; reduced
immunogenicity of fusion proteins
        by elimination of MHC class II-
restricted T-cell epitopes in junction
        region)
IT   Protein engineering
        (of fusion products for reduced
immunogenicity)
IT   Molecular modeling
        (of fusion products in relation to
engineering for reduced
        immunogenicity)
IT   Epitopes
     Human
     T cell (lymphocyte)
        (reduced immunogenicity of fusion
proteins by elimination of MHC class
        II-restricted T-cell epitopes in
junction region)
IT   Fusion proteins (chimeric proteins)
     RL: BSU (Biological study, unclassified);
PRP (Properties); BIOL
     (Biological study)
        (reduced immunogenicity of fusion
proteins by elimination of MHC class
        II-restricted T-cell epitopes in
junction region)
IT   Albumins, biological studies
     RL: BSU (Biological study, unclassified);
PRP (Properties); BIOL
     (Biological study)
        (serum, fusion products, with CD4;
reduced immunogenicity of fusion
        proteins by elimination of MHC class II-
restricted T-cell epitopes in
        junction region)
IT   466687-11-6
     RL: BSU (Biological study, unclassified);
PRP (Properties); BIOL
     (Biological study)
        (of Fc domains of immunoadhesins for
reduced immunogenicity)
IT   11096-26-7D, Erythropoietin, Fc fragment
fusion proteins  83869-56-1D,
     GM-CSF, Fc fragment fusion proteins
185243-69-0, Enbrel
     RL: BSU (Biological study, unclassified);
PRP (Properties); BIOL
     (Biological study)
        (reduced immunogenicity of fusion
proteins by elimination of MHC class
        II-restricted T-cell epitopes in
junction region of)
IT   468842-52-6   468843-51-8   468843-52-9
468843-53-0   468843-54-1
     468843-55-2   468843-56-3   468843-57-4
468843-58-5   468843-59-6
     468843-60-9   468843-61-0   468843-62-1
468843-63-2   468843-64-3
     468843-65-4   468843-66-5   468843-67-6
468843-68-7   468843-69-8
     468843-70-1   468843-71-2   468843-72-3
468843-73-4
     RL: PRP (Properties)
        (unclaimed protein sequence; reducing
immunogenicity of fusion
        proteins)
IT   111286-19-2   460706-88-1   460706-89-2
460706-90-5   468712-64-3
     468712-65-4   468712-66-5   468712-67-6
468712-68-7   468712-69-8
     468712-70-1   468712-71-2   468712-72-3
468712-73-4   468712-74-5
     468712-75-6   468712-76-7   468712-77-8
468712-78-9   468712-79-0
     468712-80-3   468712-81-4   468712-82-5
468712-83-6   468712-84-7
     468712-85-8   468712-86-9   468712-87-0
468712-88-1   468712-89-2
     468712-90-5   468712-91-6   468712-92-7
     RL: PRP (Properties)
        (unclaimed sequence; reducing
immunogenicity of fusion proteins)

L7   ANSWER 4 OF 74  REGISTRY  COPYRIGHT 2004
ACS on STN
RN   443303-16-0  REGISTRY
ED   Entered STN:  09 Aug 2002
CN   L-Isoleucine, L-alanyl-L-valyl-L-prolyl-N-
methyl- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   52: PN: WO02096930 SEQID: 66 claimed
protein
FS   PROTEIN SEQUENCE; STEREOSEARCH
SQL  4
NTE  modified (modifications unspecified)
-------------------------------------------------
----------------------
 type            ------ location ------
description
-------------------------------------------------
----------------------
modification     Ile-4           -
methyl<Me>
-------------------------------------------------
----------------------

PATENT ANNOTATIONS (PNTE):
Sequence |Patent
Source   |Reference
==========+============
Not Given|WO2002096930
         |claimed
         |SEQID 66


SEQ      1 AVPI
           ====
HITS AT:   1-4

SEQ3     1 Ala-Val-Pro-Ile
           === === === ===
HITS AT:   1-4

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

MF   C20 H36 N4 O5
SR   CA
LC   STN Files:   CA, CAPLUS
DT.CA  CAplus document type:  Journal; Patent
RL.P   Roles from patents:  BIOL (Biological
study)
RL.NP  Roles from non-patents:  BIOL (Biological
study); PRP (Properties)
```

Ring System Data

Elemental Ring Analysis Identifier	Elemental |Sequence |the Rings| Occurrence	Size of Ring System| Formula	RID
EA	ES	SZ	RF	RID Count
C4N	NC4	5	C4N	
16.136.1	1			

Absolute stereochemistry.



Calculated Properties (CALC)

PROPERTY (CODE) | CONDITION | NOTE	VALUE
Bioconc. Factor (BCF) |pH 1 |(1) ACD	1
Bioconc. Factor (BCF) |pH 4 |(1) ACD	1
Bioconc. Factor (BCF) |pH 7 |(1) ACD	1
Bioconc. Factor (BCF) |pH 8 |(1) ACD	1
Bioconc. Factor (BCF) |pH 10 |(1) ACD	1
Boiling Point (BP) |760.0 Torr |(1) ACD	662.7+/-55.0 deg C
Enthalpy of Vap. (HVAP) kJ/mol| |(1) ACD	106.30+/-6.0
Flash Point (FP) | |(1) ACD	354.6+/-56.7 deg C
Freely Rotatable Bonds (FRB) | |(1) ACD	14
H acceptors (HAC) | |(1) ACD	9
H donors (HD) | |(1) ACD	4
Koc (KOC) |pH 1 |(1) ACD	1
Koc (KOC) |pH 4 |(1) ACD	1
Koc (KOC) |pH 7 |(1) ACD	1
Koc (KOC) |pH 8 |(1) ACD	1
Koc (KOC) |pH 10 |(1) ACD	1
logD (LOGD) |pH 1 |(1) ACD	-2.47
logD (LOGD) |pH 4 |(1) ACD	-1.98
logD (LOGD) |pH 7 |(1) ACD	-1.89
logD (LOGD) |pH 8 |(1) ACD	-2.09
logD (LOGD) |pH 10 |(1) ACD	-3.28
logP (LOGP) | |(1) ACD	0.636+/-0.738
Molar Solubility (SLB.MOL) |pH 1 |(1) ACD	>=1 mol/L
Molar Solubility (SLB.MOL) |pH 4 |(1) ACD	>=0.1 - <1 mol/L
Molar Solubility (SLB.MOL) |pH 7 |(1) ACD	>=0.1 - <1 mol/L
Molar Solubility (SLB.MOL) |pH 8 |(1) ACD	>=0.1 - <1 mol/L
Molar Solubility (SLB.MOL) |pH 10 |(1) ACD	>=1 mol/L
Molecular Weight (MW) | |(1) ACD	412.52
pKa (PKA) |Most Acidic|(1) ACD	3.70+/-0.22
pKa (PKA) |Most Basic |(1) ACD	8.13+/-0.29
Vapor Pressure (VP) |25.0 deg C |(1) ACD	2.82E-19 Torr

(1) Calculated using Advanced Chemistry Development (ACD/Labs) Software Solaris V4.76 ((C) 1994-2004 ACD/Labs)

See HELP PROPERTIES for information about property data sources in REGISTRY.

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

AN 138:19527 CA Full-text

TI IAP binding peptides and assays for identifying compounds that bind IAP

IN McLendon, George; Kipp, Rachel A.; Case, Martin; Shi, Yigong

PA The Trustees of Princeton University, USA

SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2

DT Patent

LA English

IC ICM C07K

CC 1-12 (Pharmacology)
Section cross-reference(s): 34

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002096930	A2	20021205	WO 2002-US17342	20020531
WO 2002096930	A3	20040318		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1421204 A2 20040526 EP 2002-729333 20020531

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRAI US 2001-294682P 20010531
US 2002-345630P 20020103

WO 2002-US17342 20020531

AB Assays are disclosed for identifying peptides and peptidomimetics for promoting apoptosis in cells, through a pathway involving the Inhibitor of Apoptosis Proteins (IAPs), exemplified by XIAP, and the mitochondrial protein Smac/DIABLO (hereinafter Smac) and homologs thereof. The present invention features an assay for use in high throughput screening or rational drug design of agents that can, like the Smac tetrapeptide or its homologs in other species, bind to a BIR domain of an IAP, thereby relieving IAP-mediated suppression of apoptosis. The assay comprises the following basic steps: (a) providing a labeled mimetic of an IAP-binding tetrapeptide that binds to the appropriate BIR domain (preferably BIR3), wherein at least one measurable feature of the label changes as a function of the mimetic being bound to the IAP or free in solution; (b) contacting the BIR domain of an IAP with the labeled mimetic under conditions enabling binding of the mimetic to the BIR domain, thereby forming a BIR-labeled mimetic complex having the measurable feature; (c) contacting the BIR-labeled mimetic complex with the compound to be tested for BIR binding; and (d) measuring displacement of the labeled mimetic from the BIR-labeled mimetic complex, if any, by the test compound, by measuring the change in the measurable feature of the labeled mimetic, thereby determining if the test compound is capable of binding to the IAP. In a preferred embodiment, the labeled mimetic is AVPX, wherein X is directly or indirectly linked to a fluorogenic dye. Preferably, it is AVPC attached to a badan dye. The present invention also provides a library of peptides or peptidomimetics that have been demonstrated by the methods of the invention to bind to the BIR3 domain of XIAP.

ST IAP binding peptide identification apoptosis promotion; peptidomimetic IAP binding identification apoptosis promotion

IT Protein motifs
(BIR domain; IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)

IT Protein motifs
(BIR2 domain; IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)

IT Protein motifs
(BIR3 domain; IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)

IT Proteins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(DIABLO; IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)

IT Proteins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(IAP (inhibitor of apoptosis proteins); IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)

IT Apoptosis
Drug design
Drug screening
High throughput screening
Peptide library
Peptidomimetics
(IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)

IT Peptides, biological studies
RL: PAC (Pharmacological activity); BIOL (Biological study)
(IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)

IT Fluorescent dyes
Fluorescent indicators
Indicators
(IAP-binding peptides and peptidomimetics containing; IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)

IT Structure-activity relationship
(IAP-binding; IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)

IT Proteins
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(XIAP (X-linked inhibitor of apoptosis protein); IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)

IT 477724-03-1D, labeled derivs.
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)

IT 477328-79-3P
RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(IAP binding peptides and assays for identifying compds. that bind IAP BIR domain using labeled mimetic in relation to stimulation of apoptosis)

IT 243647-68-9 401913-54-0 401913-59-5 401913-64-2 402594-17-6 411230-24-5 433717-47-6 443302-76-9 443302-77-0 443302-78-1 443302-79-2 443302-80-5 443302-81-6 443302-82-7 443302-83-8 443302-84-9 443302-85-0 443302-86-1 443302-87-2 443302-88-3 443302-89-4 443302-90-7 443302-91-8 443302-92-9 443302-93-0 443302-94-1 443302-95-2 443302-96-3 443302-97-4 443302-98-5 443302-99-6 443303-00-2 443303-01-3 443303-02-4 443303-03-5

443303-04-6 443303-05-7 443303-06-8
443303-07-9 443303-08-0
443303-09-1 443303-10-4 443303-11-5
443303-12-6 443303-13-7
443303-14-8 443303-15-9 443303-16-0
443303-17-1 443303-18-2
477328-80-6 477328-83-9
RL: PAC (Pharmacological activity); BIOL (Biological study)
(IAP binding peptides and assays for identifying compds. that bind IAP
BIR domain using labeled mimetic in relation to stimulation of
apoptosis)
IT 210832-86-3, Badan
RL: RCT (Reactant); RACT (Reactant or reagent)
(IAP binding peptides and assays for identifying compds. that bind IAP
BIR domain using labeled mimetic in relation to stimulation of
apoptosis)
IT 477998-57-5 477998-58-6 477998-59-7
RL: PRP (Properties)
(unclaimed protein sequence; iAP binding peptides and assays for
identifying compds. that bind IAP)
IT 401913-62-0 411230-31-4 477978-39-5
477978-40-8 477978-41-9
477978-42-0 477978-43-1 477978-44-2
477978-45-3 477978-46-4
RL: PRP (Properties)
(unclaimed sequence; iAP binding peptides and assays for identifying
compds. that bind IAP)

REFERENCE 2

AN 137:105391 CA Full-text
TI Molecular Targeting of Inhibitor of Apoptosis Proteins Based on Small
Molecule Mimics of Natural Binding Partners
AU Kipp, Rachael A.; Case, Martin A.; Wist, Aislyn D.; Cresson, Catherine M.;
Carrell, Maria; Griner, Erin; Wiita, Arun; Albiniak, Philip A.; Chai,
Jijie; Shi, Yigong; Semmelhack, Martin F.; McLendon, George L.
CS Department of Chemistry, Frick Laboratory and Department of Molecular
Biology, Lewis Thomas Laboratory, Princeton University, Princeton, NJ,
08544, USA
SO Biochemistry (2002), 41(23), 7344-7349
CODEN: BICHAW; ISSN: 0006-2960
PB American Chemical Society
DT Journal
LA English
CC 6-3 (General Biochemistry)
AB An assay based on a solvent-sensitive fluorogenic dye mol., badan, is used to test the binding affinity of a library of tetrapeptide mols. for the BIR3 (baculovirus IAP repeat) domain of XIAP (X-linked inhibitor of apoptosis protein). The fluorophore is attached to a tetrapeptide, Ala-Val-Pro-Cys-NH2, through a thiol linkage and, upon binding to XIAP, undergoes a solvatochromic shift in fluorescence emission. When a mol. (e.g., a natural protein known to bind to XIAP or a tetrapeptide mimic) displaces the dye, the emission shifts back to the spectrum observed in water. As emission intensity is related to the binding of the tetrapeptide, the intensity can be used to determine the equilibrium constant, K, for the displacement of the dye by the tetrapeptide. The results permit residue-specific anal. of the interaction. Furthermore, we show that hydrophobic effects in the fourth position are general and can effectively increase overall affinity.
ST apoptosis inhibitor protein XIAP targeting peptide ligand; peptide ligand
combinatorial library XIAP protein targeting
IT Protein motifs
(BIR3 domain; mol. targeting of inhibitor of apoptosis proteins based
on small mol. mimics of natural binding partners)
IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(DIABLO, binding; mol. targeting of inhibitor of apoptosis proteins
based on small mol. mimics of natural binding partners)
IT Proteins
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)
(XIAP (X-linked inhibitor of apoptosis protein); mol. targeting of
inhibitor of apoptosis proteins based on small mol. mimics of natural
binding partners)
IT Dissociation constant
Molecular association
Peptide library
(mol. targeting of inhibitor of apoptosis proteins based on small mol.
mimics of natural binding partners)
IT Structure-activity relationship
(protein-binding, XIAP protein-binding; mol. targeting of inhibitor of
apoptosis proteins based on small mol. mimics of natural binding
partners)
IT 243647-68-9 401913-54-0 401913-59-5
401913-64-2 402594-17-6
411230-24-5 433717-47-6 443302-76-9
443302-77-0 443302-78-1
443302-79-2 443302-80-5 443302-81-6
443302-82-7 443302-83-8
443302-84-9 443302-85-0 443302-86-1
443302-87-2 443302-88-3
443302-89-4 443302-90-7 443302-91-8
443302-92-9 443302-93-0
443302-94-1 443302-95-2 443302-96-3
443302-97-4 443302-98-5
443302-99-6 443303-00-2 443303-01-3
443303-02-4 443303-03-5
443303-04-6 443303-05-7 443303-06-8
443303-07-9 443303-08-0
443303-09-1 443303-10-4 443303-11-5
443303-12-6 443303-13-7
443303-14-8 443303-15-9 443303-16-0
443303-17-1 443303-18-2
443303-19-3
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
(Biological study)
(mol. targeting of inhibitor of apoptosis proteins based on small mol.
mimics of natural binding partners)
RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
(1) Boxrud, P; J Biol Chem 2000, V275, P14579 CAPLUS
(2) Cantor, C; Biophysical Chemistry, Part 1: The Conformation of Biological
Macromolecules 1980, P52
(3) Chai, J; Cell 2001, V104, P769 CAPLUS
(4) Chai, J; Nature 2000, V406, P855 CAPLUS
(5) Chan, W; Fmoc Solid-Phase Peptide Synthesis:A Practical Approach 2000
(6) Devereaux, Q; EMBO J 1999, V18, P5242 CAPLUS
(7) Devereaux, Q; Genes Dev 1999, V13, P239
(8) Du, C; Cell 2000, V102, P33 CAPLUS
(9) Ekert, P; J Cell Biol 2001, V152, P483 CAPLUS
(10) Fesik, S; Cell 2000, V103, P273 CAPLUS
(11) Freidinger, R; J Org Chem 1983, V48, P77 CAPLUS
(12) Green, D; Cell 2000, V102, P1 CAPLUS
(13) Hiratsuka, T; J Biol Chem 1999, V274, P29156 CAPLUS
(14) Huang, Y; Cell 2001, V104, P781 CAPLUS
(15) Lacasse, E; Oncogene 1998, V17, P3247
(16) Liu, Z; Nature 2000, V408, P1004 CAPLUS
(17) Owenius, R; Biophys J 1999, V77, P2237 CAPLUS
(18) Riedl, S; Cell 2001, V104, P791 CAPLUS
(19) Shi, Y; Nat Struct Biol 2001, V8, P394 CAPLUS
(20) Srinivasula, S; Nature 2001, V410, P112 CAPLUS
(21) Verhagen, A; Cell 2000, V102, P43 CAPLUS
(22) Wu, G; Nature 2000, V408, P1008 CAPLUS
(23) Wu, J; Mol Cell 2001, V8, P95 CAPLUS

=> d his full

(FILE 'HOME' ENTERED AT 15:51:43 ON 26 JUL 2004)

FILE 'REGISTRY' ENTERED AT 15:51:52 ON 26 JUL 2004
L1 898099 SEA PLU=ON A[VTI][PA][GAVLIPSTCMNQ]/SQSP

FILE 'CAPLUS' ENTERED AT 15:52:42 ON 26 JUL 2004

FILE 'REGISTRY' ENTERED AT 15:52:49 ON 26 JUL 2004
L2 0 SEA PLU=ON L1 AND PD<20010208
D L1 1-3
SET LINE 250
SET DETAIL OFF
SET LINE LOGIN
SET DETAIL LOGIN
L3 5628 SEA PLU=ON L1 AND SQL<=20
L4 1977 SEA PLU=ON L3 AND SQL<=10
L5 75 SEA PLU=ON L4 AND SQL=4
L6 1903 SEA PLU=ON L4 AND SQL>=5
L7 74 SEA PLU=ON L4 NOT L6
L8 0 SEA PLU=ON L7 NOT L5
D L7 1-4 ALL

FILE HOME

FILE REGISTRY
Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 25 JUL 2004
HIGHEST RN 716315-35-4
DICTIONARY FILE UPDATES: 25 JUL 2004
HIGHEST RN 716315-35-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:

http://www.cas.org/ONLINE/DBSS/registryss.html

FILE CAPLUS

FILE COVERS 1907 - 26 Jul 2004 VOL 141 ISS 5
FILE LAST UPDATED: 25 Jul 2004 (20040725/ED)

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> fil caplus
COST IN U.S. DOLLARS
SINCE FILE TOTAL

ENTRY SESSION
FULL ESTIMATED COST
72.22 99.81

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
SINCE FILE TOTAL

ENTRY SESSION
CA SUBSCRIBER PRICE
-2.64 -2.64

FILE 'CAPLUS' ENTERED AT 15:59:09 ON 26 JUL 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 26 Jul 2004 VOL 141 ISS 5
FILE LAST UPDATED: 25 Jul 2004 (20040725/ED)

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s pd<20010208
SYSTEM LIMITS EXCEEDED - SEARCH ENDED
The search profile you entered was too complex or gave too many
answers. Simplify or subdivide the query and try again. If you have
exceeded the answer limit, enter DELETE HISTORY at an arrow prompt
(=>) to remove all previous answers sets and begin at L1. Use the
SAVE command to store any important profiles or answer sets before
using DELETE HISTORY.

=> s l1

```
TOO MANY TERMS FOR FILE CROSSOVER IN L1
There are limits on the size of an answer set
being crossed over from
one file to another.  Enter HELP CROSSOVER at an
arrow prompt (=>)
for specific information.

=> s l1 and pd<20010208
TOO MANY TERMS FOR FILE CROSSOVER IN L1
There are limits on the size of an answer set
being crossed over from
one file to another.  Enter HELP CROSSOVER at an
arrow prompt (=>)
for specific information.

=> s a[vti][pa][gavlipstcmnq]/sqsp
   REGISTRY INITIATED
Substance data SEARCH and crossover from CAS
REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view
retrieved structures.


UNMATCHED BRACKETS FOUND FOR AUTOMATED SEARCH
AND CROSSOVER
Invalid automated search and crossover syntax.
The query for the
automated search and crossover field contained
an unmatched bracket
symbol, either left bracket [ or right bracket
], which is not
supported by automated search and crossover.

=> d his full

     (FILE 'HOME' ENTERED AT 15:51:43 ON 26 JUL
2004)

     FILE 'REGISTRY' ENTERED AT 15:51:52 ON 26
JUL 2004
L1        898099 SEA PLU=ON
A[VTI][PA][GAVLIPSTCMNQ]/SQSP

     FILE 'CAPLUS' ENTERED AT 15:52:42 ON 26 JUL
2004

     FILE 'REGISTRY' ENTERED AT 15:52:49 ON 26
JUL 2004
L2             0 SEA PLU=ON  L1 AND PD<20010208
                 D L1 1-3
                 SET LINE 250
                 SET DETAIL OFF
                 SET LINE LOGIN
                 SET DETAIL LOGIN
L3          5628 SEA PLU=ON  L1 AND SQL<=20
L4          1977 SEA PLU=ON  L3 AND SQL<=10
L5            75 SEA PLU=ON  L4 AND SQL=4
L6          1903 SEA PLU=ON  L4 AND SQL>=5
L7            74 SEA PLU=ON  L4 NOT L6
L8             0 SEA PLU=ON  L7 NOT L5
                 D L7 1-4 ALL

     FILE 'CAPLUS' ENTERED AT 15:59:09 ON 26 JUL
2004
               S A[VTI][PA][GAVLIPSTCMNQ]/SQSP


     FILE HOME

     FILE REGISTRY
     Property values tagged with IC are from the
ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   25 JUL 2004
HIGHEST RN 716315-35-4
     DICTIONARY FILE UPDATES:  25 JUL 2004
HIGHEST RN 716315-35-4

     TSCA INFORMATION NOW CURRENT THROUGH MAY
21, 2004

      Please note that search-term pricing does
apply when
       conducting SmartSELECT searches.

     Crossover limits have been increased.  See
HELP CROSSOVER for details.

     Experimental and calculated property data
are now available.  For more
     information enter HELP PROP at an arrow
prompt in the file or refer
     to the file summary sheet on the web at:

http://www.cas.org/ONLINE/DBSS/registryss.html

     FILE CAPLUS

     Copyright of the articles to which records
in this database refer is
     held by the publishers listed in the
PUBLISHER (PB) field (available
     for records published or updated in
Chemical Abstracts after December
     26, 1996), unless otherwise indicated in
the original publications.
     The CA Lexicon is the copyrighted
intellectual property of the
     American Chemical Society and is provided
to assist you in searching
     databases on STN.  Any dissemination,
distribution, copying, or storing
     of this information, without the prior
written consent of CAS, is
     strictly prohibited.

     FILE COVERS 1907 - 26 Jul 2004  VOL 141 ISS
5
     FILE LAST UPDATED: 25 Jul 2004
(20040725/ED)

       This file contains CAS Registry Numbers
for easy and accurate
       substance identification.


=> FIL REGISTRY
COST IN U.S. DOLLARS
SINCE FILE       TOTAL

ENTRY    SESSION
FULL ESTIMATED COST
1.84     101.65

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
SINCE FILE       TOTAL

ENTRY    SESSION
CA SUBSCRIBER PRICE
0.00       -2.64

FILE 'REGISTRY' ENTERED AT 16:01:38 ON 26 JUL
2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER
AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society
(ACS)

Property values tagged with IC are from the
ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   25 JUL 2004  HIGHEST
RN 716315-35-4
DICTIONARY FILE UPDATES:  25 JUL 2004  HIGHEST
RN 716315-35-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 21,
2004

  Please note that search-term pricing does
apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP
CROSSOVER for details.

Experimental and calculated property data are
now available.  For more
information enter HELP PROP at an arrow prompt
in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> S L1 AND (PATENT)/DT
      15314351 (PATENT)/DT
L9       289282 L1 AND (PATENT)/DT

=> DIS L9 1

L9   ANSWER 1 OF 289282  REGISTRY  COPYRIGHT
2004 ACS on STN
RN   715134-09-1  REGISTRY
CN   Peptide, (Met-Ala-Thr-Pro-Ala-Asn-Ala-Xaa-
Phe-Ser-Phe-Tyr-Ser-Glu-Asn)
     (9CI)  (CA INDEX NAME)
FS   PROTEIN SEQUENCE
MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   CAPLUS
DT.CA  CAplus document type:  Patent
RL.P   Roles from patents:  PRP (Properties)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY
SEQUENCE ***
               1 REFERENCES IN FILE CAPLUS (1907
TO DATE)


=> FIL CAPLUS
COST IN U.S. DOLLARS
SINCE FILE       TOTAL

ENTRY    SESSION
FULL ESTIMATED COST
7.04     108.69

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
SINCE FILE       TOTAL

ENTRY    SESSION
CA SUBSCRIBER PRICE
0.00       -2.64

FILE 'CAPLUS' ENTERED AT 16:02:37 ON 26 JUL 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER
AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY
(ACS)


Copyright of the articles to which records in
this database refer is
held by the publishers listed in the PUBLISHER
(PB) field (available
for records published or updated in Chemical
Abstracts after December
26, 1996), unless otherwise indicated in the
original publications.
The CA Lexicon is the copyrighted intellectual
property of the
American Chemical Society and is provided to
assist you in searching
databases on STN.  Any dissemination,
distribution, copying, or storing
of this information, without the prior written
consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 26 Jul 2004  VOL 141 ISS 5
FILE LAST UPDATED: 25 Jul 2004  (20040725/ED)

  This file contains CAS Registry Numbers for
easy and accurate
  substance identification.


=> d l9 1 ibib
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' -
CONTINUE? (Y)/N:y

'IBIB' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

The following are valid formats:

Substance information can be displayed by
requesting individual
fields or predefined formats.  The predefined
substance formats
are:  (RN = CAS Registry Number)

REG    - RN
SAM    - Index Name, MF, and structure - no RN
FIDE   - All substance data, except sequence
data
IDE    - FIDE, but only 50 names
SQIDE  - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid
codes are used
SQD    - Protein sequence data, includes RN
SQD3   - Same as SQD, but 3-letter amino acid
codes are used
SQN    - Protein sequence name information,
includes RN

CALC   - Table of calculated properties
EPROP  - Table of experimental properties
PROP   - EPROP and CALC

Any CA File format may be combined with any
substance format to
obtain CA references citing the substance.  The
substance formats
must be cited first.  The CA File predefined
formats are:

ABS  -- Abstract
APPS -- Application and Priority Information
BIB  -- CA Accession Number, plus Bibliographic
Data
CAN  -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic
Data (compressed)
IND  -- Index Data
IPC  -- International Patent Classification
PATS -- PI, SO
STD  -- BIB, IPC, and NCL

IABS -- ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB -------- AN, plus Bibliographic Data
(original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus
sequence data when
it is available.
The MAX format is the same as ALL.
The IALL format is the same as ALL with BIB ABS
and IND indented,
with text labels.

For additional information, please consult the
following help
messages:

HELP DFIELDS -- To see a complete list of
individual display fields.
HELP FORMATS -- To see detailed descriptions of
the predefined formats.
ENTER DISPLAY FORMAT (IDE):ide

L9   ANSWER 1 OF 289282  REGISTRY  COPYRIGHT
2004 ACS on STN
RN   715134-09-1  REGISTRY
CN   Peptide, (Met-Ala-Thr-Pro-Ala-Asn-Ala-Xaa-
Phe-Ser-Phe-Tyr-Ser-Glu-Asn)
     (9CI)  (CA INDEX NAME)
FS   PROTEIN SEQUENCE
```

```
MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   CAPLUS
DT.CA  CAplus document type:  Patent
RL.P   Roles from patents:  PRP (Properties)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY
SEQUENCE ***
               1 REFERENCES IN FILE CAPLUS (1907
TO DATE)


=> s l1 and alnemri/au
TOO MANY TERMS FOR FILE CROSSOVER IN L1
There are limits on the size of an answer set
being crossed over from
one file to another.  Enter HELP CROSSOVER at an
arrow prompt (=>)
for specific information.

=> d his

     (FILE 'HOME' ENTERED AT 15:51:43 ON 26 JUL
2004)

     FILE 'REGISTRY' ENTERED AT 15:51:52 ON 26
JUL 2004
L1        898099 S A[VTI][PA][GAVLIPSTOMNQ]/SQSP

     FILE 'CAPLUS' ENTERED AT 15:52:42 ON 26 JUL
2004

     FILE 'REGISTRY' ENTERED AT 15:52:49 ON 26
JUL 2004
L2             0 S L1 AND PD<20010208
L3          5628 L1 AND SQL<=20
L4          1977 L3 AND SQL<=10
L5            75 L4 AND SQL=4
L6          1903 L4 AND SQL>=5
L7            74 L4 NOT L6
L8             0 L7 NOT L5

     FILE 'CAPLUS' ENTERED AT 15:59:09 ON 26 JUL
2004
               S A[VTI][PA][GAVLIPSTOMNQ]/SQSP

     FILE 'REGISTRY' ENTERED AT 16:01:38 ON 26
JUL 2004
L9        289282 S L1 AND (PATENT)/DT

     FILE 'CAPLUS' ENTERED AT 16:02:37 ON 26 JUL
2004

     FILE 'REGISTRY' ENTERED AT 16:03:01 ON 26
JUL 2004

     FILE 'CAPLUS' ENTERED AT 16:03:04 ON 26 JUL
2004

=> l6 and sql=6
'6' NOT A VALID FIELD CODE
            845 L6
              0 SQL=6
L10           0 L6 AND SQL=6

=> fil reg
COST IN U.S. DOLLARS
SINCE FILE       TOTAL

ENTRY    SESSION
FULL ESTIMATED COST
1.84      113.18

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
SINCE FILE       TOTAL

ENTRY    SESSION
CA SUBSCRIBER PRICE
0.00       -2.64

FILE 'REGISTRY' ENTERED AT 16:05:22 ON 26 JUL
2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER
AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society
(ACS)

Property values tagged with IC are from the
ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   25 JUL 2004  HIGHEST
RN 716315-35-4
DICTIONARY FILE UPDATES:  25 JUL 2004  HIGHEST
RN 716315-35-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 21,
2004

  Please note that search-term pricing does
apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP
CROSSOVER for details.

Experimental and calculated property data are
now available. For more
information enter HELP PROP at an arrow prompt
in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> l6 and sql=6
          59885 SQL=6
L11         172 L6 AND SQL=6

=> s a[vti][pa][sfyvi]/sqsp
L12      430210 A[VTI][PA][SFYVI]/SQSP

=> l12 and sql=10
         139376 SQL=10
L13         208 L12 AND SQL=10

=> l12 and sql=20
         377919 SQL=20
L14         148 L12 AND SQL=20

=> l12 and sql=50
          58158 SQL=50
L15         430 L12 AND SQL=50

=> l12 and sql=25
         285921 SQL=25
L16         163 L12 AND SQL=25

=> l12 and sql=23
          71713 SQL=23
L17          73 L12 AND SQL=23

=> l12 and sql=22
          90773 SQL=22
L18          74 L12 AND SQL=22

=> d l18 1 all

L18  ANSWER 1 OF 74  REGISTRY  COPYRIGHT 2004
ACS on STN
RN   710729-80-9  REGISTRY
ED   Entered STN:  15 Jul 2004
CN   Peptide, (Ser-Ser-Pro-Val-Thr-Lys-Ser-Phe-
Asn-Arg-Gly-Glu-Cys-Xaa-Met-Lys-
     Lys-Thr-Ala-Ile-Ala-Ile) (9CI)  (CA INDEX
NAME)
FS   PROTEIN SEQUENCE
SQL  22
NTE
-----------------------------------------------
----------------------
 type             ------ location ------
description
-----------------------------------------------
----------------------
uncommon         Aaa-14          -         -
-----------------------------------------------
----------------------
SEQ      1 SSPVTKSFNR GECXMKKTAI AI
                           == ==
HITS AT:   19-22

SEQ3     1 Ser-Ser-Pro-Val-Thr-Lys-Ser-Phe-Asn-
Arg-
        11 Gly-Glu-Cys-Aaa-Met-Lys-Lys-Thr-Ala-
Ile-
                                           ===
===
        21 Ala-Ile
           === ===
HITS AT:   19-22

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER
DT.CA  CAplus document type:  Patent
RL.P   Roles from patents:  PRP (Properties)
               1 REFERENCES IN FILE CA (1907 TO
DATE)
               1 REFERENCES IN FILE CAPLUS (1907
TO DATE)

REFERENCE  1

AN   141:76685  CA Full-text
TI   Engineered anti-tumor necrosis factor alpha
antibody Fab' fragment CDP870
     in combination with disease modifying anti-
rheumatic drugs, and
     therapeutic uses
IN   Woulfe, Susan L.; Jain, Rita; Burr, Aimee
PA   Pharmacia Corporation, USA
SO   PCT Int. Appl., 93 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
IC   ICM  C12N
CC   63-3 (Pharmaceuticals)
     Section cross-reference(s): 1, 3, 15
FAN.CNT 1
     PATENT NO.        KIND  DATE
APPLICATION NO.  DATE
     ---------------   ----  --------        -----
----------  --------
PI   WO 2004053064     A2    20040624        WO
2003-US38499  20031205
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB,
BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ,
EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG,
MK, MN, MW, MX, MZ, NI, NO,
             NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ,
             TM, TN, TR, TT, TZ, UA, UG, UZ, VC,
VN, YU, ZA, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL,
SZ, TZ, UG, ZM, ZW, AT, BE,
             BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU,
             MC, NL, PT, RO, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN,
             GQ, GW, ML, MR, NE, SN, TD, TG
PRAI US 2002-431053P  20021205
AB       The present invention provides a
combination therapeutic compn. useful in
modulating, treating and/or preventing
inflammatory diseases.  The therapeutic
composition includes antibody Fab'
fragment CDP870 that is specific for
antigenic determinants of tumor necrosis
factor alpha (TNF) and at least one
Disease Modifying Anti-Rheumatic Disease
drug such as methotrexate or
sulfasalazine.  The therapeutic
composition can be administered to
either a human or animal subject in
single or multiple doses over time in
the treatment of rheumatoid arthritis,
Crohn's Disease or any other
inflammatory disease.
ST   antiinflammatory engineered antitumor
necrosis factor antibody Fab CDP870
     sequence; antirheumatic combination TNF
antibody Fab CDP870 rheumatoid
     arthritis therapy
IT   Intestine, disease
     (Crohn's; engineered anti-tumor necrosis
factor alpha antibody Fab'
     fragment CDP870 in combination with
disease modifying anti-rheumatic
     drugs, and therapeutic uses)
IT   Antirheumatic agents
     (combination therapy with; engineered
anti-tumor necrosis factor alpha
     antibody Fab' fragment CDP870 in
combination with disease modifying
     anti-rheumatic drugs, and therapeutic
uses)
IT   DNA sequences
     (encoding CDP870; engineered anti-tumor
necrosis factor alpha antibody
     Fab' fragment CDP870 in combination with
disease modifying
     anti-rheumatic drugs, and therapeutic
uses)
IT   Analgesics
     Animal
     Antiarthritics
     Arthritis
     Drug delivery systems
     Human
     Inflammation
     Rheumatoid arthritis
     (engineered anti-tumor necrosis factor
alpha antibody Fab' fragment
     CDP870 in combination with disease
modifying anti-rheumatic drugs, and
     therapeutic uses)
IT   Tumor necrosis factors
     RL: BSU (Biological study, unclassified);
BIOL (Biological study)
     (engineered anti-tumor necrosis factor
alpha antibody Fab' fragment
     CDP870 in combination with disease
modifying anti-rheumatic drugs, and
     therapeutic uses)
IT   Antibodies and Immunoglobulins
     RL: PAC (Pharmacological activity); PRP
(Properties); THU (Therapeutic
     use); BIOL (Biological study); USES (Uses)
     (fragments, Fab', anti-TNF, CDP870;
engineered anti-tumor necrosis
     factor alpha antibody Fab' fragment
CDP870 in combination with disease
     modifying anti-rheumatic drugs, and
therapeutic uses)
IT   Anti-inflammatory agents
     (kit; engineered anti-tumor necrosis
factor alpha antibody Fab'
     fragment CDP870 in combination with
disease modifying anti-rheumatic
     drugs, and therapeutic uses)
IT   Protein sequences
     (of CDP870; engineered anti-tumor
necrosis factor alpha antibody Fab'
     fragment CDP870 in combination with
disease modifying anti-rheumatic
     drugs, and therapeutic uses)
IT   Pain
     (rheumatoid arthritis-associated;
engineered anti-tumor necrosis factor
     alpha antibody Fab' fragment CDP870 in
combination with disease
     modifying anti-rheumatic drugs, and
therapeutic uses)
IT   710728-88-4   710728-89-5
     RL: PAC (Pharmacological activity); PRP
(Properties); THU (Therapeutic
     use); BIOL (Biological study); USES (Uses)
     (amino acid sequence; engineered anti-
tumor necrosis factor alpha
```

antibody Fab' fragment CDP870 in combination with disease modifying anti-rheumatic drugs, and therapeutic uses)
IT 59-05-2, Methotrexate 599-79-1, Sulfasalazine
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy with; engineered anti-tumor necrosis factor alpha antibody Fab' fragment CDP870 in combination with disease modifying anti-rheumatic drugs, and therapeutic uses)
IT 710728-90-8
RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(nucleotide sequence; engineered anti-tumor necrosis factor alpha antibody Fab' fragment CDP870 in combination with disease modifying anti-rheumatic drugs, and therapeutic uses)
IT 710729-47-8 710729-48-9 710729-49-0 710729-50-3 710729-51-4
710729-54-7 710729-55-8 710729-56-9 710729-57-0 710729-58-1
710729-60-5 710729-79-6
RL: PRP (Properties)
(unclaimed nucleotide sequence; engineered anti-tumor necrosis factor alpha antibody Fab' fragment CDP870 in combination with disease modifying anti-rheumatic drugs, and therapeutic uses)
IT 710729-52-5 710729-53-6 710729-59-2
RL: PRP (Properties)
(unclaimed protein sequence; engineered anti-tumor necrosis factor alpha antibody Fab' fragment CDP870 in combination with disease modifying anti-rheumatic drugs, and therapeutic uses)
IT 145060-92-0 145060-93-1 145060-99-7 145061-00-3 158512-03-9
164268-99-9 246223-11-0 256475-24-8 380648-32-8 380648-34-0
380648-36-2 380648-39-5 380648-41-9 380648-43-1 380648-47-5
380648-50-0 380648-53-3 380648-61-3 380648-63-5 380648-66-8
380648-69-1 380648-73-7 380648-83-9 710292-82-3 710729-75-2
710729-76-3 710729-77-4 710729-78-5 710729-80-9 710729-81-0
710729-82-1 710733-78-1 710733-79-2
RL: PRP (Properties)
(unclaimed sequence; engineered anti-tumor necrosis factor alpha antibody Fab' fragment CDP870 in combination with disease modifying anti-rheumatic drugs, and therapeutic uses)

=> fil caplus
COST IN U.S. DOLLARS
SINCE FILE TOTAL

ENTRY SESSION
FULL ESTIMATED COST
71.19 184.37

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
SINCE FILE TOTAL

ENTRY SESSION
CA SUBSCRIBER PRICE
-0.66 -3.30

FILE 'CAPLUS' ENTERED AT 16:12:42 ON 26 JUL 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 26 Jul 2004 VOL 141 ISS 5
FILE LAST UPDATED: 25 Jul 2004 (20040725/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> l18 and pd<20010208
66 L18
21324333 PD<20010208
(PD<20010208)
L19 32 L18 AND PD<20010208

=> d l19 1-4 all

L19 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:327200 CAPLUS Full-text
DN 140:333565
ED Entered STN: 22 Apr 2004
TI Mice having a mutant superoxide dismutase SOD-1 transgene, and diagnostic and therapeutic use for neurodegenerative diseases
IN Brown, Robert; Horvitz, H. Robert; Rosen, Daniel R.
PA Massachusetts Institute of Technology, USA; The General Hospital Corporation, Inc.
SO U.S., 54 pp., Cont.-in-part of U.S. Ser. No. 23,980.
CODEN: USXXAM
DT Patent
LA English
IC ICM A01K067-00
ICS A01K067-033; A01K067-02; G01N033-00
NCL 800018000; 800009000; 800003000
CC 3-2 (Biochemical Genetics)
Section cross-reference(s): 1, 7, 13
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6723893	B1	20040420	US 1994-204052	19940228
US 5843641	A	19981201	US 1993-23980	19930226 <--
CA 2157041	AA	19940901	CA 1994-2157041	19940228 <--
US 5849290	A	19981215	US 1995-486953	19950607 <--
PRAI US 1993-23980	A2	19930226		
US 1994-204052	A3	19940228		

AB Disclosed is the family of genes responsible for the neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis. Methods and compds. for the diagnosis, prevention, and therapy of the disease are also disclosed.
ST mouse mutant superoxide dismutase SOD1 gene diagnosis neurodegenerative disease
IT Gene, animal
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(SOD-1 (superoxide dismutase); mice having mutant superoxide dismutase SOD-1 transgene, and diagnostic and therapeutic use for neurodegenerative diseases)
IT Nervous system, disease
(amyotrophic lateral sclerosis, diagnosis and treatment of; mice having mutant superoxide dismutase SOD-1 transgene, and diagnostic and therapeutic use for neurodegenerative diseases)
IT Nervous system, disease
(degeneration, diagnosis and treatment of; mice having mutant superoxide dismutase SOD-1 transgene, and diagnostic and therapeutic use for neurodegenerative diseases)
IT Transgene
RL: BPN (Biosynthetic preparation); BIOL (Biological study); PREP (Preparation)
(for mutant SOD-1; mice having mutant superoxide dismutase SOD-1 transgene, and diagnostic and therapeutic use for neurodegenerative diseases)
IT Diagnosis
(genetic; mice having mutant superoxide dismutase SOD-1 transgene, and diagnostic and therapeutic use for neurodegenerative diseases)
IT Molecular cloning
Susceptibility (genetic)
(mice having mutant superoxide dismutase SOD-1 transgene, and diagnostic and therapeutic use for neurodegenerative diseases)
IT Promoter (genetic element)
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(mice having mutant superoxide dismutase SOD-1 transgene, and diagnostic and therapeutic use for neurodegenerative diseases)
IT Mutation
(on SOD-1 gene; mice having mutant superoxide dismutase SOD-1 transgene, and diagnostic and therapeutic use for neurodegenerative diseases)
IT Mus
(transgenic; mice having mutant superoxide dismutase SOD-1 transgene, and diagnostic and therapeutic use for neurodegenerative diseases)
IT 9054-89-1P, Superoxide dismutase
RL: BPN (Biosynthetic preparation); DGN (Diagnostic use); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(mice having mutant superoxide dismutase SOD-1 transgene, and diagnostic and therapeutic use for neurodegenerative diseases)
IT 680294-80-8, 1: PN: US6723893 SEQID: 1 unclaimed DNA 680294-81-9, 2: PN: US6723893 SEQID: 2 unclaimed DNA 680294-82-0, 3: PN: US6723893 SEQID: 3 unclaimed DNA 680294-83-1 680294-84-2 680294-85-3 680294-86-4 680294-87-5 680294-88-6 680294-89-7 680294-90-0 680294-91-1 680294-92-2 680294-93-3 680294-94-4 680294-95-5 680294-96-6 680295-07-2
RL: PRP (Properties)
(unclaimed nucleotide sequence; mice having a mutant superoxide dismutase SOD-1 transgene, and diagnostic and therapeutic use for neurodegenerative diseases)
IT 680294-97-7 680294-98-8 680294-99-9 680295-00-5 680295-01-6 680295-02-7 680295-03-8 680295-04-9 680295-05-0 680295-06-1 680295-08-3 680295-09-4 680295-10-7
RL: PRP (Properties)
(unclaimed protein sequence; mice having a mutant superoxide dismutase SOD-1 transgene, and diagnostic and therapeutic use for neurodegenerative diseases)
IT 680209-82-9 680209-83-0 680209-84-1 680209-85-2 680209-86-3 680209-87-4 680209-88-5 680209-89-6 680209-90-9 680209-91-0 680209-92-1 680209-93-2 680209-94-3 680209-95-4 680209-96-5 680209-97-6 680209-98-7 680209-99-8 680210-00-8 680210-01-9 680210-02-0 680210-03-1
RL: PRP (Properties)
(unclaimed sequence; mice having a mutant superoxide dismutase SOD-1 transgene, and diagnostic and therapeutic use for neurodegenerative diseases)
RE.CNT 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Anon; WO 9104315 1991 CAPLUS
(2) Anon; WO 9205178 1992 CAPLUS
(3) Beauchamp, C; Analytical Biochemistry 1971, V44, P276 CAPLUS
(4) Beckman; PNAS USA 1990, V87, P1620 CAPLUS
(5) Beckman, J; J of Biological Chemistry 1988, V263, P6884 CAPLUS
(6) Bowling, A; Journal of Neurochemistry 1993, V61, P2322 CAPLUS
(7) Bracco, F; Superoxide Dismutase in CSF 1990, V196, P36
(8) Brock; The Lancet 1993, V342, P1050
(9) Carlioz, A; EMBO Journal 1986, V5, P623 CAPLUS
(10) Ceballos, I; Neuroscience Letters 1989, V105, P41 CAPLUS
(11) Chang; J Biological Chemistry 1991, V266, P4417 CAPLUS
(12) Cho, J; Human superoxidedismutase gene preparation-by cloning cDNA, chemical synthesis and mutation
(13) Crapo; PNAS USA 1992, V89, P10405 CAPLUS
(14) Deng, H; Science 1993, V261, P1047 CAPLUS
(15) Djinovic; J Molecular Biology 1992, V225, P791 CAPLUS
(16) Eisen, A; Canadian Journal of Neurological Sciences 1993, V20, P286
MEDLINE
(17) Elroy-Stein; EMBO Journal 1986, V5, P615 CAPLUS
(18) Epstein; PNAS USA 1987, V84, P8044 CAPLUS
(19) Groner; US 5196335 A 1993 CAPLUS
(20) Hallewell; US 5066591 A 1991 CAPLUS
(21) Hallewell; US 5084390 A 1992 CAPLUS
(22) Hallewell; Biochem Biophys Research Comm 1991, V181, P474 CAPLUS
(23) Hallewell, R; Biology and Medicine 1986, P249 CAPLUS
(24) Halliwell, B; FASEB Journal 1987, V1, P358 CAPLUS
(25) Hartmann, H; Medical Hypotheses 1992, V38, P75 CAPLUS
(26) Hjalmarsson, K; Proc Natl Acad Sci USA 1987, V84, P6340 CAPLUS
(27) Huang, T; FASEB Journal 1992, V6, P903 CAPLUS
(28) Hudson, A; Brain 1981, V104, P217 MEDLINE
(29) Imlay, J; Science 1988, V240, P640 CAPLUS
(30) Jabusch; Biochemistry 1980, V19, P2310 CAPLUS
(31) Kirby; Analyt Biochemistry 1982, V127, P435

CAPLUS
(32) Krall; J Biological Chemistry 1988, V263, P1910 CAPLUS
(33) Lannfelt; Behav Brain Res 1993, V57, P207 CAPLUS
(34) Leopock; J Biol Chem 1990, V265(216), P21612
(35) Levanon, D; EMBO Journal 1985, V4, P77 CAPLUS
(36) Lieman-Hurwitz; PNAS USA 1982, V79, P2808 CAPLUS
(37) Liu, T; American Journal of Physiology 1989, V256, P589
(38) Malinowski; Biochemistry 1979, V18, P5055 CAPLUS
(39) Marklund; US 5248603 A 1993 CAPLUS
(40) McCord, J; Journal of Biological Chemistry 1969, V244, P6049 CAPLUS
(41) Misra; Analyt Biochemistry 1977, V79, P553 CAPLUS
(42) Mullins; Hypertension 1993, V22, P630 MEDLINE
(43) Ogasawara; Nature Genetics 1993, V5, P323
(44) Olanow, C; Annals of Neurology 1992, V32, Ps2 CAPLUS
(45) Oury, T; Proc Natl Acad Sci USA 1992, V89, P9715 CAPLUS
(46) Oyanagui; Analyt Biochemistry 1984, P290 CAPLUS
(47) Parge; J Biological Chem 1986, V261, P16215 CAPLUS
(48) Parge; PNAS USA 1992, V89, P6109 CAPLUS
(49) Rosen; Nature 1993, V362, P59 CAPLUS
(50) Sawada; Biochem Biophys Acta 1973, V327, P257 CAPLUS
(51) Sherman; Human Cu/Zn superoxide dismutase gene:molecular characterization of its two mRNA species 1984, V12, P9349 CAPLUS
(52) Sherman; PNAS USA 1983, V80, P5465 CAPLUS
(53) Siddique, T; New England Journal of Medicine 1991, V324, P1381 MEDLINE
(54) Spitz; Analyt Biochem 1989, V179, P8 CAPLUS
(55) Wispe, J; Biochimica et Biophysica Acta 1989, V994, P30 CAPLUS
(56) Yim, M; Journal of Biological Chemistry 1993, V268, P4099 CAPLUS

L19 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:329822 CAPLUS Full-text
DN 135:148786
ED Entered STN: 09 May 2001
TI Energetics of target peptide binding by calmodulin reveals different modes of binding
AU Brokx, Richard D.; Lopez, Maria M.; Vogel, Hans J.; Makhatadze, George I.
CS Department of Biological Sciences, University of Calgary, Calgary, AB, T2N 1N4, Can.
SO Journal of Biological Chemistry (2001), 276(17), 14083-14091
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English
CC 6-3 (General Biochemistry)
AB Thermodn. parameters of interactions of calcium-satd. calmodulin (Ca2+-CaM) with melittin, C-terminal fragment of melittin, or peptides derived from the CaM binding regions of constitutive (cerebellar) nitric-oxide synthase, cyclic nucleotide phosphodiesterase, calmodulin-dependent protein kinase I, and caldesmon (CaD-A, CaD-A*) have been measured using isothermal titration calorimetry. The peptides could be separated into two groups according to the change in heat capacity upon complex formation, ΔCp. The calmodulin-dependent protein kinase I, constitutive (cerebellar) nitric-oxide synthase, and melittin peptides have ΔCp values clustered around -3.2 kJ•mol-1•K-1, consistent with the formation of a globular CaM-peptide complex in the canonical fashion. In contrast, phosphodiesterase, the C-terminal fragment of melittin, CaD-A, and CaD-A* have ΔCp values clustered around -1.6 kJ•mol-1•K-1, indicative of interactions between the peptide and mostly one lobe of CaM, probably the C-terminal lobe. It is also shown that the interactions for different peptides with Ca2+-CaM can be either enthalpically or entropically driven. The difference in the energetics of peptide/Ca2+-CaM complex formation appears to be due to the coupling of peptide/Ca2+-CaM complex formation to the coil-helix transition of the peptide. The binding of a helical peptide to Ca2+-CaM is dominated by favorable entropic effects, which are probably mostly due to hydrophobic interactions between nonpolar groups of the peptide and Ca2+-CaM. Applications of these findings to the design of potential CaM inhibitors are discussed.
ST calmodulin peptide binding model conformation transition
IT Calmodulins
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(complexes with peptides; energetics of target peptide binding by calmodulin reveals different modes of binding)
IT Conformational transition
Molecular modeling
(energetics of target peptide binding by calmodulin reveals different modes of binding)
IT 123168-46-7 137133-62-1 153478-23-0 154132-94-2 172960-20-2 205598-38-5 220948-89-0 352707-33-6 352707-34-7
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(complexes with calmodulin; energetics of target peptide binding by calmodulin reveals different modes of binding)
RE.CNT 97 THERE ARE 97 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Amzel, L; Proteins 1997, V28, P144 CAPLUS
(2) Babu, Y; J. Mol Biol 1988, V204, P191 CAPLUS
(3) Baker, E; Biophys J 1996, V71, P2049 CAPLUS
(4) Baker, E; J Mol Biol 1997, V268, P557 CAPLUS
(5) Baldwin, R; Trends Biochem Sci 1999, V24, P26 CAPLUS
(6) Baldwin, R; Trends Biochem Sci 1999, V24, P77 CAPLUS
(7) Barbato, G; Biochemistry 1992, V31, P5269 CAPLUS
(8) Bayley, P; Protein Sci 1996, V5, P1215 CAPLUS
(9) Bluementhal, D; Proc Natl Acad Sci U.S.A. 1985, V82, P3187
(10) Blumenthal, D; Biochemistry 1982, V21, P2386 CAPLUS
(11) Charbonneau, H; Biochemistry 1991, V30, P7931 CAPLUS
(12) Chattopadhyaya, R; J Mol Biol 1992, V228, P1177 CAPLUS
(13) Comte, M; Biochem J 1983, V209, P269 CAPLUS
(14) Cox, J; J Biol Chem 1985, V260, P2527 CAPLUS
(15) Crivici, A; Annu Rev Biophys Biomol Struct 1995, V24, P85 CAPLUS
(16) DeGrado, W; J Cell Biochem 1985, V29, P83 CAPLUS
(17) Dunitz, J; Chem Biol 1995, V2, P709 CAPLUS
(18) Elshorst, B; Biochemistry 1999, V38, P12320 CAPLUS
(19) Erickson-Viitanen, S; Methods Enzymol 1987, V139, P455 CAPLUS
(20) Ferrari, M; Biochemistry 1994, V33, P12896 CAPLUS
(21) Gill, S; Anal Biochem 1989, V182, P319 CAPLUS
(22) Goldberg, J; Cell 1996, V84, P875 CAPLUS
(23) Gomes, A; Arch Biochem Biophys 2000, V379, P28 CAPLUS
(24) Gopalakrishna, R; Biochem Biophys Res Commun 1982, V104, P830 CAPLUS
(25) Gribenko, A; J Mol Biol 1998, V283, P679 CAPLUS
(26) Heidorn, D; Biochemistry 1988, V27, P909 CAPLUS
(27) Heidorn, D; Biochemistry 1989, V28, P6757 CAPLUS
(28) Holtzer, A; Biopolymers 1995, V35, P595 CAPLUS
(29) Ikura, M; Science 1992, V256, P632 CAPLUS
(30) Kauzmann, W; Adv Protein Chem 1959, V14, P1 CAPLUS
(31) Krueger, J; Biochemistry 1997, V36, P6017 CAPLUS
(32) Krueger, J; Biochemistry 1998, V37, P13997 CAPLUS
(33) Krueger, J; Biochemistry 2000, V39, P3979 CAPLUS
(34) Kuboniwa, H; Nat Struct Biol 1995, V2, P768 CAPLUS
(35) Lazaridis, T; Adv Protein Chem 1995, V47, P231 CAPLUS
(36) Lee, A; Nat Struct Biol 2000, V7, P72 CAPLUS
(37) Lopez, M; J Biol Chem 1999, V274, P33601 CAPLUS
(38) Lumry, R; Biopolymers 1970, V9, P1125 CAPLUS
(39) Luque, I; Biochemistry 1998, V37, P5791 CAPLUS
(40) Makhatadze, G; Adv Protein Chem 1995, V47, P307 CAPLUS
(41) Makhatadze, G; J Mol Biol 1990, V213, P375 CAPLUS
(42) Makhatadze, G; Nat Struct Biol 1995, V2, P852 CAPLUS
(43) Makhatadze, G; Protein Sci 1998, V7, P689 CAPLUS
(44) McCrary, B; J Mol Biol 1998, V276, P203 CAPLUS
(45) Meador, W; Science 1992, V257, P1251 CAPLUS
(46) Meador, W; Science 1993, V262, P1718 CAPLUS
(47) Means, A; Pharmacol Ther 1991, V50, P255 CAPLUS
(48) Milos, M; J Biol Chem 1987, V262, P2746 CAPLUS
(49) Montigiani, S; J Mol Biol 1996, V258, P6 CAPLUS
(50) Murphy, K; Proteins 1993, V15, P113 CAPLUS
(51) Murphy, K; Proteins 1994, V18, P63 CAPLUS
(52) Nelson, M; Protein Sci 1998, V7, P270 CAPLUS
(53) Ohki, S; Biochemistry 1997, V36, P4309 CAPLUS
(54) O'Neil, K; Trends Biochem 1990, V15, P59 CAPLUS
(55) Petrosian, S; Protein Sci 2000, V9, P387 CAPLUS
(56) Petrosian, S; Proteins 1998, V33, P159
(57) Privalov, P; J Mol Biol 1990, V213, P385 CAPLUS
(58) Protasevich, I; Biochemistry 1997, V36, P2017 CAPLUS
(59) Putkey, J; J Biol Chem 1983, V258, P11864 CAPLUS
(60) Rhoads, A; FASEB J 1997, V11, P331 CAPLUS
(61) Richardson, J; Biochemistry 1999, V38, P12869 CAPLUS
(62) Rohl, C; Methods Enzymol 1998, V295, P1 CAPLUS
(63) Scholtz, J; Annu Rev Biophys Biomol Struct 1992, V21, P95 CAPLUS
(64) Siivari, K; FEBS Lett 1995, V366, P104 CAPLUS
(65) Sonnenburg, W; J Biol Chem 1995, V270, P30989 CAPLUS
(66) Spolar, R; Biochemistry 1992, V31, P3947 CAPLUS
(67) Spolar, R; Science 1994, V263, P777 CAPLUS
(68) Tamura, A; J Mol Biol 1997, V273, P1048 CAPLUS
(69) Todd, M; Proteins 1999, V36, P147 CAPLUS
(70) Torchinski, Y; Sulphur in Proteins 1980
(71) Torok, K; Biochemistry 1998, V37, P6188 MEDLINE
(72) Trewhella, J; Biochemistry 1990, V29, P9316 CAPLUS
(73) Tsalkova, T; J Mol Biol 1985, V181, P533 CAPLUS
(74) Vogel, H; Biochem Cell Biol 1994, V72, P357 CAPLUS
(75) Vogel, H; FEBS Lett 1983, V157, P241 CAPLUS
(76) Vogel, H; Mol Cell Biochem 1995, V149-150, P3 MEDLINE
(77) Vorherr, T; Biochemistry 1993, V32, P6081 CAPLUS
(78) Wang, E; Biochemistry 1997, V36, P15026 CAPLUS
(79) Watersson, Y; Biochemistry 1993, V32, P7866
(80) Weljie, A; Protein Eng 2000, V13, P59 CAPLUS
(81) Wilcox, W; Protein Sci 1992, V1, P641 CAPLUS
(82) Winder, A; Biopolymers 1971, V10, P1243 CAPLUS
(83) Wintrode, P; J Mol Biol 1997, V266, P1050 CAPLUS
(84) Wiseman, T; Anal Biochem 1989, V179, P131 CAPLUS
(85) Wyman, J; Binding and Linkage 1990
(86) Yap, K; Proteins 1999, V37, P499 CAPLUS
(87) Yuan, T; Biochemistry 1999, V38, P1446 CAPLUS
(88) Yuan, T; Biopolymers 2001, V58, P50 CAPLUS
(89) Yuan, T; J Biol Chem 1999, V274, P8411 CAPLUS
(90) ZXhang, M; Nat Struct Biol 1995, V2, P758
(91) Zhan, Q; J Biol Chem 1991, V266, P21810 CAPLUS
(92) Zhang, M; J Biol Chem 1993, V268, P22420 CAPLUS
(93) Zhang, M; J Biol Chem 1994, V269, P15546 CAPLUS
(94) Zhang, M; J Biol Chem 1994, V269, P981 CAPLUS
(95) Zhang, M; J Biol Chem 1995, V270, P20901 CAPLUS
(96) Zhang, M; Protein Pept Lett 1997, V4, P291 CAPLUS
(97) Zhou, N; Biochemistry 1997, V36, P2817 CAPLUS

L19 ANSWER 3 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:814324 CAPLUS Full-text
DN 134:505
ED Entered STN: 21 Nov 2000
TI Antiangiogenic endostatin peptides, endostatin variants and methods of use
IN Vuori, Kristiina
PA The Burnham Institute, USA
SO PCT Int. Appl., 146 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K038-00
ICS A61K038-04; C07K016-00; C07K017-00; C07K014-00; C12P021-06;
G01N033-574
CC 1-6 (Pharmacology)
FAN.CNT 1
PATENT NO. KIND DATE
APPLICATION NO. DATE
--- --- --- --- ---
PI WO 2000067771 A1 20001116 WO 2000-US12063 20000502 <--

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRAI US 1999-132907P P 19990506
US 1999-353333 A2 19990714
AB The invention provides an endostatin peptide having at least 4-7 endostatin amino acid residues containing substantially the amino acid sequence of RLQD, RAD, DGK/A, or a functional equivalent thereof. The invention also provides an endostatin variant containing the amino acid sequence RGD, or a functional fragment thereof. Methods of inhibiting angiogenesis are also provided.
ST antiangiogenic endostatin peptide sequence
IT Glycosaminoglycans, biological studies
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(-binding peptides; antiangiogenic endostatin peptides, endostatin variants and methods of use)
IT Angiogenic factors
Growth inhibitors, animal
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(angiogenic growth-inhibiting factors; antiangiogenic endostatin peptides, endostatin variants and methods of use)
IT Angiogenesis inhibitors
Cell adhesion
Protein sequences
(antiangiogenic endostatin peptides, endostatin variants and methods of use)
IT RGD peptides
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(antiangiogenic endostatin peptides, endostatin variants and methods of use)
IT Blood vessel
(endothelium; antiangiogenic endostatin peptides, endostatin variants and methods of use)
IT Molecular cloning
(of human endostatin; antiangiogenic endostatin peptides, endostatin variants and methods of use)
IT Collagens, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(type XV, endostatin derived from; antiangiogenic endostatin peptides, endostatin variants and methods of use)
IT Integrins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(αv, -binding peptides; antiangiogenic endostatin peptides, endostatin variants and methods of use)
IT Integrins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(αvβ1, -binding peptides; antiangiogenic endostatin peptides, endostatin variants and methods of use)
IT Integrins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(αvβ3, -binding peptides; antiangiogenic endostatin peptides, endostatin variants and methods of use)
IT Integrins
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(αvβ5, -binding peptides; antiangiogenic endostatin peptides, endostatin variants and methods of use)
IT 9056-36-4, Keratan sulfate 24967-94-0, Chondroitin sulfate b
25322-46-7, Chondroitin sulfate c
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(-binding peptides; antiangiogenic endostatin peptides, endostatin variants and methods of use)
IT 307561-76-8, Endostatin (Mus musculus) 307561-79-1
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
(amino acid sequence; antiangiogenic endostatin peptides, endostatin variants and methods of use)
IT 86579-08-0 110767-10-7 205109-79-1 252681-58-6 307555-20-0
307555-21-1 307555-22-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiangiogenic endostatin peptides, endostatin variants and methods of use)
IT 187888-07-9, Endostatin 307555-23-3 307555-24-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiangiogenic endostatin peptides, endostatin variants and methods of use)
IT 307924-80-7
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
(antiangiogenic endostatin peptides, endostatin variants and methods of use)
IT 274272-70-7 307563-13-9, 3: PN: WO0067771 SEQID: 3 unclaimed DNA
307563-14-0, 5: PN: WO0067771 SEQID: 5 unclaimed DNA 307563-16-2, 7: PN: WO0067771 SEQID: 7 unclaimed DNA 307563-18-4, 13: PN: WO0067771 SEQID: 9 unclaimed DNA 307563-20-8 307563-21-9 307563-22-0 307563-23-1
RL: PRP (Properties)
(unclaimed nucleotide sequence; antiangiogenic endostatin peptides, endostatin variants and methods of use)
IT 224308-23-0 255811-02-0 307563-15-1 307563-17-3 307563-19-5
RL: PRP (Properties)
(unclaimed protein sequence; antiangiogenic endostatin peptides, endostatin variants and methods of use)
IT 307555-25-5 307555-26-6 307555-27-7 307555-28-8 307555-29-9
307555-30-2 307555-31-3 307555-32-4 307555-33-5 307555-34-6
307555-35-7 307555-36-8 307555-37-9 307555-38-0 307555-39-1
307555-40-4 307555-41-5 307555-42-6 307555-43-7 307555-44-8
307555-45-9 307555-46-0 307555-47-1 307555-48-2 307555-49-3
307555-50-6 307555-51-7 307555-52-8 307555-53-9 307555-54-0
307555-55-1 307555-56-2 307555-57-3 307555-58-4 307555-59-5
307555-60-8 307555-61-9 307555-62-0 307555-63-1 307555-64-2
307555-65-3 307555-66-4 307555-67-5 307555-68-6 307555-69-7
307555-70-0 307555-71-1 307555-72-2 307555-73-3 307555-74-4
307555-75-5 307555-76-6 307555-77-7 307555-78-8 307555-79-9
307555-80-2 307555-81-3 307555-82-4 307555-83-5
307555-84-6 307555-85-7 307555-86-8 307555-87-9 307555-88-0
307555-89-1 307555-90-4 307555-91-5 307555-92-6
RL: PRP (Properties)
(unclaimed sequence; antiangiogenic. endostatin peptides, endostatin variants and methods of use)
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Brooks; US 5753230 A 1998 CAPLUS
(2) Koivunen, E; Journal of Biological Chemistry 1993, V268(27), P20205 CAPLUS
(3) La Jolla Cancer Research Foundation; WO 9514714 A1 1995 CAPLUS
(4) Nutt; US 5061693 A 1991 CAPLUS
(5) Oh, S; Proc Natl Acad Sci USA 1994, V91, P4229 CAPLUS
(6) O'Reilly, M; Cell 1997, V88, P277 CAPLUS
(7) Weitz; US 5744457 A 1998 CAPLUS

L19 ANSWER 4 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:780795 CAPLUS Full-text
DN 133:345559
ED Entered STN: 07 Nov 2000
TI Novel angiopoietin-like proteins PSEC0154 and PSEC0166, cDNAs, recombinant expression, and uses
IN Ohta, Norio; Nishikawa, Tetsuo; Kawai, Yumitoshi; Isogai, Takao; Matsumoto, Shunichiro; Sugiyama, Tomoyasu
PA Helix Research Institute, Japan
SO Jpn. Kokai Tokkyo Koho, 28 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
IC ICM C12N015-09
ICS C07K014-515; C07K016-22; C12N001-15; C12N001-19; C12N001-21; C12N005-10; C12P021-02; C12Q001-68
CC 3-2 (Biochemical Genetics)
Section cross-reference(s): 2, 6, 13
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
---------- ---- -------- ---------- --------
PI JP 2000308488 A2 20001107 JP 1999-99901 19990407 <--
PRAI JP 1999-45437 A 19990223
AB Novel human proteins PSEC0154 and PSEC0166, homologous to angiopoietins, their cDNAs, recombinant expression, antibody, and use in screening of ligands, receptors, or cells expressing the receptors, are disclosed. cDNAs for two novel angiopoietin-like proteins were cloned and sequenced. Putative amino acid sequences of those proteins showed homol. to human angiopoietin-1 and angiopoietin-2.
ST angiopoietin like protein PSEC0154 PSEC0166 cDNA sequence human
IT Proteins, specific or class
RL: ARU (Analytical role, unclassified); BOC (Biological occurrence); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)
(PSEC0154; novel angiopoietin-like proteins PSEC0154 and PSEC0166, cDNAs, recombinant expression, and uses)
IT Proteins, specific or class
RL: ARU (Analytical role, unclassified); BOC (Biological occurrence); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)
(PSEC0166; novel angiopoietin-like proteins PSEC0154 and PSEC0166, cDNAs, recombinant expression, and uses)
IT Drug screening
Genetic vectors
Molecular cloning
Protein sequences
cDNA sequences
(novel angiopoietin-like proteins PSEC0154 and PSEC0166, cDNAs, recombinant expression, and uses)
IT Antibodies
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(novel angiopoietin-like proteins PSEC0154 and PSEC0166, cDNAs, recombinant expression, and uses)
IT Receptors
RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study)
(screening of; novel angiopoietin-like proteins PSEC0154 and PSEC0166, cDNAs, recombinant expression, and uses)
IT 221649-76-9P 304885-90-3P 304885-91-4P 304917-32-6P
RL: ARU (Analytical role, unclassified); BOC (Biological occurrence); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)
(amino acid sequence; novel angiopoietin-like proteins PSEC0154 and PSEC0166, cDNAs, recombinant expression, and uses)
IT 186270-49-5, Angiopoietin-1 194368-66-6, Angiopoietin-2
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(homol. to; novel angiopoietin-like proteins PSEC0154 and PSEC0166, cDNAs, recombinant expression, and uses)
IT 304917-29-1 304917-31-5
RL: BOC (Biological occurrence); BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence); PROC (Process); USES (Uses)

```
      (nucleotide sequence; novel
angiopoietin-like proteins PSEC0154 and
      PSEC0166, cDNAs, recombinant expression,
and uses)
IT   273950-43-9   304920-06-7   304920-07-8
321754-46-5, 4: PN: WO0173024
     SEQID: 5 unclaimed DNA
     RL: PRP (Properties)
      (unclaimed nucleotide sequence; novel
angiopoietin-like proteins
      PSEC0154 and PSEC0166, cDNAs,
recombinant expression, and uses)


=> d his

     (FILE 'HOME' ENTERED AT 15:51:43 ON 26 JUL
2004)

     FILE 'REGISTRY' ENTERED AT 15:51:52 ON 26
JUL 2004
L1       898099 S A[VTI][PA][GAVLIPSTCMNQ]/SQSP

     FILE 'CAPLUS' ENTERED AT 15:52:42 ON 26 JUL
2004

     FILE 'REGISTRY' ENTERED AT 15:52:49 ON 26
JUL 2004
L2             0 S L1 AND PD<20010208
L3          5628 L1 AND SQL<=20
L4          1977 L3 AND SQL<=10
L5            75 L4 AND SQL=4
L6          1903 L4 AND SQL>=5
L7            74 L4 NOT L6
L8             0 L7 NOT L5

     FILE 'CAPLUS' ENTERED AT 15:59:09 ON 26 JUL
2004
               S A[VTI][PA][GAVLIPSTCMNQ]/SQSP

     FILE 'REGISTRY' ENTERED AT 16:01:38 ON 26
JUL 2004
L9       289282 S L1 AND (PATENT)/DT

     FILE 'CAPLUS' ENTERED AT 16:02:37 ON 26 JUL
2004

     FILE 'REGISTRY' ENTERED AT 16:03:01 ON 26
JUL 2004

     FILE 'CAPLUS' ENTERED AT 16:03:04 ON 26 JUL
2004
L10            0 L6 AND SQL=6

     FILE 'REGISTRY' ENTERED AT 16:05:22 ON 26
JUL 2004
L11          172 L6 AND SQL=6
L12       430210 S A[VTI][PA][SFYVI]/SQSP
L13          208 L12 AND SQL=10
L14          148 L12 AND SQL=20
L15          430 L12 AND SQL=50
L16          163 L12 AND SQL=25
L17           73 L12 AND SQL=23
L18           74 L12 AND SQL=22

     FILE 'CAPLUS' ENTERED AT 16:12:42 ON 26 JUL
2004
L19           32 L18 AND PD<20010208

=> d l19 1-32 sqd
'SQD' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI
table (default)
CAN --------- List of CA abstract numbers
without answer numbers
CBIB -------- AN, plus Compressed Bibliographic
Data
DALL -------- ALL, delimited (end of each field
identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus
Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent
Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random
display, no answer numbers;
              SCAN must be entered on the same
line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, IPC, and NCL

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data
(original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index
field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its
CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its
CA index name, its
              structure diagram, plus NTE and
SEQ fields
FHITSTR ----- First HIT RN, its text
modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text
modification, its CA index name, its
              structure diagram, plus NTE and
SEQ fields
KWIC -------- Hit term plus 20 words on either
side
OCC --------- Number of occurrence of hit term
and field in which it occurs

To display a particular field or fields, enter
the display field
codes.  For a list of the display field codes,
enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats
include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format
fields in any order and the
information will be displayed in the same order
as the format
specification.

All of the formats (except for SAM, SCAN, HIT,
HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be
used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):d l19 1-32 fhitseq
'D' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'
'L19' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'
'1-32' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI
table (default)
CAN --------- List of CA abstract numbers
without answer numbers
CBIB -------- AN, plus Compressed Bibliographic
Data
DALL -------- ALL, delimited (end of each field
identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus
Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent
Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SO
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random
display, no answer numbers;
              SCAN must be entered on the same
line as the DISPLAY,
              e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, IPC, and NCL

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data
(original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index
field (ST and IT)
              containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its
CA index name, and
              its structure diagram
HITSEQ ------ HIT RN, its text modification, its
CA index name, its
              structure diagram, plus NTE and
SEQ fields
FHITSTR ----- First HIT RN, its text
modification, its CA index name, and
              its structure diagram
FHITSEQ ----- First HIT RN, its text
modification, its CA index name, its
              structure diagram, plus NTE and
SEQ fields
KWIC -------- Hit term plus 20 words on either
side
OCC --------- Number of occurrence of hit term
and field in which it occurs

To display a particular field or fields, enter
the display field
codes.  For a list of the display field codes,
enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats
include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format
fields in any order and the
information will be displayed in the same order
as the format
specification.

All of the formats (except for SAM, SCAN, HIT,
HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be
used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):hitseq

L19  ANSWER 1 OF 32  CAPLUS  COPYRIGHT 2004 ACS
on STN
IT   680210-01-9 680210-03-1
     RL: PRP (Properties)
       (unclaimed sequence; mice having a
mutant superoxide dismutase SOD-1
       transgene, and diagnostic and
therapeutic use for neurodegenerative
       diseases)
RN   680210-01-9  CAPLUS
CN   L-Glutamic acid, L-methionyl-L-valyl-L-
lysyl-L-alanyl-L-valyl-L-alanyl-L-
     valyl-L-leucyl-L-alanylglycyl-L-threonyl-L-
α-aspartyl-L-valyl-L-
     lysylglycyl-L-threonyl-L-isoleucyl-L-
phenylalanyl-L-phenylalanyl-L-seryl-L-
     glutaminyl- (9CI)  (CA INDEX NAME)

SEQ      1 MVKAVAVLAG TDVKGTIFFS QE

Absolute stereochemistry.
```









```
RN   680210-03-1  CAPLUS
CN   L-Alanine, L-valyl-L-glutaminyl-L-alanyl-L-
valyl-L-alanyl-L-valyl-L-leucyl-
     L-lysylglycyl-L-α-aspartyl-L-alanylglycyl-
L-valyl-L-serylglycyl-L-
     valyl-L-valyl-L-lysyl-L-phenylalanyl-L-α-
glutamyl-L-glutaminyl-
     (9CI)  (CA INDEX NAME)

SEQ      1 VQAVAVLKGD AGVSGVVKFE QA

Absolute stereochemistry.
```

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



L19 ANSWER 2 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
IT 205598-38-5
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(complexes with calmodulin; energetics of target peptide binding by calmodulin reveals different modes of binding)
RN 205598-38-5 CAPLUS
CN L-Glutamine, L-alanyl-L-lysyl-L-seryl-L-lysyl-L-tryptophyl-L-lysyl-L-glutaminyl-L-alanyl-L-phenylalanyl-L-asparaginyl-L-alanyl-L-threonyl-L-alanyl-L-valyl-L-valyl-L-arginyl-L-histidyl-L-methionyl-L-arginyl-L-lysyl-L-leucyl- (9CI) (CA INDEX NAME)

SEQ 1 AKSKWKQAFN ATAVVRHMRK LQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A

PAGE 2-B



PAGE 2-C

L19 ANSWER 3 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
IT 307555-82-4
RL: PRP (Properties)
(unclaimed sequence; antiangiogenic endostatin peptides, endostatin variants and methods of use)
RN 307555-82-4 CAPLUS
CN L-Phenylalanine, L-seryl-L-isoleucyl-L-valyl-L-arginyl-L-arginyl-L-alanyl-L-α-aspartyl-L-arginyl-L-alanyl-L-alanyl-L-valyl-L-prolyl-L-isoleucyl-L-valyl-L-asparaginyl-L-leucyl-L-lysyl-L-α-aspartyl-L-α-glutamyl-L-leucyl-L-leucyl- (9CI) (CA INDEX NAME)

SEQ 1 SIVRRADRAA VPIVNLKDEL LF

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 2-B

PAGE 3-A



PAGE 3-B



L19 ANSWER 4 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
IT 304885-91-4P
RL: ARU (Analytical role, unclassified); BOC (Biological occurrence); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation)
(amino acid sequence; novel angiopoietin-like proteins PSEC0154 and PSEC0166, cDNAs, recombinant expression, and uses)
RN 304885-91-4 CAPLUS
CN L-Serine, L-methionyl-L-serylglycyl-L-alanyl-L-prolyl-L-threonyl-L-alanylglycyl-L-alanyl-L-alanyl-L-leucyl-L-methionyl-L-leucyl-L-cysteinyl-L-alanyl-L-alanyl-L-threonyl-L-alanyl-L-valyl-L-leucyl-L-leucyl- (9CI) (CA INDEX NAME)

SEQ 1 MSGAPTAGAA LMLCAATAVL LS

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-C



L19 ANSWER 5 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
IT 286834-36-4P 286834-37-5P 286834-38-6P
286834-39-7P 286834-40-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL
(Biological study); PREP (Preparation)
(amino acid sequence; novel agouti and agouti-related peptide analogs
and uses thereof in modulating feeding behavior)
RN 286834-36-4 CAPLUS
CN L-Leucine, L-cysteinyl-L-alanyl-L-α-aspartyl-L-prolyl-L-alanyl-L-
alanyl-L-threonyl-L-alanyl-L-tyrosyl-L-cysteinyl-L-arginyl-L-phenylalanyl-
L-phenylalanyl-L-asparaginyl-L-alanyl-L-phenylalanyl-L-cysteinyl-L-tyrosyl-
L-cysteinyl-L-arginyl-L-lysyl- (9CI) (CA INDEX NAME)

SEQ 1 CADPAATAYC RFFNAFCYCR KL

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



RN 286834-37-5 CAPLUS
CN L-Leucine, L-cysteinyl-L-alanyl-L-alanyl-L-prolyl-L-alanyl-L-alanyl-L-
threonyl-L-alanyl-L-tyrosyl-L-cysteinyl-L-arginyl-L-phenylalanyl-L-
phenylalanyl-L-asparaginyl-L-alanyl-L-phenylalanyl-L-cysteinyl-L-tyrosyl-L-
cysteinyl-L-arginyl-L-lysyl- (9CI) (CA INDEX NAME)

SEQ 1 CAAPAATAYC RFFNAFCYCR KL

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



RN 286834-38-6 CAPLUS
CN L-Leucine, L-cysteinyl-L-alanyl-L-α-aspartyl-L-prolyl-L-alanyl-L-
alanyl-L-threonyl-L-alanyl-L-tyrosyl-L-cysteinyl-L-alanyl-L-phenylalanyl-L-
phenylalanyl-L-asparaginyl-L-alanyl-L-phenylalanyl-L-cysteinyl-L-tyrosyl-L-
cysteinyl-L-arginyl-L-lysyl- (9CI) (CA INDEX NAME)

SEQ 1 CADPAATAYC AFFNAFCYCR KL

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



RN 286834-39-7 CAPLUS
CN L-Leucine, L-cysteinyl-L-alanyl-L-α-aspartyl-L-prolyl-L-alanyl-L-
alanyl-L-threonyl-L-alanyl-L-tyrosyl-L-cysteinyl-L-arginyl-L-alanyl-L-
phenylalanyl-L-asparaginyl-L-alanyl-L-phenylalanyl-L-cysteinyl-L-tyrosyl-L-
cysteinyl-L-arginyl-L-lysyl- (9CI) (CA INDEX NAME)

SEQ 1 CADPAATAYC RAFNAFCYCR KL

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



RN 286834-40-0 CAPLUS
CN L-Leucine, L-cysteinyl-L-alanyl-L-α-aspartyl-L-prolyl-L-alanyl-L-alanyl-L-threonyl-L-alanyl-L-tyrosyl-L-cysteinyl-L-arginyl-L-phenylalanyl-L-alanyl-L-asparaginyl-L-alanyl-L-phenylalanyl-L-cysteinyl-L-tyrosyl-L-cysteinyl-L-arginyl-L-lysyl- (9CI) (CA INDEX NAME)

SEQ 1 CADPAATAYC RFANAFCYCR KL

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



L19 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
IT 138142-92-4
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(multi-epitope schistosome vaccine candidates tested for protective immunogenicity in mice)
RN 138142-92-4 CAPLUS
CN L-Phenylalanine, L-α-glutamyl-L-asparaginyl-L-leucyl-L-leucyl-L-alanyl-L-seryl-L-seryl-L-prolyl-L-arginyl-L-leucyl-L-alanyl-L-lysyl-L-tyrosyl-L-leucyl-L-seryl-L-asparaginyl-L-arginyl-L-prolyl-L-alanyl-L-threonyl-L-prolyl- (9CI) (CA INDEX NAME)

SEQ 1 ENLLASSPRL AKYLSNRPAT PF

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



L19 ANSWER 7 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
IT 275798-60-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(identification of B-cell and T-cell epitopes of Escherichia coli outer membrane protein F in mouse)
RN 275798-60-2 CAPLUS
CN L-Threonine, L-asparaginyl-L-isoleucyl-L-tyrosyl-L-leucyl-L-alanyl-L-alanyl-L-asparaginyl-L-tyrosylglycyl-L-α-glutamyl-L-threonyl-L-arginyl-L-asparaginyl-L-alanyl-L-threonyl-L-proly-L-isoleucyl-L-threonyl-L-asparaginyl-L-lysyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 NIYLAANYGE TRNATPITNK FT

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



L19 ANSWER 8 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
IT 209623-62-1P, Plantaricin A-22 219528-26-4P,
enantio-Plantaricin A-22
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation); PROC (Process)
(bioactivity and membrane conformation of plantaricin A truncated enantiomers)
RN 209623-62-1 CAPLUS
CN Plantaricin A-22 (9CI) (CA INDEX NAME)

SEQ 1 YSLQMGATAI KQVKKLFKKW GW

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



RN 219528-26-4 CAPLUS
CN enantio-Plantaricin A-22 (9CI) (CA INDEX NAME)

SEQ 1 YSLQMGATAI KQVKKLFKKW GW

Absolute stereochemistry.

PAGE 1-A





PAGE 1-B



PAGE 1-C

PAGE 1-D

L19 ANSWER 9 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
IT 209623-62-1, Plantaricin A-22
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(antagonistic activity of Lactobacillus plantarum C11: two new two-peptide bacteriocins, plantaricins EF and JK, and induction factor plantaricin A)
RN 209623-62-1 CAPLUS
CN Plantaricin A-22 (9CI) (CA INDEX NAME)

SEQ 1 YSLQMGATAI KQVKKLFKKW GW

Absolute stereochemistry.



PAGE 1-A



PAGE 1-B



PAGE 1-C

PAGE 1-D

L19 ANSWER 10 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
IT 205598-38-5
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(CaM kinase I model peptide; tryptophan fluorescence quenching by methionine and selenomethionine residues of calmodulin and orientation of peptide and protein binding)
RN 205598-38-5 CAPLUS
CN L-Glutamine, L-alanyl-L-lysyl-L-seryl-L-lysyl-L-tryptophyl-L-lysyl-L-glutaminyl-L-alanyl-L-phenylalanyl-L-asparaginyl-L-alanyl-L-threonyl-L-alanyl-L-valyl-L-valyl-L-arginyl-L-histidyl-L-methionyl-L-arginyl-L-lysyl-L-leucyl- (9CI) (CA INDEX NAME)

SEQ 1 AKSKWKQAFN ATAVVRHMRK LQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A

PAGE 2-B



PAGE 2-C

L19 ANSWER 11 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
IT 164415-69-4 168217-02-5 168217-04-7 204376-85-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(antisense homol. box-derived peptides as endothelin receptor inhibitors)
RN 164415-69-4 CAPLUS
CN L-Isoleucine, L-valyl-L-leucyl-L-asparaginyl-L-leucyl-L-cysteinyl-L-alanyl-L-leucyl-L-seryl-L-valyl-L-α-aspartyl-L-arginyl-L-tyrosyl-L-arginyl-L-alanyl-L-valyl-L-alanyl-L-seryl-L-tryptophyl-L-seryl-L-arginyl-L-valyl- (9CI) (CA INDEX NAME)

SEQ 1 VLNLCALSVD RYRAVASWSR VI

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-B



PAGE 3-A



PAGE 3-B

RN 168217-02-5 CAPLUS
CN L-Isoleucine, L-valyl-L-leucyl-L-asparaginyl-L-leucyl-L-cysteinyl-L-alanyl-L-leucyl-L-seryl-L-valyl-L-α-aspartyl-L-arginyl-L-tyrosylglycyl-L-alanyl-L-valyl-L-alanyl-L-seryl-L-tryptophyl-L-seryl-L-arginyl-L-valyl- (9CI) (CA INDEX NAME)

SEQ 1 VLNLCALSVD RYGAVASWSR VI

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-B



PAGE 2-C



RN 168217-04-7 CAPLUS
CN L-Isoleucine, L-valyl-L-leucyl-L-asparaginyl-L-leucylglycyl-L-alanyl-L-leucyl-L-seryl-L-valyl-L-α-aspartyl-L-arginyl-L-tyrosyl-L-arginyl-L-alanyl-L-valyl-L-alanyl-L-seryl-L-tryptophyl-L-seryl-L-arginyl-L-valyl- (9CI) (CA INDEX NAME)

SEQ 1 VLNLGALSVD RYRAVASWSR VI

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-B



PAGE 3-A



PAGE 3-B

RN 204376-85-2 CAPLUS
CN L-Isoleucine, L-valyl-L-leucyl-L-asparaginyl-L-leucyl-L-cysteinyl-L-alanyl-L-leucyl-L-seryl-L-valyl-L-α-aspartylglycyl-L-tyrosyl-L-arginyl-L-alanyl-L-valyl-L-alanyl-L-seryl-L-tryptophyl-L-seryl-L-arginyl-L-valyl- (9CI) (CA INDEX NAME)

SEQ 1 VLNLCALSVD GYRAVASWSR VI

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-B



L19 ANSWER 12 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
IT 164415-69-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(endothelin ETA receptor antisense peptide effect on endothelin-induced renal arcuate artery constriction in rats)
RN 164415-69-4 CAPLUS
CN L-Isoleucine, L-valyl-L-leucyl-L-asparaginyl-L-leucyl-L-cysteinyl-L-alanyl-L-leucyl-L-seryl-L-valyl-L-α-aspartyl-L-arginyl-L-tyrosyl-L-arginyl-L-alanyl-L-valyl-L-alanyl-L-seryl-L-tryptophyl-L-seryl-L-arginyl-L-valyl- (9CI) (CA INDEX NAME)

SEQ 1 VLNLCALSVD RYRAVASWSR VI

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-B

PAGE 3-A



PAGE 3-B

L19 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
IT 164415-69-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); MSC (Miscellaneous); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(search of antisense homol. box within protein mol. at amino acid level and its application to design of physiol. active peptides)
RN 164415-69-4 CAPLUS
CN L-Isoleucine, L-valyl-L-leucyl-L-asparaginyl-L-leucyl-L-cysteinyl-L-alanyl-L-leucyl-L-seryl-L-valyl-L-α-aspartyl-L-arginyl-L-tyrosyl-L-arginyl-L-alanyl-L-valyl-L-alanyl-L-seryl-L-tryptophyl-L-seryl-L-arginyl-L-valyl- (9CI) (CA INDEX NAME)

SEQ 1 VLNLCALSVD RYRAVASWSR VI

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-B



PAGE 3-A



PAGE 3-B

L19 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
IT 197159-78-7
RL: PRP (Properties)
(linear B cell epitopes of Env glycoproteins of feline immunodeficiency virus are immunogenically silent in infected cats)
RN 197159-78-7 CAPLUS
CN L-Isoleucine, L-histidyl-L-valyl-L-methionyl-L-leucyl-L-alanyl-L-leucyl-L-alanyl-L-threonyl-L-valyl-L-leucyl-L-seryl-L-isoleucyl-L-alanylglycyl-L-alanylglycyl-L-threonylglycyl-L-alanyl-L-threonyl-L-alanyl- (9CI) (CA INDEX NAME)

SEQ 1 HVMLALATVL SIAGAGTGAT AI

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



L19 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
IT 187607-48-3
RL: PRP (Properties)
(of C-terminal fragment of human membrane-type matrix metalloproteinase-3; novel human membrane-type matrix metalloproteinase-3 and monoclonal antibody specific thereto)
RN 187607-48-3 CAPLUS
CN L-Phenylalanine, L-alanyl-L-isoleucyl-L-alanyl-L-isoleucyl-L-prolyl-L-cysteinyl-L-isoleucyl-L-leucyl-L-alanyl-L-leucyl-L-cysteinyl-L-leucyl-L-leucyl-L-valyl-L-leucyl-L-valyl-L-tyrosyl-L-threonyl-L-valyl-L-phenylalanyl-L-glutaminyl- (9CI) (CA INDEX NAME)

SEQ 1 AIAIPCILAL CLLVLVYTVF QF

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



L19 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
IT 183556-32-3 183556-33-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(structure-antimicrobial activity studies on cecropin P1)
RN 183556-32-3 CAPLUS
CN L-Arginine, L-seryl-L-tryptophyl-L-leucyl-L-alanyl-L-lysyl-L-threonyl-L-alanyl-L-lysyl-L-lysyl-L-leucyl-L-α-glutamylglycyl-L-isoleucyl-L-alanyl-L-isoleucyl-L-alanyl-L-isoleucyl-L-glutaminylglycylglycyl-L-prolyl- (9CI) (CA INDEX NAME)

SEQ 1 SWLAKTAKKL EGIAIAIQGG PR

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-B



PAGE 1-C



PAGE 1-C



PAGE 1-D



PAGE 1-D



RN 183556-33-4 CAPLUS
CN L-Arginine, L-lysyl-L-tryptophyl-L-leucyl-L-lysyl-L-lysyl-L-threonyl-L-alanyl-L-lysyl-L-lysyl-L-leucyl-L-α-glutamylglycyl-L-isoleucyl-L-alanyl-L-isoleucyl-L-alanyl-L-isoleucyl-L-glutaminylglycylglycyl-L-prolyl- (9CI) (CA INDEX NAME)

SEQ 1 KWLKKTAKKL EGIAIAIQGG PR

Absolute stereochemistry.

PAGE 1-A



L19 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
IT 138142-92-4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Schistosoma mansoni peptide and lipopeptide induction of immune response)
RN 138142-92-4 CAPLUS
CN L-Phenylalanine, L-α-glutamyl-L-asparaginyl-L-leucyl-L-leucyl-L-alanyl-L-seryl-L-seryl-L-prolyl-L-arginyl-L-leucyl-L-alanyl-L-lysyl-L-tyrosyl-L-leucyl-L-seryl-L-asparaginyl-L-arginyl-L-prolyl-L-alanyl-L-threonyl-L-prolyl- (9CI) (CA INDEX NAME)

SEQ 1 ENLLASSPRL AKYLSNRPAT PF

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



L19 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
IT 169199-94-4DP, extension peptide derivs. with human thrombopoietin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(polypeptide ligands for the gene c-mpl hemopoietin receptor, their preparation, and application for the production of thrombopoietin and treatment of thrombocytopenias)
RN 169199-94-4 CAPLUS
CN L-Glutamic acid, L-valyl-L-arginyl-L-arginyl-L-alanyl-L-prolyl-L-prolyl-L-threonyl-L-threonyl-L-alanyl-L-valyl-L-prolyl-L-seryl-L-arginyl-L-threonyl-L-seryl-L-leucyl-L-valyl-L-leucyl-L-threonyl-L-leucyl-L-asparaginyl- (9CI) (CA INDEX NAME)

SEQ 1 VRRAPPTTAV PSRTSLVLTL NE

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



L19 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
IT 164415-69-4 168217-02-5 168217-03-6 168217-04-7
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(antisense homol. box is a new motif within proteins that encodes biol. active peptides)
RN 164415-69-4 CAPLUS
CN L-Isoleucine, L-valyl-L-leucyl-L-asparaginyl-L-leucyl-L-cysteinyl-L-alanyl-L-leucyl-L-seryl-L-valyl-L-α-aspartyl-L-arginyl-L-tyrosyl-L-arginyl-L-alanyl-L-valyl-L-alanyl-L-seryl-L-tryptophyl-L-seryl-L-arginyl-L-valyl- (9CI) (CA INDEX NAME)

SEQ 1 VLNLCALSVD RYRAVASWSR VI

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-B



PAGE 3-A



PAGE 3-B

RN 168217-02-5 CAPLUS
CN L-Isoleucine, L-valyl-L-leucyl-L-asparaginyl-L-leucyl-L-cysteinyl-L-alanyl-
L-leucyl-L-seryl-L-valyl-L-α-aspartyl-L-arginyl-L-tyrosylglycyl-L-
alanyl-L-valyl-L-alanyl-L-seryl-L-tryptophyl-L-seryl-L-arginyl-L-valyl-
(9CI) (CA INDEX NAME)

SEQ 1 VLNLCALSVD RYGAVASWSR VI

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-B



PAGE 2-C



RN 168217-03-6 CAPLUS
CN L-Isoleucine, L-valyl-L-leucyl-L-asparaginyl-L-leucyl-L-cysteinyl-L-alanyl-
L-leucyl-L-seryl-L-valyl-L-α-aspartyl-L-arginyl-L-tyrosyl-L-arginyl-
L-alanyl-L-valyl-L-alanyl-L-serylglycyl-L-seryl-L-arginyl-L-valyl- (9CI)
(CA INDEX NAME)

SEQ 1 VLNLCALSVD RYRAVASGSR VI

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 3-A



RN 168217-04-7 CAPLUS
CN L-Isoleucine, L-valyl-L-leucyl-L-asparaginyl-L-leucylglycyl-L-alanyl-L-
leucyl-L-seryl-L-valyl-L-α-aspartyl-L-arginyl-L-tyrosyl-L-arginyl-L-
alanyl-L-valyl-L-alanyl-L-seryl-L-tryptophyl-L-seryl-L-arginyl-L-valyl-
(9CI) (CA INDEX NAME)

SEQ 1 VLNLGALSVD RYRAVASWSR VI

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-B



PAGE 3-A



PAGE 3-B

L19 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
IT 164415-69-4P 164415-75-2P 164415-76-3P
164415-77-4P 164473-34-1P 164473-35-2P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
study); PREP (Preparation); USES (Uses)
(synthetic peptide as endothelin inhibitor)
RN 164415-69-4 CAPLUS
CN L-Isoleucine, L-valyl-L-leucyl-L-asparaginyl-L-leucyl-L-cysteinyl-L-alanyl-
L-leucyl-L-seryl-L-valyl-L-α-aspartyl-L-arginyl-L-tyrosyl-L-arginyl-
L-alanyl-L-valyl-L-alanyl-L-seryl-L-tryptophyl-L-seryl-L-arginyl-L-valyl-
(9CI) (CA INDEX NAME)

SEQ 1 VLNLCALSVD RYRAVASWSR VI

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-B



PAGE 3-A



PAGE 3-B

RN 164415-75-2 CAPLUS
CN L-Isoleucinamide, L-valyl-L-leucyl-L-asparaginyl-L-leucyl-L-cysteinyl-L-alanyl-L-leucyl-L-seryl-L-valyl-L-α-aspartyl-L-arginyl-L-tyrosylglycyl-L-alanyl-L-valyl-L-alanyl-L-seryl-L-tryptophyl-L-seryl-L-arginyl-L-valyl- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 VLNLCALSVD RYGAVASWSR VI

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-B



PAGE 2-C



RN 164415-76-3 CAPLUS
CN L-Isoleucinamide, L-valyl-L-leucyl-L-asparaginyl-L-leucyl-L-cysteinyl-L-alanyl-L-leucyl-L-seryl-L-valyl-L-α-aspartylglycyl-L-tyrosyl-L-arginyl-L-alanyl-L-valyl-L-alanyl-L-seryl-L-tryptophyl-L-seryl-L-arginyl-L-valyl- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 VLNLCALSVD GYRAVASWSR VI

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-B



RN 164415-77-4 CAPLUS
CN L-Isoleucinamide, L-valyl-L-leucyl-L-asparaginyl-L-leucylglycyl-L-alanyl-L-leucyl-L-seryl-L-valyl-L-α-aspartyl-L-arginyl-L-tyrosyl-L-arginyl-L-alanyl-L-valyl-L-alanyl-L-seryl-L-tryptophyl-L-seryl-L-arginyl-L-valyl- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 VLNLGALSVD RYRAVASWSR VI

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-B



PAGE 3-A



PAGE 3-B

RN 164473-34-1 CAPLUS
CN L-Isoleucinamide, L-valyl-L-leucyl-L-asparaginyl-L-leucyl-L-cysteinyl-L-alanyl-L-leucyl-L-seryl-L-valyl-L-α-aspartyl-L-arginyl-L-tyrosyl-L-arginyl-L-alanyl-L-valyl-L-alanyl-L-seryl-L-tryptophyl-L-seryl-L-arginyl-L-valyl- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 VLNLCALSVD RYRAVASWSR VI

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-B



PAGE 3-A



PAGE 3-B

RN 164473-35-2 CAPLUS
CN L-Isoleucinamide, L-valyl-L-leucyl-L-asparaginyl-L-leucyl-L-cysteinyl-L-alanyl-L-leucyl-L-seryl-L-valyl-L-α-aspartyl-L-arginyl-L-tyrosyl-L-arginyl-L-alanyl-L-valyl-L-alanyl-L-serylglycyl-L-seryl-L-arginyl-L-valyl-(9CI) (CA INDEX NAME)

NTE modified

SEQ 1 VLNLCALSVD RYRAVASGSR VI

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 3-A



L19 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
IT 168216-11-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of protected amino(mercapto)hexanoic acid and application to the synthesis of a large cyclic disulfide peptide)
RN 168216-11-3 CAPLUS
CN L-Leucinamide, L-threonyl-L-threonyl-6-[[(4-methylphenyl)methyl]thio]-L-norleucyl-L-threonyl-L-alanyl-L-seryl-L-alanyl-L-arginyl-L-α-glutamyl-L-α-aspartyl-L-leucyl-L-alanyl-L-histidyl-L-leucyl-L-threonyl-L-threonyl-L-threonyl-L-histidyl-L-alanyl-6-[[(4-methylphenyl)methyl]thio]-L-norleucyl-L-histidyl- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 TTATASARED LAHLTTTHAA HL

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



L19 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
IT 99108-25-5, Peptide p 2 (Rous-associated virus 0 clone pAS2 reduced)
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)
(amino acid sequence; HPRS-103 (exogenous avian leukosis virus, subgroup J) has an env gene related to those of endogenous elements EAV-0 and ES1 and an E element found previously only in sarcoma viruses)
RN 99108-25-5 CAPLUS
CN Peptide p 2 (Rous-associated virus 0 clone pAS2 reduced) (9CI) (CA INDEX NAME)

SEQ 1 HCGTAIGCNC ATASAPPPPY VG

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D

CO2H

L19 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
IT 150155-81-0
RL: USES (Uses)
(microbe-resistant plants producing, proteolytic cleavage site-containing fusion proteins in relation to)
RN 150155-81-0 CAPLUS
CN L-Leucine, glycyl-L-methionyl-L-alanyl-L-seryl-L-lysyl-L-alanylglycyl-L-alanyl-L-isoleucyl-L-alanyl-L-isoleucylglycyl-L-lysyl-L-isoleucyl-L-alanyl-L-lysyl-L-valyl-L-alanyl-L-leucyl-L-lysyl-

L-alanyl- (9CI) (CA INDEX NAME)

SEQ 1 GMASKAGAIA IGKIAKVALK AL

Absolute stereochemistry.







L19 ANSWER 24 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
IT 147000-47-3 147000-53-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(antibacterial activity of, structure in relation to)
RN 147000-47-3 CAPLUS
CN Cecropin A (Platysamia cecropia antibacterial peptide), 14-de-L-asparagine-15-de-L-isoleucine-16-de-L-arginine-17-de-L-aspartic acid-18-deglycine-19-de-L-isoleucine-20-de-L-isoleucine-21-de-L-lysine-22-de-L-alanine-23-deglycine-24-de-L-proline-33-L-threoninamide-34-de-L-glutamine-35-de-L-isoleucine-36-de-L-alanine-37-de-L-lysinamide- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 KWKLFKKIEK VGQAVAVVGQ AT

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 2-B



PAGE 3-A



RN 147000-53-1 CAPLUS
CN L-Lysinamide, L-seryl-L-tryptophyl-L-isoleucyl-L-lysyl-L-arginyl-L-lysyl-L-arginyl-L-glutaminyl-L-glutaminyl-L-alanyl-L-valyl-L-alanyl-L-valyl-L-valylglycyl-L-glutaminyl-L-alanyl-L-threonyl-L-glutaminyl-L-isoleucyl-L-alanyl- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 SWIKRKRQQA VAVVGQATQI AK

PAGE 1-A



PAGE 1-B



PAGE 2-B



PAGE 2-C



L19 ANSWER 25 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
IT 147024-00-8P
RL: PREP (Preparation)
(preparation and immune response to, of Schistosoma mansoni glutathione transferase, structure in)
RN 147024-00-8 CAPLUS
CN L-Phenylalanine, glycyl-L-asparaginyl-L-leucyl-L-leucyl-L-alanyl-L-seryl-L-prolyl-L-arginyl-L-leucyl-L-alanyl-L-lysyl-L-tyrosyl-L-leucyl-L-seryl-L-asparaginyl-L-arginyl-L-prolyl-L-alanyl-L-threonyl-L-prolyl- (9CI) (CA INDEX NAME)

SEQ 1 GNLLASSPRL AKYLSNRPAT PF

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

PAGE 1-B



PAGE 1-C



L19 ANSWER 26 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
IT 99108-24-4, Peptide p 2 (avian endogenous retrovirus ev-1 clone pGD27 reduced)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence of, structure in)
RN 99108-24-4 CAPLUS
CN Peptide p 2 (avian endogenous retrovirus ev-1 clone pGD27 reduced) (9CI) (CA INDEX NAME)

SEQ 1 QCGTATGCNC ATASAPPPPY VG

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



L19 ANSWER 27 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
IT 139481-13-3
RL: PRP (Properties)
(amino acid sequence of)
RN 139481-13-3 CAPLUS
CN L-Methionine, L-valyl-L-serylglycylglycyl-L-valyl-L-tryptophyl-L-α-aspartyl-L-seryl-L-seryl-L-valyl-L-α-glutamyl-L-threonyl-L-asparaginyl-L-alanyl-L-threonyl-L-alanyl-L-seryl-L-leucyl-L-valyl-L-seryl-L-α-glutamyl- (9CI) (CA INDEX NAME)

SEQ 1 VSGGVWDSSV ETNATASLVS EM

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-C



L19 ANSWER 28 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
IT 138142-92-4P
RL: PREP (Preparation)
(preparation of, as Schistosoma mansoni P28 antigen residues 190-211 analog, immune recognition of, in infected animals)
RN 138142-92-4 CAPLUS
CN L-Phenylalanine, L-α-glutamyl-L-asparaginyl-L-leucyl-L-leucyl-L-alanyl-L-seryl-L-seryl-L-prolyl-L-arginyl-L-leucyl-L-alanyl-L-lysyl-L-tyrosyl-L-leucyl-L-seryl-L-asparaginyl-L-arginyl-L-prolyl-L-alanyl-L-threonyl-L-prolyl- (9CI) (CA INDEX NAME)

SEQ 1 ENLLASSPRL AKYLSNRPAT PF

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



L19 ANSWER 29 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
IT 127316-74-9P
RL: PREP (Preparation)
(of carcinoembryonic antigen, monoclonal antibodies to, preparation and characterization of)
RN 127316-74-9 CAPLUS
CN L-Alanine, L-asparaginyl-L-seryl-L-lysyl-L-prolyl-L-valyl-L-α-glutamyl-L-α-aspartyl-L-lysyl-L-α-aspartyl-L-alanyl-L-valyl-L-alanyl-L-phenylalanyl-L-threonyl-L-cysteinyl-L-α-glutamyl-L-prolyl-L-α-glutamyl-L-threonyl-L-glutaminyl-L-α-asparty- (9CI) (CA INDEX NAME)

SEQ 1 NSKPVEDKDA VAFTCEPETQ DA

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



PAGE 2-C



L19 ANSWER 30 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
IT 127316-74-9
RL: BIOL (Biological study)
(monoclonal antibodies to, preparation of, antigen CEA in relation to)
RN 127316-74-9 CAPLUS
CN L-Alanine, L-asparaginyl-L-seryl-L-lysyl-L-prolyl-L-valyl-L-α-glutamyl-L-α-aspartyl-L-lysyl-L-α-aspartyl-L-alanyl-L-valyl-L-alanyl-L-phenylalanyl-L-threonyl-L-cysteinyl-L-α-glutamyl-L-prolyl-L-α-glutamyl-L-threonyl-L-glutaminyl-L-α-asparty- (9CI) (CA INDEX NAME)

SEQ 1 NSKPVEDKDA VAFTCEPETQ DA

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A



PAGE 2-C



L19 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
IT 99108-24-4 99108-25-5
RL: PRP (Properties)
(amino acid sequence of)

RN 99108-24-4 CAPLUS
CN Peptide p 2 (avian endogenous retrovirus ev-1 clone pGD27 reduced) (9CI) (CA INDEX NAME)

SEQ 1 QCGTATGCNC ATASAPPPPY VG

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



RN 99108-25-5 CAPLUS
CN Peptide p 2 (Rous-associated virus 0 clone pAS2 reduced) (9CI) (CA INDEX NAME)

SEQ 1 HCGTAIGCNC ATASAPPPPY VG

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D

L19 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2004 ACS on STN
IT 94040-24-1
RL: PRP (Properties)
(signal peptide, construction of cloning vector plasmids containing
DNA-specifying)
RN 94040-24-1 CAPLUS
CN L-Threonine, L-methionyl-L-arginyl-L-prolyl-L-seryl-L-isoleucyl-L-histidyl-
L-arginyl-L-threonyl-L-alanyl-L-isoleucyl-L-alanyl-L-alanyl-L-valyl-L-
leucyl-L-alanyl-L-threonyl-L-alanyl-L-phenylalanyl-L-valyl-L-alanylglycyl-
(9CI) (CA INDEX NAME)

SEQ 1 MRPSIHRTAI AAVLATAFVA GT

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



=> d l19 1 sqd 1,3
'SQD' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'

The following are valid formats:

ABS --------- GI and AB
ALL --------- BIB, AB, IND, RE
APPS -------- AI, PRAI
BIB --------- AN, plus Bibliographic Data and PI table (default)
CAN --------- List of CA abstract numbers without answer numbers
CBIB -------- AN, plus Compressed Bibliographic Data
DALL -------- ALL, delimited (end of each field identified)
DMAX -------- MAX, delimited for post-processing
FAM --------- AN, PI and PRAI in table, plus Patent Family data
FBIB -------- AN, BIB, plus Patent FAM
IND --------- Indexing data
IPC --------- International Patent Classifications
MAX --------- ALL, plus Patent FAM, RE
PATS -------- PI, SQ
SAM --------- CC, SX, TI, ST, IT
SCAN -------- CC, SX, TI, ST, IT (random display, no answer numbers;
SCAN must be entered on the same line as the DISPLAY,
e.g., D SCAN or DISPLAY SCAN)
STD --------- BIB, IPC, and NCL

IABS -------- ABS, indented with text labels
IALL -------- ALL, indented with text labels
IBIB -------- BIB, indented with text labels
IMAX -------- MAX, indented with text labels
ISTD -------- STD, indented with text labels

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

HIT --------- Fields containing hit terms
HITIND ------ IC, ICA, ICI, NCL, CC and index field (ST and IT)
containing hit terms
HITRN ------- HIT RN and its text modification
HITSTR ------ HIT RN, its text modification, its CA index name, and
its structure diagram
HITSEQ ------ HIT RN, its text modification, its

```
CA index name, its
            structure diagram, plus NTE and
SEQ fields
FHITSTR ----- First HIT RN, its text
modification, its CA index name, and
            its structure diagram
FHITSEQ ----- First HIT RN, its text
modification, its CA index name, its
            structure diagram, plus NTE and
SEQ fields
KWIC -------- Hit term plus 20 words on either
side
OCC --------- Number of occurrence of hit term
and field in which it occurs

To display a particular field or fields, enter
the display field
codes.  For a list of the display field codes,
enter HELP DFIELDS at
an arrow prompt (=>).  Examples of formats
include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO.  You may specify the format
fields in any order and the
information will be displayed in the same order
as the format
specification.

All of the formats (except for SAM, SCAN, HIT,
HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be
used with DISPLAY ACC
to view a specified Accession Number.
ENTER DISPLAY FORMAT (BIB):end

=> fil reg
COST IN U.S. DOLLARS
SINCE FILE       TOTAL

ENTRY    SESSION
FULL ESTIMATED COST
242.02      426.39

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
SINCE FILE       TOTAL

ENTRY    SESSION
CA SUBSCRIBER PRICE
-2.94       -6.24

FILE 'REGISTRY' ENTERED AT 16:22:04 ON 26 JUL
2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER
AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society
(ACS)

Property values tagged with IC are from the
ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   25 JUL 2004  HIGHEST
RN 716315-35-4
DICTIONARY FILE UPDATES:  25 JUL 2004  HIGHEST
RN 716315-35-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 21,
2004

  Please note that search-term pricing does
apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP
CROSSOVER for details.

Experimental and calculated property data are
now available.  For more
information enter HELP PROP at an arrow prompt
in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registrysss.html

=> d l19 1 sqd
YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' -
CONTINUE? (Y)/N:n

=> d his

     (FILE 'HOME' ENTERED AT 15:51:43 ON 26 JUL
2004)

     FILE 'REGISTRY' ENTERED AT 15:51:52 ON 26
JUL 2004
L1        898099 S A[VTI][PA][GAVLIPSTCMNQ]/SQSP

     FILE 'CAPLUS' ENTERED AT 15:52:42 ON 26 JUL
2004

     FILE 'REGISTRY' ENTERED AT 15:52:49 ON 26
JUL 2004
L2              0 S L1 AND PD<20010208
L3           5628 L1 AND SQL<=20
L4           1977 L3 AND SQL<=10
L5             75 L4 AND SQL=4
L6           1903 L4 AND SQL>=5
L7             74 L4 NOT L6
L8              0 L7 NOT L5

     FILE 'CAPLUS' ENTERED AT 15:59:09 ON 26 JUL
2004
                  S A[VTI][PA][GAVLIPSTCMNQ]/SQSP

     FILE 'REGISTRY' ENTERED AT 16:01:38 ON 26
JUL 2004
L9         289282 S L1 AND (PATENT)/DT

     FILE 'CAPLUS' ENTERED AT 16:02:37 ON 26 JUL
2004

     FILE 'REGISTRY' ENTERED AT 16:03:01 ON 26
JUL 2004

     FILE 'CAPLUS' ENTERED AT 16:03:04 ON 26 JUL
2004
L10             0 L6 AND SQL=6

     FILE 'REGISTRY' ENTERED AT 16:05:22 ON 26
JUL 2004
L11           172 L6 AND SQL=6
L12        430210 S A[VTI][PA][SFYVI]/SQSP
L13           208 L12 AND SQL=10
L14           148 L12 AND SQL=20
L15           430 L12 AND SQL=50
L16           163 L12 AND SQL=25
L17            73 L12 AND SQL=23
L18            74 L12 AND SQL=22

     FILE 'CAPLUS' ENTERED AT 16:12:42 ON 26 JUL
2004
L19            32 L18 AND PD<20010208

     FILE 'REGISTRY' ENTERED AT 16:22:04 ON 26
JUL 2004

=> d l18 1 sqd

L18  ANSWER 1 OF 74  REGISTRY  COPYRIGHT 2004
ACS on STN
RN   710729-80-9  REGISTRY
FS   PROTEIN SEQUENCE
SQL  22
NTE
----------------------------------------------
----------------------
 type            ------ location ------
description
----------------------------------------------
----------------------
uncommon          Aaa-14          -         -
----------------------------------------------
----------------------

SEQ      1 SSPVTKSFNR GECXMKKTAI AI
                              == ==
HITS AT:   19-22

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

=> d l18 1

L18  ANSWER 1 OF 74  REGISTRY  COPYRIGHT 2004
ACS on STN
RN   710729-80-9  REGISTRY
CN   Peptide, (Ser-Ser-Pro-Val-Thr-Lys-Ser-Phe-
Asn-Arg-Gly-Glu-Cys-Xaa-Met-Lys-
     Lys-Thr-Ala-Ile-Ala-Ile) (9CI)  (CA INDEX
NAME)
FS   PROTEIN SEQUENCE
MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER
DT.CA  CAplus document type:  Patent
RL.P   Roles from patents:  PRP (Properties)

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
*** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY
SEQUENCE ***
              1 REFERENCES IN FILE CA (1907 TO
DATE)
              1 REFERENCES IN FILE CAPLUS (1907
TO DATE)


=> s atpfqeglrtfdqld/sqsp
L20           25 ATPFQEGLRTFDQLD/SQSP

=> s avpiaqk
              0 AVPIAQK
L21           0 AVPIAQK

=> s avpiaqk/sqsp
L22           53 AVPIAQK/SQSP

=> fil caplus
COST IN U.S. DOLLARS
SINCE FILE       TOTAL

ENTRY    SESSION
FULL ESTIMATED COST
67.97       494.36

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
SINCE FILE       TOTAL

ENTRY    SESSION
CA SUBSCRIBER PRICE
0.00        -6.24

FILE 'CAPLUS' ENTERED AT 16:28:29 ON 26 JUL 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER
AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY
(ACS)


Copyright of the articles to which records in
this database refer is
held by the publishers listed in the PUBLISHER
(PB) field (available
for records published or updated in Chemical
Abstracts after December
26, 1996), unless otherwise indicated in the
original publications.
The CA Lexicon is the copyrighted intellectual
property of the
American Chemical Society and is provided to
assist you in searching
databases on STN.  Any dissemination,
distribution, copying, or storing
of this information, without the prior written
consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 26 Jul 2004  VOL 141 ISS 5
FILE LAST UPDATED: 25 Jul 2004  (20040725/ED)

  This file contains CAS Registry Numbers for
easy and accurate
  substance identification.

=> l21 and pd<20010208
              0 L21
     21324333 PD<20010208
                   (PD<20010208)
L23           0 L21 AND PD<20010208

=> l20 and pd<20010208
             20 L20
     21324333 PD<20010208
                   (PD<20010208)
L24           5 L20 AND PD<20010208

=> l22 and pd<20010208
             46 L22
     21324333 PD<20010208
                   (PD<20010208)
L25           7 L22 AND PD<20010208

=> d l25 kwic

L25  ANSWER 1 OF 7  CAPLUS  COPYRIGHT 2004 ACS
on STN
     PATENT NO.          KIND  DATE
APPLICATION NO.  DATE
     ----------------    ----  --------       -----
----------  --------
PI   US 2002081659       A1    20020627       US
2001-925297   20010810
     WO 2000055320       A1    20000921       WO
2000-US5989   20000308 <--
         W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR,
BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE,
             KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MD, MG, MK, MN, MW,
             MX, NO, NZ, PL, PT, RO, RU, SD, SE,
SG, SI, SK, SL, TJ, TM, TR,
             TT, UA, UG, US, UZ, VN, YU, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ,
UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE,
SN, TD, TG
IT   291758-44-6P   291758-45-7P   291758-46-8P
291758-47-9P   291758-48-0P
     438510-46-4P   438510-47-5P   438510-48-6P
438510-49-7P   438510-50-0P
     438510-51-1P   438510-52-2P   438510-53-3P
438510-54-4P   438510-55-5P
     438510-56-6P   438510-57-7P   438510-58-8P
438510-59-9P   438510-60-2P
     438510-61-3P   438510-62-4P   438510-63-5P
438510-64-6P   438510-65-7P
     438510-66-8P   438510-67-9P   438510-68-0P
438510-69-1P   438510-70-4P
     438510-71-5P   438510-72-6P   438510-73-7P
438510-74-8P   438510-75-9P
     438510-76-0P   438510-77-1P   438510-78-2P
438510-79-3P   438510-80-6P
     438510-81-7P   438510-82-8P   438510-83-9P
438510-84-0P   438510-85-1P
     438510-86-2P   438510-87-3P   438510-88-4P
438510-89-5P   438510-90-8P
     438510-91-9P   438510-92-0P   438510-93-1P
438510-94-2P   438510-95-3P
     438510-96-4P   438510-97-5P   438510-98-6P
438510-99-7P   438511-00-3P
     438511-01-4P   438511-02-5P   438511-03-6P
438511-04-7P   438511-05-8P
     438511-06-9P   438511-07-0P   438511-08-1P
438511-09-2P   438511-10-5P
     438511-11-6P   438511-12-7P   438511-13-8P
438511-14-9P   438511-15-0P
     438511-16-1P   438511-17-2P   438511-18-3P
438511-19-4P   438511-20-7P
     438511-21-8P   438511-22-9P   438511-23-0P
438511-24-1P   438511-25-2P
     438511-26-3P   438511-27-4P   438511-28-5P
438511-29-6P   438511-30-9P
```

438511-31-0P 438511-32-1P 438511-33-2P
438511-34-3P 438511-35-4P
438511-36-5P 438511-37-6P 438511-38-7P
438511-39-8P 438511-40-1P
438511-41-2P 438511-42-3P 438511-43-4P
438511-44-5P 438511-45-6P
438511-46-7P 438511-47-8P 438511-48-9P
438511-49-0P 438511-50-3P
438511-51-4P 438511-52-5P 438511-53-6P
438511-54-7P 438511-55-8P
438511-56-9P 438511-57-0P 438511-58-1P
438511-59-2P 438511-60-5P
438511-61-6P 438511-62-7P 438511-63-8P
438511-64-9P 438511-65-0P
438511-66-1P 438511-67-2P 438511-68-3P
438511-69-4P 438511-70-7P
438511-71-8P 438511-72-9P 438511-73-0P
438511-74-1P 438511-75-2P
438511-76-3P 438511-77-4P 438511-78-5P
438511-79-6P
438511-80-9P 438511-81-0P 438511-82-1P
438511-83-2P 438511-84-3P
438511-85-4P 438511-86-5P 438511-87-6P
438511-88-7P 438511-89-8P
438511-90-1P 438511-91-2P 438511-92-3P
438511-93-4P 438511-94-5P
438511-95-6P 438511-96-7P 438511-97-8P
438511-98-9P 438511-99-0P
438512-00-6P 438512-01-7P 438512-02-8P
438512-03-9P 438512-04-0P
438512-05-1P 438512-06-2P 438512-07-3P
438512-08-4P 438512-09-5P
438512-10-8P 438512-11-9P 438512-12-0P
438512-13-1P 438512-14-2P
438512-15-3P 438512-16-4P 438512-17-5P
438512-18-6P 438512-19-7P
438512-20-0P 438512-21-1P 438512-22-2P
438512-23-3P 438512-24-4P
438512-25-5P 438512-26-6P 438512-27-7P
438512-28-8P 438512-29-9P
438512-30-2P 438512-31-3P 438512-32-4P
438512-33-5P 438512-34-6P
438512-35-7P 438512-36-8P 438512-37-9P
438512-38-0P 438512-39-1P
438512-40-4P 438512-41-5P 438512-42-6P
438512-43-7P 438512-44-8P
438512-45-9P 438512-46-0P 438512-47-1P
438512-48-2P 438512-49-3P
438512-50-6P 438512-51-7P 438512-52-8P
438512-53-9P 438512-54-0P
438512-55-1P 438512-56-2P 438512-57-3P
438512-58-4P 438512-59-5P
438512-60-8P 438512-61-9P 438512-62-0P
438512-63-1P 438512-64-2P
438512-65-3P 438512-66-4P 438512-67-5P
438512-68-6P 438512-69-7P
438512-70-0P 438512-71-1P
RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP
(Preparation); USES (Uses)
(amino acid sequence; human pancreatic cancer-associated proteins and their encoding cDNA sequences and antibodies)

=> DIS L25 1-5 FHITSEQ

L25 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
IT 438511-77-4P
RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP
(Preparation); USES (Uses)
(amino acid sequence; human pancreatic cancer-associated proteins and their encoding cDNA sequences and antibodies)
RN 438511-77-4 CAPLUS
CN Pancreas tumor-associated protein (human clone HEBFI18 fragment) (9CI)
(CA INDEX NAME)

SEQ 1 XSFFRYRQCL CVPVVANFKK RCFSELIRPW
HKTVTIGFGV TLCAVPIAQK
51 SEPHSLSSEA LMRRAVSLVT DSTSTFLSQT
TYALIEAITE YTKAVYTLTS
101 LYRQYTSLLG KMNSEEEDEV WQVIIGARAE
MTSKHQEYLK LETTWMTAVG
151 LSEMAAEAAY QTGADQASIT ARNHIQLVKL
QVEEVHQLSR KAETKLAEAQ
201 IEELRQKTQE EGEERAESEQ EAYLRED

L25 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
IT 364604-53-5
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(structural anal. of a functional DIAP1 fragment bound to grim and hid peptides)
RN 364604-53-5 CAPLUS
CN L-Proline, L-alanyl-L-valyl-L-prolyl-L-isoleucyl-L-alanyl-L-glutaminyl-L-lysyl-L-seryl-L-α-glutamyl- (9CI) (CA INDEX NAME)

SEQ 1 AVPIAQKSEP

Absolute stereochemistry.



PAGE 1-A

PAGE 1-B

L25 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
IT 326049-22-3
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; functional annotation of a full-length mouse cDNA collection)
RN 326049-22-3 CAPLUS
CN Protein (mouse strain C57BL/6J clone 0610041G12 220-amino acid) (9CI) (CA INDEX NAME)

SEQ 1 MAALRSWVTR SVCSLFRYRQ RFPVLANSKK
RCFSELIKPW HKTVLTGFGM
51 TLCAVPIAQK SEPQSLSNEA LMRRAVSLVT
DSTSTFLSQT TYALIEAITE
101 YTKAVYTLVS LYRQYTSLLG KMNSQEEDEV
WQVIIGARVE MTSKQQEYLK
151 LETTWMTAVG LSEMAAEAAY QTGADQASIT
ARNHIQLVKS QVQEVRQLSQ
201 KAETKLAEAQ TKELHQKAQE VSDEGADQEE
EAYLRED

L25 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
IT 326526-67-4
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; functional annotation of a full-length mouse cDNA collection)
RN 326526-67-4 CAPLUS
CN Protein (mouse strain C57BL/6J clone 2810018B18 237-amino acid) (9CI) (CA INDEX NAME)

SEQ 1 MAALRSWVTR SVCSLFRYRQ RFPVLANSKK
RCFSELIKPW HKTVLTGFGM
51 TLCAVPIAQK SEPQSLSNEA LMRRAVSLVT
DSTSTFLSQT TYALIEAITE
101 YTKAVYTLVS LYRQYTSLLG KMNSQEEDEV
WQVIIGARVE MTSKQQEYLK
151 LETTWMTAVG LSEMAAEAAY QTGADQASIT
ARNHIQLVKS QVQEVRQLSQ
201 KAETKLAEAQ TKELHQKAQE VSDEGADQEE
EAYLRED

L25 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
IT 291796-39-9
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(amino acid sequence; human pancreas cancer-associated gene sequences and polypeptides)
RN 291796-39-9 CAPLUS
CN Pancreas tumor-associated protein (human clone HEBFI18) (9CI) (CA INDEX NAME)

SEQ 1 XSFFRYRQCL CVPVVANFKK RCFSELIRPW
HKTVTIGFGV TLCAVPIAQK
51 SEPHSLSSEA LMRRAVSLVT DSTSTFLSQT
TYALIEAITE YTKAVYTLTS
101 LYRQYTSLLG KMNSEEEDEV WQVIIGARAE
MTSKHQEYLK LETTWMTAVG
151 LSEMAAEAAY QTGADQASIT ARNHIQLVKL
QVEEVHQLSR KAETKLAEAQ
201 IEELRQKTQE EGEERAESEQ EAYLRED

=> DIS L25 1-5 FHITSEQ kwic

L25 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
IT 438511-77-4P
RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP
(Preparation); USES (Uses)
(amino acid sequence; human pancreatic cancer-associated proteins and their encoding cDNA sequences and antibodies)
RN 438511-77-4 CAPLUS
CN Pancreas tumor-associated protein (human clone HEBFI18 fragment) (9CI)
(CA INDEX NAME)

SEQ 1 XSFFRYRQCL CVPVVANFKK RCFSELIRPW
HKTVTIGFGV TLCAVPIAQK
51 SEPHSLSSEA LMRRAVSLVT DSTSTFLSQT
TYALIEAITE YTKAVYTLTS
101 LYRQYTSLLG KMNSEEEDEV WQVIIGARAE
MTSKHQEYLK LETTWMTAVG
151 LSEMAAEAAY QTGADQASIT ARNHIQLVKL
QVEEVHQLSR KAETKLAEAQ
201 IEELRQKTQE EGEERAESEQ EAYLRED

PATENT NO. KIND DATE
APPLICATION NO. DATE
PI US 2002081659 A1 20020627 US 2001-925297 20010810
WO 2000055320 A1 20000921 WO 2000-US5989 20000308 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
IT INDEXING IN PROGRESS
IT 291758-44-6P 291758-45-7P 291758-46-8P 291758-47-9P 291758-48-0P
438510-46-4P 438510-47-5P 438510-48-6P
438510-49-7P 438510-50-0P
438510-51-1P 438510-52-2P 438510-53-3P
438510-54-4P 438510-55-5P
438510-56-6P 438510-57-7P 438510-58-8P
438510-59-9P 438510-60-2P
438510-61-3P 438510-62-4P 438510-63-5P
438510-64-6P 438510-65-7P
438510-66-8P 438510-67-9P 438510-68-0P
438510-69-1P 438510-70-4P
438510-71-5P 438510-72-6P 438510-73-7P
438510-74-8P 438510-75-9P
438510-76-0P 438510-77-1P 438510-78-2P
438510-79-3P 438510-80-6P
438510-81-7P 438510-82-8P 438510-83-9P
438510-84-0P 438510-85-1P
438510-86-2P 438510-87-3P 438510-88-4P
438510-89-5P 438510-90-8P
438510-91-9P 438510-92-0P 438510-93-1P
438510-94-2P 438510-95-3P
438510-96-4P 438510-97-5P 438510-98-6P
438510-99-7P 438511-00-3P
438511-01-4P 438511-02-5P 438511-03-6P
438511-04-7P 438511-05-8P
438511-06-9P 438511-07-0P 438511-08-1P
438511-09-2P 438511-10-5P
438511-11-6P 438511-12-7P 438511-13-8P
438511-14-9P 438511-15-0P
438511-16-1P 438511-17-2P 438511-18-3P
438511-19-4P 438511-20-7P
438511-21-8P 438511-22-9P 438511-23-0P
438511-24-1P 438511-25-2P
438511-26-3P 438511-27-4P 438511-28-5P

438511-29-6P 438511-30-9P
438511-31-0P 438511-32-1P 438511-33-2P
438511-34-3P 438511-35-4P
438511-36-5P 438511-37-6P 438511-38-7P
438511-39-8P 438511-40-1P
438511-41-2P 438511-42-3P 438511-43-4P
438511-44-5P 438511-45-6P
438511-46-7P 438511-47-8P 438511-48-9P
438511-49-0P 438511-50-3P
438511-51-4P 438511-52-5P 438511-53-6P
438511-54-7P 438511-55-8P
438511-56-9P 438511-57-0P 438511-58-1P
438511-59-2P 438511-60-5P
438511-61-6P 438511-62-7P 438511-63-8P
438511-64-9P 438511-65-0P
438511-66-1P 438511-67-2P 438511-68-3P
438511-69-4P 438511-70-7P
438511-71-8P 438511-72-9P 438511-73-0P
438511-74-1P 438511-75-2P
438511-76-3P 438511-77-4P 438511-78-5P
438511-79-6P
438511-80-9P 438511-81-0P 438511-82-1P
438511-83-2P 438511-84-3P
438511-85-4P 438511-86-5P 438511-87-6P
438511-88-7P 438511-89-8P
438511-90-1P 438511-91-2P 438511-92-3P
438511-93-4P 438511-94-5P
438511-95-6P 438511-96-7P 438511-97-8P
438511-98-9P 438511-99-0P
438512-00-6P 438512-01-7P 438512-02-8P
438512-03-9P 438512-04-0P
438512-05-1P 438512-06-2P 438512-07-3P
438512-08-4P 438512-09-5P
438512-10-8P 438512-11-9P 438512-12-0P
438512-13-1P 438512-14-2P
438512-15-3P 438512-16-4P 438512-17-5P
438512-18-6P 438512-19-7P
438512-20-0P 438512-21-1P 438512-22-2P
438512-23-3P 438512-24-4P
438512-25-5P 438512-26-6P 438512-27-7P
438512-28-8P 438512-29-9P
438512-30-2P 438512-31-3P 438512-32-4P
438512-33-5P 438512-34-6P
438512-35-7P 438512-36-8P 438512-37-9P
438512-38-0P 438512-39-1P
438512-40-4P 438512-41-5P 438512-42-6P
438512-43-7P 438512-44-8P
438512-45-9P 438512-46-0P 438512-47-1P
438512-48-2P 438512-49-3P
438512-50-6P 438512-51-7P 438512-52-8P
438512-53-9P 438512-54-0P
438512-55-1P 438512-56-2P 438512-57-3P
438512-58-4P 438512-59-5P
438512-60-8P 438512-61-9P 438512-62-0P
438512-63-1P 438512-64-2P
438512-65-3P 438512-66-4P 438512-67-5P
438512-68-6P 438512-69-7P
438512-70-0P 438512-71-1P
RL: ANT (Analyte); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; human pancreatic cancer-associated proteins and their encoding cDNA sequences and antibodies)

L25 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
IT 364604-53-5
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(structural anal. of a functional DIAP1 fragment bound to grim and hid peptides)
RN 364604-53-5 CAPLUS
CN L-Proline, L-alanyl-L-valyl-L-prolyl-L-isoleucyl-L-alanyl-L-glutaminyl-L-lysyl-L-seryl-L-α-glutamyl- (9CI) (CA INDEX NAME)

SEQ 1 AVPIAQKSEP

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



SO Molecular Cell (2001), 8(1), 95-104
CODEN: MOCEFL; ISSN: 1097-2765
IT INDEXING IN PROGRESS
IT 364604-52-4 364604-53-5
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
(structural anal. of a functional DIAP1 fragment bound to grim and hid peptides)

L25 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
IT 326049-22-3
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; functional annotation of a full-length mouse cDNA collection)
RN 326049-22-3 CAPLUS
CN Protein (mouse strain C57BL/6J clone 0610041G12 220-amino acid) (9CI) (CA INDEX NAME)

SEQ 1 MAALRSWVTR SVCSLFRYRQ RFPVLANSKK
RCFSELIKPW HKTVLTGFGM
51 TLCAVPIAQK SEPQSLSNEA LMRRAVSLVT
DSTSTFLSQT TYALIEAITE
101 YTKAVYTLVS LYRQYTSLLG KMNSQEEDEV
WQVIIGARVE MTSKQQEYLK
151 LETTWMTAVG LSEMAAEAAY QTGADQASIT
ARNHIQLVKS QVQEVRHSPR
201 RQKPSWLKHR QKSCTRKHRK

SO Nature (London) (2001), 409(6821), 685-690
CODEN: NATUAS; ISSN: 0028-0836
IT INDEXING IN PROGRESS
IT 326047-32-9 326047-47-6 326047-48-7
326047-51-2 326047-52-3
326047-53-4 326047-54-5 326047-55-6
326047-56-7 326047-57-8
326047-58-9 326047-59-0 326047-60-3
326047-61-4 326047-62-5
326047-63-6 326047-64-7 326047-65-8
326047-66-9 326047-67-0
326047-68-1 326047-76-1 326047-77-2
326047-78-3 326047-79-4
326047-80-7 326047-81-8 326047-82-9
326047-83-0 326047-84-1
326047-85-2 326047-86-3 326047-87-4
326047-88-5 326047-89-6
326047-90-9 326048-12-8 326048-13-9
326048-14-0 326048-15-1
326048-16-2 326048-17-3 326048-18-4
326048-19-5 326048-20-8
326048-21-9 326048-22-0 326048-23-1
326048-24-2 326048-25-3
326048-26-4 326048-27-5 326048-28-6
326048-29-7 326048-30-0
326048-31-1 326048-32-2 326048-33-3
326048-34-4 326048-35-5
326048-36-6 326048-37-7 326048-38-8
326048-39-9 326048-40-2
326048-41-3 326048-42-4 326048-43-5
326048-44-6 326048-45-7
326048-46-8 326048-47-9 326048-48-0
326048-49-1 326048-50-4
326048-51-5 326048-52-6 326048-53-7
326048-54-8 326048-55-9
326048-58-2 326048-59-3 326048-60-6
326048-61-7 326048-62-8
326048-63-9 326048-64-0 326048-65-1
326048-66-2 326048-67-3
326048-68-4 326048-69-5 326048-70-8
326048-71-9 326048-72-0
326048-73-1 326048-74-2 326048-75-3
326048-76-4 326048-77-5
326048-78-6 326048-79-7 326048-84-4
326048-85-5 326048-86-6
326048-87-7 326048-88-8 326048-89-9
326048-90-2 326048-91-3
326048-92-4 326048-93-5 326048-94-6
326048-95-7 326048-96-8
326048-97-9 326048-98-0 326048-99-1
326049-00-7 326049-01-8
326049-02-9 326049-03-0 326049-04-1
326049-05-2 326049-06-3
326049-07-4 326049-08-5 326049-10-9
326049-11-0 326049-12-1
326049-13-2 326049-14-3 326049-16-5
326049-17-6 326049-18-7
326049-19-8 326049-20-1 326049-21-2
326049-22-3
326049-23-4 326049-24-5 326049-25-6
326049-29-0 326049-30-3
326049-31-4 326049-32-5 326049-33-6
326049-34-7 326049-35-8
326049-36-9 326049-37-0 326049-38-1
326049-39-2 326049-41-6
326049-42-7 326049-43-8 326049-44-9
326049-45-0 326049-46-1
326049-47-2 326049-50-7 326049-51-8
326049-52-9 326049-55-2
326049-56-3 326049-57-4 326049-58-5
326049-59-6 326049-60-9
326049-61-0 326049-62-1 326049-63-2
326049-64-3 326049-65-4
326049-66-5 326049-67-6 326049-68-7
326049-69-8 326049-70-1
326049-71-2 326049-72-3 326049-73-4
326049-74-5 326049-75-6
326049-76-7 326049-77-8 326049-78-9
326049-80-3 326049-81-4
326049-82-5 326049-83-6 326049-84-7
326049-85-8 326049-86-9
326049-87-0 326049-88-1 326049-89-2
326049-90-5 326049-92-7
326049-93-8 326049-94-9 326049-95-0
326049-96-1 326049-97-2
326049-99-4 326050-00-4 326050-01-5
326050-02-6 326050-03-7
326050-04-8 326050-05-9 326050-06-0
326050-07-1 326050-08-2
326050-09-3 326050-10-6 326050-11-7
326050-12-8 326050-13-9
326050-14-0 326050-15-1 326050-16-2
326050-17-3 326050-18-4
326050-19-5 326050-20-8 326050-21-9
326050-22-0 326050-23-1
326050-24-2 326050-25-3 326050-26-4
326050-27-5 326050-28-6
326050-29-7 326050-30-0 326050-31-1
326050-32-2
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; functional annotation of a full-length mouse cDNA collection)

L25 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
IT 326526-67-4
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; functional annotation of a full-length mouse cDNA collection)
RN 326526-67-4 CAPLUS
CN Protein (mouse strain C57BL/6J clone 2810018B18 237-amino acid) (9CI) (CA INDEX NAME)

SEQ 1 MAALRSWVTR SVCSLFRYRQ RFPVLANSKK
RCFSELIKPW HKTVLTGFGM
51 TLCAVPIAQK SEPQSLSNEA LMRRAVSLVT
DSTSTFLSQT TYALIEAITE
101 YTKAVYTLVS LYRQYTSLLG KMNSQEEDEV
WQVIIGARVE MTSKQQEYLK
151 LETTWMTAVG LSEMAAEAAY QTGADQASIT
ARNHIQLVKS QVQEVRQLSQ
201 KAETKLAEAQ TKELHQKAQE VSDEGADQEE
EAYLRED

SO Nature (London) (2001), 409(6821), 685-690
CODEN: NATUAS; ISSN: 0028-0836
IT INDEXING IN PROGRESS
IT 326524-17-8 326524-19-0 326524-20-3
326524-21-4 326524-23-6
326524-24-7 326524-27-0 326524-28-1
326524-31-6 326524-34-9
326524-36-1 326524-37-2 326524-39-4
326524-41-8 326524-42-9
326524-44-1 326524-45-2 326524-55-4
326524-57-6 326524-58-7
326524-60-1 326524-62-3 326524-66-7
326524-68-9 326524-69-0
326524-70-3 326524-74-7 326524-75-8
326524-78-1 326524-81-6
326524-83-8 326524-88-3 326524-90-7
326524-93-0 326524-95-2
326524-97-4 326524-99-6 326525-04-6
326525-06-8 326525-08-0
326525-10-4 326525-12-6 326525-14-8
326525-17-1 326525-20-6
326525-22-8 326525-25-1 326525-27-3
326525-28-4 326525-29-5
326525-31-9 326525-33-1 326525-34-2
326525-38-6 326525-41-1
326525-43-3 326525-46-6 326525-48-8
326525-49-9 326525-50-2
326525-52-4 326525-53-5 326525-54-6
326525-55-7 326525-57-9
326525-58-0 326525-59-1 326525-60-4
326525-61-5 326525-63-7
326525-69-3 326525-71-7 326525-72-8
326525-73-9 326525-74-0
326525-75-1 326525-77-3 326525-79-5
326525-80-8 326525-83-1
326525-84-2 326525-85-3 326525-87-5
326525-89-7 326525-90-0
326525-91-1 326525-93-3 326525-95-5
326525-96-6 326525-97-7
326525-99-9 326526-02-7 326526-05-0
326526-07-2 326526-10-7
326526-13-0 326526-14-1 326526-16-3
326526-18-5 326526-19-6
326526-20-9 326526-21-0 326526-22-1
326526-23-2 326526-25-4
326526-26-5 326526-27-6 326526-28-7

326526-29-8 326526-30-1
326526-31-2 326526-32-3 326526-33-4
326526-34-5 326526-36-7
326526-37-8 326526-38-9 326526-40-3
326526-41-4 326526-42-5
326526-43-6 326526-44-7 326526-46-9
326526-47-0 326526-51-6
326526-52-7 326526-54-9 326526-55-0
326526-56-1 326526-57-2
326526-58-3 326526-59-4 326526-60-7
326526-61-8 326526-62-9
326526-63-0 326526-64-1 326526-65-2
326526-66-3 326526-67-4
326526-68-5 326526-69-6 326526-70-9
326526-71-0 326526-72-1
326526-73-2 326526-74-3 326526-75-4
326526-76-5 326526-77-6
326526-78-7 326526-79-8 326526-80-1
326526-81-2 326526-82-3
326526-83-4 326526-84-5 326526-85-6
326526-86-7 326526-87-8
326526-88-9 326526-89-0 326526-90-3
326526-91-4 326526-92-5
326526-93-6 326526-94-7 326526-95-8
326526-96-9 326526-97-0
326526-98-1 326526-99-2 326527-00-8
326527-01-9 326527-02-0
326527-03-1, Protein NudE (mouse) 326527-04-2 326527-05-3
326527-06-4 326527-07-5 326527-08-6
326527-09-7 326527-10-0
326527-11-1 326527-12-2 326527-13-3
326527-14-4 326527-15-5
326527-16-6 326527-17-7 326527-18-8
326527-19-9 326527-20-2
326527-21-3 326527-22-4 326527-23-5
326527-24-6 326527-25-7
326527-26-8 326527-27-9 326527-28-0
326527-29-1 326527-30-4
326527-31-5 326527-32-6 326527-33-7
326527-34-8 326527-35-9
326527-36-0 326527-37-1 326527-38-2
326527-39-3 326527-40-6
326527-41-7 326527-42-8 326527-43-9
326527-44-0 326527-45-1
326527-46-2 326527-47-3 326527-48-4
326527-49-5 326527-50-8
326527-51-9 326527-52-0 326527-53-1
326527-54-2 326527-55-3
326527-56-4 326527-57-5 326527-58-6
326527-59-7 326527-60-0
326527-61-1 326527-62-2 326527-63-3
326527-64-4 326527-65-5
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(amino acid sequence; functional annotation of a full-length mouse cDNA collection)

L25 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
IT 291796-39-9
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(amino acid sequence; human pancreas cancer-associated gene sequences and polypeptides)
RN 291796-39-9 CAPLUS
CN Pancreas tumor-associated protein (human clone HEBFI18) (9CI) (CA INDEX NAME)

SEQ 1 XSFFRYRQCL CVPVVANFKK RCFSELIRPW HKTVTIGFGV TLCAVPIAQK
51 SEPHSLSSEA LMRRAVSLVT DSTSTFLSQT TYALIEAITE YTKAVYTLTS
101 LYRQYTSLLG KMNSEEEDEV WQVIIGARAE MTSKHQEYLK LETTWMTAVG
151 LSEMAAEAAY QTGADQASIT ARNHIQLVKL QVEEVHQLSR KAETKLAEAQ
201 IEELRQKTQE EGEERAESEQ EAYLRED

PI WO 2000055320 A1 20000921
PATENT NO. KIND DATE
APPLICATION NO. DATE
---------- ---- --------
---------- --------
PI WO 2000055320 A1 20000921 WO
2000-US5989 20000308 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1159420 A1 20011205 EP
2000-914861 20000308
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
JP 2003514510 T2 20030422 JP
2000-605738 20000308
US 2002081659 A1 20020627 US
2001-925297 20010810
IT INDEXING IN PROGRESS
IT 244249-83-0 291758-44-6 291758-45-7
291758-46-8 291758-47-9
291758-48-0 291795-32-9 291795-33-0
291795-34-1 291795-35-2
291795-36-3 291795-37-4 291795-38-5
291795-39-6 291795-40-9
291795-41-0 291795-42-1 291795-43-2
291795-44-3 291795-45-4
291795-46-5 291795-47-6 291795-48-7
291795-49-8 291795-50-1
291795-51-2 291795-52-3 291795-53-4
291795-54-5 291795-55-6
291795-56-7 291795-57-8 291795-58-9
291795-59-0 291795-60-3
291795-61-4 291795-62-5 291795-63-6
291795-64-7 291795-65-8
291795-66-9 291795-67-0 291795-68-1
291795-69-2 291795-70-5
291795-71-6 291795-72-7 291795-73-8
291795-74-9 291795-75-0
291795-76-1 291795-77-2 291795-78-3
291795-79-4 291795-80-7
291795-81-8 291795-82-9 291795-83-0
291795-84-1 291795-85-2
291795-86-3 291795-87-4 291795-88-5
291795-89-6 291795-90-9
291795-91-0 291795-92-1 291795-93-2
291795-94-3 291795-95-4
291795-96-5 291795-97-6 291795-98-7
291795-99-8 291796-00-4
291796-01-5 291796-02-6 291796-03-7
291796-04-8 291796-05-9
291796-06-0 291796-07-1 291796-08-2
291796-09-3 291796-10-6
291796-11-7 291796-12-8 291796-13-9
291796-14-0 291796-15-1
291796-16-2 291796-17-3 291796-18-4
291796-19-5 291796-20-8
291796-21-9 291796-22-0 291796-23-1
291796-24-2 291796-25-3
291796-26-4 291796-27-5 291796-28-6
291796-29-7 291796-30-0
291796-31-1 291796-32-2 291796-33-3
291796-34-4 291796-35-5
291796-36-6 291796-37-7 291796-38-8
291796-39-9
291796-40-2 291796-41-3 291796-42-4
291796-43-5 291796-44-6
291796-45-7 291796-46-8 291796-47-9
291796-48-0 291796-49-1
291796-50-4 291796-51-5 291796-52-6
291796-53-7 291796-54-8
291796-55-9 291796-56-0 291796-57-1
291796-58-2 291796-59-3
291796-60-6 291796-61-7 291796-62-8
291796-63-9 291796-64-0
291796-65-1 291796-66-2 291796-67-3
291796-68-4 291796-69-5
291796-70-8 291796-71-9 291796-72-0
291796-73-1 291796-74-2
291796-75-3 291796-76-4 291796-77-5
291796-78-6 291796-79-7
291796-80-0 291796-81-1 291796-82-2
291796-83-3 291796-84-4
291796-85-5 291796-86-6 291796-87-7
291796-88-8 291796-89-9
291796-90-2 291796-91-3 291796-92-4
291796-93-5 291796-94-6
291796-95-7 291796-96-8 291796-97-9
291796-98-0 291796-99-1
291797-00-7 291797-01-8 291797-02-9
291797-03-0 291797-04-1
291797-05-2 291797-06-3 291797-07-4
291797-08-5 291797-09-6
291797-10-9 291797-11-0 291797-12-1
291797-13-2 291797-14-3
291797-15-4 291797-16-5 291797-17-6
291797-18-7 291797-19-8
291797-20-1 291797-21-2 291797-22-3
291797-23-4 291797-24-5
291797-25-6 291797-26-7 291797-27-8
291797-28-9 291797-29-0
291797-30-3 291797-31-4 291797-32-5
291797-33-6 291797-34-7
291797-35-8 291797-36-9 291797-37-0
291797-38-1 291797-39-2
291797-40-5 291797-41-6 291797-42-7
291797-43-8 291797-44-9
291797-45-0 291797-46-1 291797-47-2
291797-48-3 291797-49-4
291797-50-7 291797-51-8 291797-52-9
291797-53-0 291797-54-1
291797-55-2 291797-56-3 291797-57-4
RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)
(amino acid sequence; human pancreas cancer-associated gene sequences and polypeptides)

=> s avpy/sqsp
REGISTRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

COST IN U.S. DOLLARS
SINCE FILE TOTAL

ENTRY SESSION
FULL ESTIMATED COST
71.06 565.42

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
SINCE FILE TOTAL

ENTRY SESSION
CA SUBSCRIBER PRICE
0.00 -6.24

FILE 'REGISTRY' ENTERED AT 16:32:59 ON 26 JUL 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 JUL 2004 HIGHEST RN 716315-35-4
DICTIONARY FILE UPDATES: 25 JUL 2004 HIGHEST RN 716315-35-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at: http://www.cas.org/ONLINE/DBSS/registryss.html

S AVPY/SQSP
L26 12503 AVPY/SQSP

COST IN U.S. DOLLARS
SINCE FILE TOTAL

ENTRY SESSION
FULL ESTIMATED COST
26.92 592.34

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
SINCE FILE TOTAL

ENTRY SESSION
CA SUBSCRIBER PRICE
0.00 -6.24

FILE 'CAPLUS' ENTERED AT 16:33:03 ON 26 JUL 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 26 Jul 2004 VOL 141 ISS 5
FILE LAST UPDATED: 25 Jul 2004 (20040725/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

S L#
L27 1714 L26

```
=> l27 and pd<20010208
      21324333 PD<20010208
                (PD<20010208)
L28          807 L27 AND PD<20010208

=> s avpiaqk/sqsp
   REGISTRY INITIATED
Substance data SEARCH and crossover from CAS
REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view
retrieved structures.



COST IN U.S. DOLLARS
SINCE FILE       TOTAL

ENTRY    SESSION
FULL ESTIMATED COST
2.37      594.71

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
SINCE FILE       TOTAL

ENTRY    SESSION
CA SUBSCRIBER PRICE
0.00       -6.24

FILE 'REGISTRY' ENTERED AT 16:33:36 ON 26 JUL
2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER
AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society
(ACS)

Property values tagged with IC are from the
ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   25 JUL 2004  HIGHEST
RN 716315-35-4
DICTIONARY FILE UPDATES:  25 JUL 2004  HIGHEST
RN 716315-35-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 21,
2004

  Please note that search-term pricing does
apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP
CROSSOVER for details.

Experimental and calculated property data are
now available.  For more
information enter HELP PROP at an arrow prompt
in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

S AVPIAQK/SQSP
L29           53 AVPIAQK/SQSP


COST IN U.S. DOLLARS
SINCE FILE       TOTAL

ENTRY    SESSION
FULL ESTIMATED COST
26.92      621.63

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
SINCE FILE       TOTAL

ENTRY    SESSION
CA SUBSCRIBER PRICE
0.00       -6.24

FILE 'CAPLUS' ENTERED AT 16:33:39 ON 26 JUL 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER
AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY
(ACS)

Copyright of the articles to which records in
this database refer is
held by the publishers listed in the PUBLISHER
(PB) field (available
for records published or updated in Chemical
Abstracts after December
26, 1996), unless otherwise indicated in the
original publications.
The CA Lexicon is the copyrighted intellectual
property of the
American Chemical Society and is provided to
assist you in searching
databases on STN.  Any dissemination,
distribution, copying, or storing
of this information, without the prior written
consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 26 Jul 2004  VOL 141 ISS 5
FILE LAST UPDATED: 25 Jul 2004  (20040725/ED)

  This file contains CAS Registry Numbers for
easy and accurate
  substance identification.


S L#
L30           46 L29

=> l30 and pd<20010208
      21324333 PD<20010208
                (PD<20010208)
L31            7 L30 AND PD<20010208

=> d l31 fhitseq 1-7

L31  ANSWER 1 OF 7  CAPLUS  COPYRIGHT 2004 ACS
on STN
IT   438511-77-4P
     RL: ANT (Analyte); BPN (Biosynthetic
preparation); BSU (Biological study,
     unclassified); DGN (Diagnostic use); PRP
(Properties); THU (Therapeutic
     use); ANST (Analytical study); BIOL
(Biological study); PREP
     (Preparation); USES (Uses)
        (amino acid sequence; human pancreatic
cancer-associated proteins and
        their encoding cDNA sequences and
antibodies)
RN   438511-77-4  CAPLUS
CN   Pancreas tumor-associated protein (human
clone HEBFI18 fragment) (9CI)
     (CA INDEX NAME)


SEQ      1 XSFFRYRQCL CVPVVANFKK RCFSELIRPW
HKTVTIGFGV TLCAVPIAQK
       51 SEPHSLSSEA LMRRAVSLVT DSTSTFLSQT
TYALIEAITE YTKAVYTLTS
      101 LYRQYTSLLG KMNSEEEDEV WQVIIGARAE
MTSKHQEYLK LETTWMTAVG
      151 LSEMAAEAAY QTGADQASIT ARNHIQLVKL
QVEEVHQLSR KAETKLAEAQ
      201 IEELRQKTQE EGEERAESEQ EAYLRED



L31  ANSWER 2 OF 7  CAPLUS  COPYRIGHT 2004 ACS
on STN
IT   364604-53-5
     RL: BPR (Biological process); BSU
(Biological study, unclassified); PRP
     (Properties); BIOL (Biological study); PROC
(Process)
        (structural anal. of a functional DIAP1
fragment bound to grim and hid
        peptides)
RN   364604-53-5  CAPLUS
CN   L-Proline, L-alanyl-L-valyl-L-prolyl-L-
isoleucyl-L-alanyl-L-glutaminyl-L-
     lysyl-L-seryl-L-α-glutamyl- (9CI)  (CA
INDEX NAME)

SEQ      1 AVPIAQKSEP

Absolute stereochemistry.
```



```
PAGE 1-A
```



```
PAGE 1-B


L31  ANSWER 3 OF 7  CAPLUS  COPYRIGHT 2004 ACS
on STN
IT   326049-22-3
     RL: BSU (Biological study, unclassified);
PRP (Properties); BIOL
     (Biological study)
        (amino acid sequence; functional
annotation of a full-length mouse cDNA
        collection)
RN   326049-22-3  CAPLUS
CN   Protein (mouse strain C57BL/6J clone
0610041G12 220-amino acid) (9CI)  (CA
     INDEX NAME)


SEQ      1 MAALRSWVTR SVCSLFRYRQ RFPVLANSKK
RCFSELIKPW HKTVLTGFGM
       51 TLCAVPIAQK SEPQSLSNEA LMRRAVSLVT
DSTSTFLSQT TYALIEAITE
      101 YTKAVYTLVS LYRQYTSLLG KMNSQEEDEV
WQVIIGARVE MTSKQQEYLK
      151 LETTWMTAVG LSEMAAEAAY QTGADQASIT
ARNHIQLVKS QVQEVRQLSR
      201 RQKPSWLKHR QKSCTRKHRK



L31  ANSWER 4 OF 7  CAPLUS  COPYRIGHT 2004 ACS
on STN
IT   326526-67-4
     RL: BSU (Biological study, unclassified);
PRP (Properties); BIOL
     (Biological study)
        (amino acid sequence; functional
annotation of a full-length mouse cDNA
        collection)
RN   326526-67-4  CAPLUS
CN   Protein (mouse strain C57BL/6J clone
2810018B18 237-amino acid) (9CI)  (CA
     INDEX NAME)


SEQ      1 MAALRSWVTR SVCSLFRYRQ RFPVLANSKK
RCFSELIKPW HKTVLTGFGM
       51 TLCAVPIAQK SEPHSLSSEA LMRRAVSLVT
DSTSTFLSQT TYALIEAITE
      101 TEVTKAVYTL TSLYRQYTSL LGKMNSEEED
EVWQVIIGAR AEMTSKHQEY
      151 LKLETTWMTA VGLSEMAAEA AYQTGADQAS
ITARNHIQLV KLQVEEVHQL
      201 SRKAETKLAE AQIEELRQKT QEEGEERAES
EQEAYLRED


L31  ANSWER 5 OF 7  CAPLUS  COPYRIGHT 2004 ACS
on STN
IT   291796-39-9
     RL: ANT (Analyte); BOC (Biological
occurrence); BSU (Biological study,
     unclassified); PRP (Properties); THU
(Therapeutic use); ANST (Analytical
     study); BIOL (Biological study); OCCU
(Occurrence); USES (Uses)
        (amino acid sequence; human pancreas
cancer-associated gene sequences and
        polypeptides)
RN   291796-39-9  CAPLUS
CN   Pancreas tumor-associated protein (human
clone HEBFI18) (9CI)  (CA INDEX
     NAME)


SEQ      1 XSFFRYRQCL CVPVVANFKK RCFSELIRPW
HKTVTIGFGV TLCAVPIAQK
       51 SEPHSLSSEA LMRRAVSLVT DSTSTFLSQT
TYALIEAITE YTKAVYTLTS
      101 LYRQYTSLLG KMNSEEEDEV WQVIIGARAE
MTSKHQEYLK LETTWMTAVG
      151 LSEMAAEAAY QTGADQASIT ARNHIQLVKL
QVEEVHQLSR KAETKLAEAQ
      201 IEELRQKTQE EGEERAESEQ EAYLRED



L31  ANSWER 6 OF 7  CAPLUS  COPYRIGHT 2004 ACS
on STN
IT   288332-63-8DP, Protein Smac (human caspase-
activator),
     subfragments are claimed
     RL: BAC (Biological activity or effector,
except adverse); BOC (Biological
     occurrence); BPN (Biosynthetic
preparation); BSU (Biological study,
     unclassified); PRP (Properties); THU
(Therapeutic use); BIOL (Biological
     study); OCCU (Occurrence); PREP
(Preparation); USES (Uses)
        (amino acid sequence; protein and cDNA
sequences of second
        mitochondria-derived activators of
caspases (Smac) and diagnostic and
        therapeutic uses thereof)
RN   288332-63-8  CAPLUS
CN   Protein Smac (human caspase-activator)
(9CI)  (CA INDEX NAME)


SEQ      1 MAALKSWLSR SVTSFFRYRQ CLCVPVVANF
KKRCFSELIR PWHKTVTIGF
       51 GVTLCAVPIA QKSEPHSLSS EALMRRAVSL
VTDSTSTFLS QTTYALIEAI
      101 TEVTKAVYTL TSLYRQYTSL LGKMNSEEED
EVWQVIIGAR AEMTSKHQEY
      151 LKLETTWMTA VGLSEMAAEA AYQTGADQAS
ITARNHIQLV KLQVEEVHQL
      201 SRKAETKLAE AQIEELRQKT QEEGEERAES
EQEAYLRED


L31  ANSWER 7 OF 7  CAPLUS  COPYRIGHT 2004 ACS
on STN
IT   288332-63-8P, Protein Smac (human caspase-
activator)
```

```
    RL: BOC (Biological occurrence); BPR
(Biological process); BSU (Biological
    study, unclassified); PRP (Properties); PUR
(Purification or recovery);
    BIOL (Biological study); OCCU (Occurrence);
PREP (Preparation); PROC
    (Process)
      (amino acid sequence; Smac promotion of
cytochrome c-dependent caspase
      activation and apoptosis by eliminating
IAP inhibition)
RN   288332-63-8  CAPLUS
CN   Protein Smac (human caspase-activator)
(9CI)  (CA INDEX NAME)


SEQ      1 MAALKSWLSR SVTSFFRYRQ CLCVPVVANF
KKRCFSELIR PWHKTVTIGF
        51 GVTLCAVPIA QKSEPMSLSS EALMRRAVSL
VTDSTSTFLS QTTYALIEAI
       101 TEYTKAVYTL TSLYRQYTSL LGKMNSEEED
EVWQVIIGAR AEMTSKHQEY
       151 LKLETTWMTA VGLSEMAAEA AYQTGADQAS
ITARNHIQLV KLQVEEVHQL
       201 SRKAETKLAE AQIEELRQKT QEEGEERAES
EQEAYLRED



=> d his

    (FILE 'HOME' ENTERED AT 15:51:43 ON 26 JUL
2004)

    FILE 'REGISTRY' ENTERED AT 15:51:52 ON 26
JUL 2004
L1        898099 S A[VTI][PA][GAVLIPSTOMNQ]/SQSP

    FILE 'CAPLUS' ENTERED AT 15:52:42 ON 26 JUL
2004

    FILE 'REGISTRY' ENTERED AT 15:52:49 ON 26
JUL 2004
L2              0 S L1 AND PD<20010208
L3           5628 L1 AND SQL<=20
L4           1977 L3 AND SQL<=10
L5             75 L4 AND SQL=4
L6           1903 L4 AND SQL>=5
L7             74 L4 NOT L6
L8              0 L7 NOT L5

    FILE 'CAPLUS' ENTERED AT 15:59:09 ON 26 JUL
2004                S A[VTI][PA][GAVLIPSTOMNQ]/SQSP

    FILE 'REGISTRY' ENTERED AT 16:01:38 ON 26
JUL 2004
L9        289282 S L1 AND (PATENT)/DT

    FILE 'CAPLUS' ENTERED AT 16:02:37 ON 26 JUL
2004

    FILE 'REGISTRY' ENTERED AT 16:03:01 ON 26
JUL 2004

    FILE 'CAPLUS' ENTERED AT 16:03:04 ON 26 JUL
2004
L10             0 L6 AND SQL=6

    FILE 'REGISTRY' ENTERED AT 16:05:22 ON 26
JUL 2004
L11           172 L6 AND SQL=6
L12        430210 S A[VTI][PA][SFYVI]/SQSP
L13           208 L12 AND SQL=10
L14           148 L12 AND SQL=20
L15           430 L12 AND SQL=50
L16           163 L12 AND SQL=25
L17            73 L12 AND SQL=23
L18            74 L12 AND SQL=22

    FILE 'CAPLUS' ENTERED AT 16:12:42 ON 26 JUL
2004
L19            32 L18 AND PD<20010208

    FILE 'REGISTRY' ENTERED AT 16:22:04 ON 26
JUL 2004
L20            25 S ATPFQEGLRTFDQLD/SQSP
L21             0 S AVPIAQK
L22            53 S AVPIAQK/SQSP

    FILE 'CAPLUS' ENTERED AT 16:28:29 ON 26 JUL
2004
L23             0 L21 AND PD<20010208
L24             5 L20 AND PD<20010208
L25             7 L22 AND PD<20010208
                S AVPY/SQSP

    FILE 'REGISTRY' ENTERED AT 16:32:59 ON 26
JUL 2004
L26         12503 S AVPY/SQSP

    FILE 'CAPLUS' ENTERED AT 16:33:03 ON 26 JUL
2004
L27          1714 S L26
L28           807 L27 AND PD<20010208
                S AVPIAQK/SQSP

    FILE 'REGISTRY' ENTERED AT 16:33:36 ON 26
JUL 2004
L29            53 S AVPIAQK/SQSP

    FILE 'CAPLUS' ENTERED AT 16:33:39 ON 26 JUL
2004
L30            46 S L29
L31             7 L30 AND PD<20010208

=> d l31 ibib iabs 1-7

L31  ANSWER 1 OF 7  CAPLUS  COPYRIGHT 2004 ACS
on STN
ACCESSION NUMBER:         2002:488143  CAPLUS
Full-text
DOCUMENT NUMBER:          137:42668
TITLE:                    Human pancreatic
cancer-associated proteins and their
                          encoding cDNA sequences
and antibodies
INVENTOR(S):              Rosen, Craig A.; Ruben,
Steven M.
PATENT ASSIGNEE(S):       USA
SOURCE:                   U.S. Pat. Appl. Publ.,
196 pp., Cont.-in-part of Appl.
                          No. PCT/US00/05989.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   10
PATENT INFORMATION:

     PATENT NO.       KIND  DATE
APPLICATION NO.  DATE
     ---------------  ----  --------       -----
----------  --------
     US 2002081659    A1   20020627       US
2001-925297   20010810
     WO 2000055320    A1   20000921       WO
2000-US5989   20000308 <--
         W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR,
BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE,
             KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MD, MG, MK, MN, MW,
             MX, NO, NZ, PL, PT, RO, RU, SD, SE,
SG, SI, SK, SL, TJ, TM, TR,
             TT, UA, UG, US, UZ, VN, YU, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ,
UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE,
SN, TD, TG
PRIORITY APPLN. INFO.:                    US 1999-
124270P  P  19990312
                                          WO 2000-
US5989   A2 20000308
ABSTRACT:
The present invention relates to 459 novel
pancreatic- and pancreatic
cancer-related polynucleotides, the polypeptides
encoded by these
polynucleotides herein collectively referred to
as "pancreatic antigens," and
antibodies that immunospecifically bind these
polypeptides, and the use of such
pancreatic polynucleotides, antigens, and
antibodies for detecting, treating,
preventing and/or prognosing disorders of the
pancreas, including, but not
limited to, the presence of pancreatic cancer
and pancreatic cancer metastases.
More specifically, isolated pancreatic nucleic
acid mols. are provided encoding
novel human pancreatic polypeptides.  Novel
pancreatic polypeptides and
antibodies that bind to these polypeptides are
provided.  Also provided are
vectors, host cells, and recombinant and
synthetic methods for producing human
pancreatic polynucleotides, polypeptides, and/or
antibodies.  The invention
further relates to diagnostic and therapeutic
methods useful for diagnosing,
treating, preventing and/or prognosing disorders
related to the pancreas,
including pancreatic cancer, and therapeutic
methods for treating such
disorders.  The invention further relates to
screening methods for identifying
agonists and antagonists of polynucleotides and
polypeptides of the invention.
The invention further relates to methods and/or
compns. for inhibiting or
promoting the production and/or function of the
polypeptides of the invention.


L31  ANSWER 2 OF 7  CAPLUS  COPYRIGHT 2004 ACS
on STN
ACCESSION NUMBER:         2001:561493  CAPLUS
Full-text
DOCUMENT NUMBER:          135:284701
TITLE:                    Structural analysis of
a functional DIAP1 fragment
                          bound to grim and hid
peptides
AUTHOR(S):                Wu, Jia-Wei; Cocina,
Amy E.; Chai, Jijie; Hay, Bruce
                          A.; Shi, Yigong
CORPORATE SOURCE:         Department of Molecular
Biology Lewis Thomas
                          Laboratory, Princeton
University, Princeton, NJ,
                          08544, USA
SOURCE:                   Molecular Cell (2001),
8(1), 95-104
                          CODEN: MOCEFL; ISSN:
1097-2765
PUBLISHER:                Cell Press
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
ABSTRACT:
The inhibitor of apoptosis protein DIAP1
suppresses apoptosis in Drosophila,
with the second BIR domain (BIR2) playing an
important role.  Three proteins,
Hid, Grim, and Reaper, promote apoptosis, in
part by binding to DIAP1 through
their conserved N-terminal sequences.  The
crystal structures of DIAP1-BIR2 by
itself and in complex with the N-terminal
peptides from Hid and Grim reveal
that these peptides bind a surface groove on
DIAP1, with the first four amino
acids mimicking the binding of the Smac
tetrapeptide to XIAP.  The next 3
residues also contribute to binding through
hydrophobic interactions.
Interestingly, peptide binding induces the
formation of an addnl. α helix
in DIAP1.  Our study reveals the structural
conservation and diversity
necessary for the binding of IAPs by the
Drosophila Hid/Grim/Reaper and the
mammalian Smac proteins.

REFERENCE COUNT:         51    THERE ARE 51
CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL
CITATIONS AVAILABLE IN THE RE FORMAT

L31  ANSWER 3 OF 7  CAPLUS  COPYRIGHT 2004 ACS
on STN
ACCESSION NUMBER:         2001:208827  CAPLUS
Full-text
DOCUMENT NUMBER:          134:203316
TITLE:                    Functional annotation
of a full-length mouse cDNA
                          collection
AUTHOR(S):                Kawai, J.; Shinagawa,
A.; Shibata, K.; Yoshino, M.;
                          Itoh, M.; Ishii, Y.;
Arakawa, T.; Hara, A.; Fukunishi,
                          Y.; Konno, H.; Adachi,
J.; Fukuda, S.; Aizawa, K.;
                          Izawa, M.; Nishi, K.;
Kiyosawa, H.; Kondo, S.;
                          Yamanaka, I.; Saito,
T.; Okazaki, Y.; Gojobori, T.;
                          Bono, H.; Kasukawa, T.;
Saito, R.; Kadota, K.;
                          Matsuda, H.; Ashburner,
M.; Batalov, S.; Casavant, T.;
                          Fleischmann, W.;
Gaasterland, T.; Gissi, C.; King, B.;
                          Kochiwa, H.; Kuehl, P.;
Lewis, S.; Matsuo, Y.;
                          Nikaido, I.; Pesole,
G.; Quackenbush, J.; Schriml, L.
                          M.; Staubli, F.;
Suzuki, R.; Tomita, M.; Wagner, L.;
                          Washio, T.; Sakai, K.;
Okido, T.; Furuno, M.; Aono,
                          H.; Baldarelli, R.;
Barsh, G.; Blake, J.; Boffelli,
                          D.; Bojunga, N.;
Carninci, P.; de Bonaldo, M. F.;
                          Brownstein, M. J.;
Bult, C.; Fletcher, C.; Fujita, M.;
                          Gariboldi, M.;
Gustincich, S.; Hill, D.; Hofmann, M.;
                          Hume, D. A.; Kamiya,
M.; Lee, N. H.; Lyons, P.;
                          Marchionni, L.;
Mashima, J.; Mazzarelli, J.;
                          Mombaerts, P.; Nordone,
P.; Ring, B.; Ringwald, M.;
                          Rodriquez, I.;
Sakamoto, N.; Sasaki, H.; Sato, K.;
                          Schonbach, C.; Seya,
T.; Shibata, Y.; Storch, K.-F.;
                          Suzuki, H.; Toyo-oka,
K.; Wang, K. H.; Weitz, C.;
                          Whittaker, C.; Wilming,
L.; Wynshaw-Boris, A.;
                          Yoshida, K.; Hasegawa,
Y.; Kawaji, H.; Kohtsuki, S.
CORPORATE SOURCE:         The RIKEN Genome
Exploration Res. Group Phase II Team,
                          Lab. Genome Exploration
Res. Group, RIKEN Genomic
                          Sciences Center (GSC),
Yokohama Inst., Yokohama,
                          Kanagawa, 230-0045,
Japan; The FANTOM Consortium
SOURCE:                   Nature (London) (2001),
409(6821), 685-690
                          CODEN: NATUAS; ISSN:
0028-0836
PUBLISHER:                Nature Publishing Group
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
ABSTRACT:
The RIKEN Mouse Gene Encyclopaedia Project, a
systematic approach to determining the
full coding potential of the mouse genome,
involves collection and sequencing
```

of full-length cDNAs and phys. mapping of the corresponding genes to the mouse genome. An international functional annotation meeting (FANTOM) was organized to annotate the first 21,076 cDNAs to be analyzed in this project. This report describes the first RIKEN clone collection, which is one of the largest described for any organism. Anal. of these cDNAs extends known gene families and identifies new ones. The sequences are deposited into GenBank with Accession nos. AK002213-AK021412 and AK027261-AK027262. Information about these clones is available at RIKEN (http://www.gsc.riken.go.jp/e/FANTOM/viewer/) and Mouse Genome Informatics (http://www.informatics.jax.org and mirror sites). [This abstract record is the second of 7 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

L31 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2001:154566 CAPLUS Full-text
DOCUMENT NUMBER: 134:217891
TITLE: Functional annotation of a full-length mouse cDNA collection
AUTHOR(S): Kawai, J.; Shinagawa, A.; Shibata, K.; Yoshino, M.; Itoh, M.; Ishii, Y.; Arakawa, T.; Hara, A.; Fukunishi, Y.; Konno, H.; Adachi, J.; Fukuda, S.; Aizawa, K.; Izawa, M.; Nishi, K.; Kiyosawa, H.; Kondo, S.; Yamanaka, I.; Saito, T.; Okazaki, Y.; Gojobori, T.; Bono, H.; Kasukawa, T.; Saito, R.; Kadota, K.; Matsuda, H.; Ashburner, M.; Batalov, S.; Casavant, T.; Fleischmann, W.; Gaasterland, T.; Gissi, C.; King, B.; Kochiwa, H.; Kuehl, P.; Lewis, S.; Matsuo, Y.; Nikaido, I.; Pesole, G.; Quackenbush, J.; Schriml, L. M.; Staubli, F.; Suzuki, R.; Tomita, M.; Wagner, L.; Washio, T.; Sakai, K.; Okido, T.; Furuno, M.; Aono, H.; Baldarelli, R.; Barsh, G.; Blake, J.; Boffelli, D.; Bojunga, N.; Carninci, P.; de Bonaldo, M. F.; Brownstein, M. J.; Bult, C.; Fletcher, C.; Fujita, M.; Gariboldi, M.; Gustincich, S.; Hill, D.; Hofmann, M.; Hume, D. A.; Kamiya, M.; Lee, N. H.; Lyons, P.; Marchionni, L.; Mashima, J.; Mazzarelli, J.; Mombaerts, P.; Nordone, P.; Ring, B.; Ringwald, M.; Rodriquez, I.; Sakamoto, N.; Sasaki, H.; Sato, K.; Schonbach, C.; Seya, T.; Shibata, Y.; Storch, K.-F.; Suzuki, H.; Toyo-oka, K.; Wang, K. H.; Weitz, C.; Whittaker, C.; Wilming, L.; Wynshaw-Boris, A.; Yoshida, K.; Hasegawa, Y.; Kawaji, H.; Kohtsuki, S.
CORPORATE SOURCE: The RIKEN Genome Exploration Res. Group Phase II Team, Lab. Genome Exploration Res. Group, RIKEN Genomic Sciences Center (GSC), Yokohama Inst., Yokohama, Kanagawa, 230-0045, Japan; The FANTOM Consortium
SOURCE: Nature (London) (2001), 409(6821), 685-690
CODEN: NATUAS; ISSN: 0028-0836
PUBLISHER: Nature Publishing Group
DOCUMENT TYPE: Journal
LANGUAGE: English
ABSTRACT:
The RIKEN Mouse Gene Encyclopaedia Project, a systematic approach to determining the full coding potential of the mouse genome, involves collection and sequencing of full-length cDNAs and phys. mapping of the corresponding genes to the mouse genome. An international functional annotation meeting (FANTOM) was organized to annotate the first 21,076 cDNAs to be analyzed in this project. This report describes the first RIKEN clone collection, which is one of the largest described for any organism. Anal. of these cDNAs extends known gene families and identifies new ones. The sequences are deposited into GenBank with Accession nos. AK002213-AK021412 and AK027261-AK027262. Information about these clones is available at RIKEN (http://www.gsc.riken.go.jp/e/FANTOM/viewer/) and Mouse Genome Informatics (http://www.informatics.jax.org and mirror sites). [This abstract record is the third of 7 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.].

L31 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:666873 CAPLUS Full-text
DOCUMENT NUMBER: 133:233616
TITLE: Human pancreas and pancreatic cancer-associated gene sequences and polypeptides
INVENTOR(S): Rosen, Craig A.; Ruben, Steven M.
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA
SOURCE: PCT Int. Appl., 1379 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000055320	A1	20000921	WO 2000-US5989	20000308 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1159420	A1	20011205	EP 2000-914861	20000308
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003514510	T2	20030422	JP 2000-605738	20000308
US 2002081659	A1	20020627	US 2001-925297	20010810

PRIORITY APPLN. INFO.: US 1999-124270P P 19990312
WO 2000-US5989 W 20000308
ABSTRACT:
This invention relates to 459 newly identified pancreas or pancreatic cancer-related cDNAs and the polypeptides encoded by these polynucleotides herein collectively known as "pancreas cancer antigens", and to the complete gene sequences associated therewith and to the expression products thereof, as well as the use of such pancreas cancer antigens for detection, prevention and treatment of disorders of the pancreas, particularly the presence of pancreatic cancer. This invention relates to the pancreas cancer antigens as well as vectors, host cells, antibodies directed to pancreas cancer antigens, and recombinant and synthetic methods for producing the same. Also provided are diagnostic methods for diagnosing and treating, preventing and/or prognosing disorders related to the pancreas, including pancreatic cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of pancreas cancer antigens of the invention. The present invention further relates to methods and/or compns. for inhibiting the production and/or function of the polypeptides of the present invention.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:606788 CAPLUS Full-text
DOCUMENT NUMBER: 133:173050
TITLE: Protein and cDNA sequences of the second mitochondria-derived activators of caspases (Smac) and the diagnostic and therapeutic uses thereof
INVENTOR(S): Wang, Xiaodong; Du, Chunying
PATENT ASSIGNEE(S): Board of Regents, the University of Texas System, USA
SOURCE: U.S., 16 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6110691	A	20000829	US 2000-479309	20000106 <--
US 6534267	B1	20030318	US 2000-627393	20000728
WO 2001049719	A2	20010712	WO 2001-US321	20010105
WO 2001049719	A3	20020207		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1244787	A2	20021002	EP 2001-900896	20010105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003518943	T2	20030617	JP 2001-550259	20010105

PRIORITY APPLN. INFO.: US 2000-479309 A1 20000106
WO 2001-US321 W 20010105
ABSTRACT:
The invention provides protein and cDNA sequences of the second mitochondria-derived activators of caspases (Smac) which involved in cellular apoptosis. The invention relates to a wide variety of diagnostic and therapeutic applications involving detecting and/or modulating expression and/or function of activators or caspases or genes or transcripts encoding such activators and generating genetic and immunogenic probes specific to activators of caspases.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:494839 CAPLUS Full-text
DOCUMENT NUMBER: 133:264472
TITLE: Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition
AUTHOR(S): Du, Chunying; Fang, Min; Li, Yucheng; Li, Lily; Wang, Xiaodong
CORPORATE SOURCE: Howard Hughes Medical Institute and Department of Biochemistry, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, 75235, USA
SOURCE: Cell (Cambridge, Massachusetts) (2000), 102(1), 33-42
CODEN: CELLB5; ISSN: 0092-8674
PUBLISHER: Cell Press
DOCUMENT TYPE: Journal
LANGUAGE: English
ABSTRACT:
We report here the identification of a novel protein, Smac, which promotes caspase activation in the cytochrome c/Apaf-1/caspase-9 pathway. Smac promotes caspase-9 activation by binding to inhibitor of apoptosis proteins, IAPs, and removing their inhibitory activity. Smac is normally a mitochondrial protein but is released into the cytosol when cells